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CHAPTER 1
The controlled human infection model
Controlled human infection (CHI) models are an important research tool, where healthy 
volunteers are experimentally infected with a pathogen. So far models have been established 
for a broad range of viruses, bacteria and parasites. CHIs can be used for a variety of objectives 
and are, at the moment, mainly used to investigate the efficacy of new vaccines and drugs.1 
Generally CHI trials are performed using a randomised controlled trial (RCT) as study design. In 
these RCTs the intervention group receives the new vaccine before the controlled infection, or 
the new drug after the controlled infection (figure 1) and the control group receives a placebo. 
Besides testing new vaccines or drugs, CHIs also give the opportunity to study the host-pathogen 
interaction, to profile immune parameters and to test or optimize new diagnostic parameters.
Figure 1. Schematic overview of controlled human infection trials. A. Schematic overview of  
controlled human infection (CHI) trials for vaccine research or B. drug research. Columns represent the 
different trial stages. 1. Population, a group of volunteers is being screened to participate in a CHI. 2A. 
Intervention, participating volunteers are given a vaccine or placebo. 2B/3A. Controlled infection,  
after a predefined period volunteers are deliberately being infected with a pathogen. B3. Intervention,  
participating volunteers are given a drug or a placebo/established vaccine. 4. Outcome, volunteers are 
being tested to see whether they developed the disease, historical data can serve as a control group.  
5. Treatment, all volunteers receive pathogen specific treatment.
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General introduction
Over the last decades CHI models are increasingly used.2 They have accelerated the drug and 
vaccine development for several pathogens. This led to the development of novel vaccines,3 
but also contributed to stopping the further development of unsuccessful candidates.4 CHIs 
are increasingly being used as proof of principle for vaccines before starting phase 2 studies 
and often act as gatekeeper before moving to large scale phase 2 or 3 field studies in endemic 
countries.5
This proof of principle has several advantages compared to field trials in endemic areas.5,6 
Generally, a low number of volunteers are needed in CHIs to achieve the endpoint, often between 
20 and 100, compared to hundreds to 100,000 volunteers in phase II field trials in endemic areas.2 
As a consequence it reduces the unnecessary exposure of potentially vulnerable populations 
to interventions that might be ineffective. Another advantage is that multiple products can be 
tested in parallel and the risk of late clinical failure will be minimised (figure 2). Together, this 
leads to a reduction in the overall costs and a reduced overall risk during development.
Figure 2. Vaccine development phases. The number of vaccines, the number of volunteers and the time 
until registration of a vaccine for each phase of clinical development with (A) or without (B) the use of 
controlled human infections.
1.
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These advantages have led to the development of new CHI models. To be able to design a new 
model, the specific pathogens should be produced in a controlled process. Preferably this process 
follows the good manufacturing practice (GMP) guidelines. More important, the expected 
adverse events in volunteers should be treatable or self-curable and cannot lead to long-term 
or permanent disabilities. Well-established CHI models can be altered or refined over time, for 
example when new diagnostic tools to detect the pathogen become available.
Malaria
Malaria is one of the world’s most devastating infectious diseases with 219 million cases and 
over 435,000 deaths in 2017,7 with most cases and deaths occurring in sub-Saharan Africa. 
Plasmodium falciparum is responsible for most deaths, while the other species, Plasmodium 
ovale, Plasmodium vivax, Plasmodium malariae and Plasmodium knowlesi, mainly cause 
morbidity. The non-symptomatic liver stage of malaria precedes the symptomatic erythrocytic 
stage where patients develop symptoms such as fever, malaise, fatigue, headache, myalgia and 
arthralgia. In severe cases patients can develop neurological complications, severe anemia, 
coma and eventually they could die.
Effective treatment is available, though it is not always continuous accessible in remote 
areas. This may lead to anti-malarial drugs being administered too late. In addition, treatment 
may fail due to resistance of parasites against specific drugs. As a single infection does not induce 
complete immunity and multiple infections only induce semi-immunity, the need for a vaccine 
to prevent disease is high. Currently there is one licensed vaccine, RTS,s which is registered as 
Mosquirix,8 which has a limited efficacy of 50% in children between 5-17 months old, 14 months 
after vaccination.9 A pilot vaccine program with Mosquirix, for children up to 2 years old, started 
in Malawi, Ghana and Kenya in 2019.10,11
Controlled human malaria infections
The infection of volunteers with malaria for various objectives has been performed since the 
1940’s.12 Hereafter, the importance of controlled human malaria infection (CHMI) studies was 
increasingly recognised.
The most common used CHMI study design is the double blind RCT, where both volunteers 
and research physicians are blinded. In these studies, the administration of several immunisations 
to healthy volunteers is followed by a controlled infection, the CHMI. During the CHMI sporozoites 
are generally administered by the bites of P. falciparum‑infected laboratory reared Anopheles 
stephensi mosquitoes.13,14 These mosquitoes become infected after the feeding of a blood meal 
containing in vitro cultured P. falciparum in erythrocytes.13,14 However, the CHMI can also be 
performed by direct venous inoculation of malaria sporozoites.15
The use of CHMIs has resulted in several important scientific advances over the past decades 
in malaria vaccine research. One of the most important is the first proof of efficacy of the first 
licensed malaria vaccine, Mosquirix.8 Due to its limited efficacy which wanes over time, it is 
important to continue vaccine research aiming at a vaccine with a higher efficacy. Preferably a 
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General introduction
protective efficacy of more than 75% against clinical malaria and reduction of transmission of 
the parasite as is proposed in the malaria vaccine technology roadmap.16
Whole sporozoite vaccines
In contrast to the vaccine Mosquirix which targets the circumsporozoite protein on sporozoites,8 
new vaccines based on whole sporozoites are being developed. These whole sporozoite vaccines 
seem to be potent.17,18 Most of these vaccines are based on the P. falciparum strain NF54, 
originating from a case of airport malaria in the Netherlands,19 or its daughter strain 3D7.20
In 1999, a ground-breaking milestone was accomplished with whole sporozoite immunisation. 
Full protective immunity in nearly 100% of volunteers was induced after immunisation with 
radiation attenuated sporozoites (RAS).17 Another type of whole sporozoite immunisation 
appeared to be even more potent. Exposure of volunteers to infected mosquito bites under 
chloroquine chemoprophylaxis (chemoprophylactic sporozoites, CPS) resulted in 100% 
protection. This potency is probably related to a longer exposure time to parasites.21 Alongside 
chemoprophylaxis and RAS-based vaccines, a new type of whole sporozoite vaccines has recently 
been introduced, based on genetically attenuated parasites (GAPs). With the deletion of parasite 
genes which are crucial to develop within the liver or crucial to release merozoites into the blood 
stream, parasite development will arrest in the liver.22
Schistosomiasis
Worldwide 252 million people are infected with Schistosoma. Infections are mainly caused by 
Schistosoma mansoni and Schistosoma haematobium, but can also be caused by S. japonicum, 
S. mekongi, S. intercalatum or hybrid forms. Schistosomiasis is listed by the WHO as one of the 
main neglected tropical diseases.23,24 The endemicity of the disease is focal and is determined 
by the presence of the intermediate host, the fresh water snail. Each of the Schistosoma species 
infects another species of freshwater snails. The infected snails release cercariae, which can 
penetrate the skin of the definite host. In their host they mature and migrate through several 
tissues. Adult worms generally reside in the mesenteric venules (S. mansoni) or venous plexus 
of the bladder (S. haematobium), where they mate and start producing eggs. The eggs travel 
through the lumen of the intestine or the bladder of their host and are released with urine of 
feces. When adult worms accidentally reside in other veins, their eggs will travel through other 
tissues. When the eggs get trapped in tissue they promote inflammatory responses at their 
deposition site, which can induce formation of granulomas and fibrosis.25 Depending on the site 
this can result in various forms of pathology, such as liver cirrhosis and portal hypertension.25
Treatment of schistosomiasis relies on one drug only, praziquantel, of which the reported 
efficacy varies between 42 and 91% in endemic areas.26-28 Current control programs rely on 
mass drug administration (MDA) with praziquantel and are being used to reduce the burden 
of infection.29 There is a delay in regular treatment as people develop disease only after years 
of infections and re-infection. As a consequence of this suboptimal treatment, a vaccine would 
be an essential tool in the control of schistosomiasis. The WHO suggests that a vaccine should 
1.
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fully prevent from infection in 40% of people or reduce the worm burden by 40%.30 However, 
a more stringent goal of 75% reduction in worm burden has been proposed by the research 
community.31 Currently three vaccines against S. mansoni are in various stages of (pre-) clinical 
development: Sm-TSP-2, rSm14/GLA-SE, and Sm-p80.32-34
Controlled human Schistosoma infections
The development of a controlled human schistosome infection (CoHSI) model would enhance 
the schistosomiasis vaccine development. It can be used as a tool to select vaccine candidates 
early in clinical development and consequently prevent late clinical failure.1,2 Also, this model 
would allow characterisation of the immune response against schistosomes in the human host. 
This could give insight in symptoms involved in an acute schistosomiasis, also known as Katayama 
syndrome, and allows for optimisation of diagnostic assays.
To be able to develop this new infection model it is important that the schistosome life cycle 
is available. The maintenance of this life cycle and production of cercariae should be regulated 
in accordance with the principles of good manufacturing practice (GMP). Furthermore, it is 
important to be able to ensure the safety of volunteers at all times by optimising the infection 
(cercarial) dose, frequent follow-up control visits, availability of a research physician at all 
times, adequate diagnostic tools with the possibility to determine whether treatment has been 
sufficient, and the availability of adequate drug treatment.
Optimizing controlled human infections
The use of healthy volunteers is common in CHI studies. The ethical principles of CHIs are 
comparable to those of phase 1 trials, where there is a minimal risk, without direct benefit to 
the volunteers.6 However, there is a delicate balance between the acceptance of CHI studies 
by researchers and the community. The central ethical issue seems to lie in the risk of harm to 
volunteers.35 It is important to realize that the aim of CHI studies is not to induce harm, but to 
gain scientific benefit or benefit to society. As a consequence, this model should only be used 
under strict conditions.35,36
An ethical framework, mainly based on the Nuremberg code and declaration of Helsinki,37,38 
has been proposed to evaluate the ethics regarding CHI studies.5,6,39 In short: 1) clear scientific 
rationale 2) minimize risks and discomfort to volunteers 3) exclude vulnerable populations 
4) clear and thorough informed consent procedure 5) financial compensation for required 
time and suspected discomfort 6) compensate research-related injury 7) protect the public 
8) potential benefit of the research should outweigh harm of the volunteers, and 9) right to 
withdraw from research.5,6 It is the ethical obligation of the researcher to ensure the safety of 
his volunteers.
Marijke Langenberg BNW proef V3.indd   12 27-04-21   08:54
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Scope and outline of this thesis
In this thesis new P. falciparum strains were investigated and introduced in CHMI studies. In 
addition, the CHMI model is used to test the efficacy of a new GAP vaccine, PfSPZ-GA1 vaccine. 
Besides the use of this well-established CHI model, the design of a new model, the CoHSI model is 
introduced and the results of the first study performed with this model are presented. Ultimately, 
we describe how the use of historical controls in CHIs can be used to improve the safety of 
CHI studies.
The first part of the thesis focusses on CHMI studies.
Chapter 2 provides insight in the liver stage and blood stage development of the new strains, 
NF135.C8 and NF166.C10, compared to the generally used strain NF54. From previous CMHI 
studies with NF54 it is known that five infected mosquito bites result in 100% infection rate 
in non-vaccinated malaria naïve volunteers. In Chapter 3 the number of infected mosquito 
bites that are necessary to guarantee a 100% infection rate in non-vaccinated malaria-naïve 
volunteers after exposure to one of the two new P. falciparum strains, NF135.C8 and NF166.
C10 are tested. Additionally, in Chapter 4 the results of the first phase I and CHMI trial with a 
genetically attenuated parasite (GAP) malaria vaccine administered by direct venous inoculation 
are shown. At first the safety of the vaccine was tested in a phase I study. When these results 
were positive a CHMI study followed, where, three immunisations with a GAP vaccine, PfSPZ-GA1 
Vaccine, based on NF54 were followed by a homologous, NF54, mosquito bite CHMI.
The second part of the thesis focusses on the development of the CoHSI model
In Chapter 5 the establishment of male cercarial production for a controlled human schistosome 
infection model is described. Based on this production the CoHSI model was implemented. In 
Chapter 6 we describe the development of Katayama syndrome in two of our volunteers after 
CoHSI. Chapter 7 describes the results of the first CoHSI study, including the safety and optimal 
dose for infection for future studies.
The last part of this thesis focusses on the improvement of implemented CHI models.
In Chapter 8 we give suggestions to optimize CHI models and to reduce their risk with the use 
of historical controls.
1.
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Abstract
Malaria sporozoites must first undergo intrahepatic development before a pathogenic blood-
stage infection is established. The success of infection depends on host and parasite factors. In 
healthy human volunteers undergoing controlled human malaria infection (CHMI), we directly 
compared three clinical Plasmodium falciparum isolates for their ability to infect primary human 
hepatocytes in vitro and to drive the production of blood-stage parasites in vivo. Our data show 
a correlation between the efficiency of strain-specific sporozoite invasion of human hepatocytes 
and the dynamics of patent parasitemia in study subjects, highlighting intrinsic differences 
in infectivity among P. falciparum isolates from distinct geographical locales. The observed 
heterogeneity in infectivity among strains underscores the value of assessing the protective 
efficacy of candidate malaria vaccines against heterologous strains in the CHMI model.
CHAPTER 2
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Introduction
Malaria infections are initiated by blood-feeding female Anopheline mosquitoes injecting 
Plasmodium sporozoites into their mammalian host. Although most of the sporozoites get 
trapped in the dermis or draining lymph nodes, a small but crucial fraction succeed in penetrating 
dermal vasculature, whence they are carried into the bloodstream, including eventually the 
hepatic circulation (1). There they invade the liver parenchyma, traversing numerous cells 
before a few eventually succeed in invading a permissive hepatocyte where they undergo 
schizogony (2). Each liver-stage schizont releases an estimated ≥40,000 merozoites (3), which 
invade erythrocytes, causing blood-stage disease. The respective steps in the preerythrocytic 
life cycle of the Plasmodium parasite initially form a substantial bottleneck and subsequently an 
enormous multiplication opportunity (4).
However, it is unclear how the success rate of these various preerythrocytic steps ties 
together to determine the total burden of parasites emerging from the liver and hence the course 
of pathogenic blood-stage infection. It is also unknown to what extent malaria isolates vary in 
infectivity with regard to preerythrocytic infection or, conversely, whether humans differ in their 
intrinsic permissiveness. Addressing the latter issue is central to the rational design of controlled 
human malaria infection (CHMI) studies for clinical evaluation of candidate malaria vaccines 
(5). Here, we investigated whether three clinical isolates of Plasmodium falciparum differed 
in their intrinsic ability to accomplish the sequential steps of preerythrocytic development in 
liver hepatocytes and how this affected the course of blood-stage infection in humans. We 
studied parasite dynamics both in vivo in malaria-naïve volunteers undergoing CHMI and in 
a recently optimized in vitro model using freshly isolated human hepatocytes (6, 7). In vitro 
experiments were performed with sporozoites harvested from exactly the same batches of 
infected mosquitoes used on the same day for the human infections. Alongside the longstanding 
laboratory strain NF54 (8) and the recently reported NF135.C10 clone (9), we described the 
development and use in humans of the P. falciparum clone NF166.C8. We showed that intrinsic 
differences in infectivity existed between P. falciparum isolates with regard to their ability to 
invade and multiply within human hepatocytes in vitro. The degree of liver-stage infection 
correlated directly with the magnitude of the first wave of blood-stage parasites to emerge 
from the liver in vivo and correlated inversely with the prepatent period in CHMI subjects.
Results
Dynamics of parasitemia during CHMI
In total, 23 subjects across two separate CHMI studies were each exposed to sets of five 
mosquitoes carrying the NF54, NF135.C10, or NF166.C8 isolates of P. falciparum (study 
flowcharts, study subject demographics, and laboratory characteristics of these P. falciparum 
isolates are provided in fig. S1 and tables S1 and S2, respectively). All subjects developed patent
2.
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parasitemia and were curatively treated with atovaquone-proguanil once thick smear–positive 
(first study, CHMI-a) or quantitative real-time fluorescence polymerase chain reaction (qPCR)–
positive (second study, CHMI-b). In CHMI-a (Fig. 1A), the prepatent period as determined by thick 
smear was significantly shorter for subjects infected with either the NF135.C10 clone (mean, 
7.2 days; range, 6.5 to 8.5 days) or the NF166.C8 clone (mean, 7.4 days; range, 6.5 to 8.5 days) 
than for those infected with the NF54 strain of P. falciparum (mean, 10.2 days; range, 9.0 to 10.5 
days); mean differences were, respectively, 3.0 days [95% confidence interval (CI), 1.7 to 4.3] 
and 2.8 days (95% CI, 1.5 to 4.1) [P < 0.001 for both comparisons, one-way analysis of variance 
(ANOVA)/Tukey’s post hoc test, n = 5 per group]. No significant difference existed between 
NF135.C10 and NF166.C8 (mean difference, 0.2 day; 95% CI, −1.1 to 1.5; P > 0.05). In CHMI-b (Fig. 
1B), the prepatent period as determined by qPCR criteria did not differ significantly between 
NF135.C10 (mean, 8.0 days; range, 7.0 to 9.0 days) andNF166.C8 (7.0 days in all four subjects) P. 
falciparum strains (mean difference, 1.0 day; 95% CI, −0.3 to 2.3) (P = 0.09, one-sample t test, 
n = 4 per group). The prepatent period observed for NF54 in the CHMI-a study was similar to 
that of n = 56 malaria-naïve subjects in all 10 of our CHMI studies (mean, 10.3 days; range, 7.0 
to 16.0 days), in which treatment was initiated upon positive standardized thick blood smear 
analysis (table S3). Likewise, the prepatent period for NF135.C10 in CHMI-a was similar to that 
of n = 13 subjects across all 3 of those 10 studies that also included infections with NF135.C10 
strain parasites (mean, 8.0 days; range, 6.5 to 9.0 days; table S3). In a meta-analysis of all 10 
studies, the prepatent period of NF54 remained significantly (P < 0.001) longer than that of either 
NF135.C10 or NF166.C8 (Fig. 1C).
As determined retrospectively by qPCR in CHMI-a subjects, submicroscopic parasitemia 
became detectable before thick smear positivity in all subjects. Parasitemia was evident 6.5 
days after infection in all NF135.C10-infected and NF166.C8-infected subjects and by day 7.5 
(6.5 to 8.5) in the NF54-infected group (mean difference, 1.0 day; 95% CI, 0.1 to 1.9; Fig. 1D 
and Table 1). The magnitude of the initial wave of parasitemia emerging from the livers of both 
NF135.C10-infected and NF166.C8-infected subjects was greater compared to that of NF54-
infected subjects, although this magnitude did not itself differ significantly between NF135.
C10-infected and NF166.C8-infected subjects (Fig. 1D and Table 1). Overall, peak parasitemia 
per subject before initiation of antimalarial treatment with atovaquone-proguanil did not differ 
between groups (Table 1).
In CHMI-b, submicroscopic parasitemia was first detected by qPCR on day 6.5 after infection 
in all four subjects in both the NF135.C10 group and the NF166.C8 group. The magnitude of 
the initial wave of parasitemia emerging from the liver did not differ between NF135.C10 and 
NF166.C8 (Fig. 1E and Table 1). Although the initial wave of parasitemia in CHMI-a was slightly 
lower for the NF54 strain (P = 0.046) and somewhat higher for the NF135.C10 strain (P = 0.0045), 
as compared to our other CHMI studies (table S3), the magnitude of the first wave of NF54 
parasitemia was around 10-fold lower compared to either NF135.C10 or NF166.C8 parasitemias 
in a meta-analysis of all 18 of our CHMI studies (Fig. 1F and Table 1).
2.
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Clinical course and adverse events in subjects undergoing CHMI
Mild-moderate adverse events were experienced by all CHMI-a subjects after infection (table S4A). 
Grade 3 adverse events occurred in five subjects, including general malaise/fatigue prohibiting 
daily activities in four subjects (across all three groups) and fever >39.0°C in two NF166.C8-infected 
subjects (table S4A). The duration of general fatigue/malaise was greater in NF54-infected subjects 
[5.0 (3.0 to 7.8) days] compared to NF135.C10-infected [2.7 (1.3 to 4.6) days] or NF166.C8-infected 
subjects [2.7 (1.6 to 4.0) days]; the mean difference for both comparisons was 2.6 days (95% CI, 
0.0 to 5.1) (P < 0.05,one-way ANOVA/Tukey’s post hoc test, n = 5 per group; table S4A). Overall, no 
other statistically significant difference in frequency,duration, or gradation of adverse events was 
observed between the three groups (table S4A). The clinical characteristics of the CHMI-b study 
did not differ markedly from those of the CHMI-a study, and no statistically significant differences 
were observed between the NF135.C10-infected and NF166.C8-infected groups (table S4B). No 
serious adverse events (SAEs) occurred in either study.
Genetic characterization of P. falciparum isolates
The genetic identity of the three P. falciparum isolates used in the CHMI-a and CHMI-b studies 
was assessed by PCR for the polymorphic repetitive RII region of Glutamate-Rich Protein (GLURP); 
the K1, MAD20, and R033 allelic variants of block 2 of Merozoite Surface Protein 1 (MSP1); and 
the IC1 and FC27 variants of block 3 of MSP2 (fig. S2). GLURP bands were observed corresponding 
to amplified DNA fragment lengths of about 950, 980, and 680 base pairs (bp) for NF54, NF166.
C8, and NF135.C10 strains, respectively (fig. S2). MSP1 K1 bands corresponding to fragment 
lengths of 220 and 210 bp were observed for NF54 and NF166.C8 strains, but these isolates failed 
to produce an MSP1 MAD20 band (fig. S2). NF135.C10, in contrast, did produce an MSP1 MAD20 
band with a fragment length of 180 bp (fig. S2). MSP2 IC1 bands corresponded to fragment 
lengths of 480, 580, and 560 bp for NF54, NF166.C8, and NF135.C10 strains, respectively (fig. S2). 
18S bands were detectable as amplified DNA fragments of around 130 bp in all isolates (fig. S2).
Hepatocyte invasion and schizogony by sporozoites in vitro
In parallel, we assessed the infectivity of the three clinical P. falciparum isolates NF54, NF135.C10, 
and NF166.C8 for fresh human hepatocytes in vitro, using sporozoites dissected from the same 
batches of mosquitoes used to infect subjects in the CHMI-a study (experiment A) and derived from 
independent gametocyte cultures used in the CHMI-b study up to 2 years later (experiments B1 and 
B2) (Fig. 2). A higher proportion of NF135.C10 and NF166.C8 sporozoites established infection in 
human hepatocytes compared to the NF54 strain in these three experiments (P < 0.001 overall by 
repeated-measures ANOVA and P < 0.01 for NF54 versus NF135 and NF54 versus NF166 individually 
by Tukey’s post hoc test; Fig. 2). In addition, mature NF166.C8 and NF135.C10 schizonts tended to 
be larger than NF54 schizonts, and concomitantly, the increase in the number of nuclei per schizont 
from day 2 to day 6 appeared to be greater for NF135.C10 and NF166.C8 compared to NF54 (Table 
2). These combined data indicated that both sporozoite invasion and schizont development were 
more efficient in the NF135.C10 and NF166.C8 strains than in the NF54 strain.
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Table 2. Characteristics of P. falciparum infectivity of human hepatocytes in vitro.
NF54 NF135.C10 NF166.C8


















#nuclei/schizont4 16.8 8.3 7.3


















#nuclei/schizont4 40.6 76.2 87.6
multiplication rate5 2.4 9.2 12.1


















#nuclei/schizont4 23.8 18.5 20.0

















#nuclei/schizont4 218 361 ND
multiplication rate5 11.5 19.4 ND
ND = not determined. 1Number of liver-stage schizonts per well, counted by immunofluorescence 
microscopy following staining with anti-HSP70 MAbs, as in Fig 2. Data represent median [range] across 
triplicate wells. 2Schizont diameters, as measured by immunofluorescence microscopy and digital image 
analysis. Data represent mean [range] of n=19 to 49 schizonts per sample. NF135.C10 schizonts were 
larger than NF54 schizonts at day 2 (P < 0.05) and day 6 (P < 0.001) in both experiments and were also 
larger than NF166.C8 schizonts (P < 0.05 to P < 0.001 in all comparisons except experiment B2, day 2); 
NF166.68 schizonts were larger than NF54 schizonts at day 2 in experiment B2 (P < 0.001) and at day 6 in 
experiment B1 (P < 0.001). P values by one-way ANOVA with Tukey’s posttest. 3Number of parasite nuclei 
per well, as determined by qPCR; data represent median [range] of triplicate wells. 4Number of nuclei per 
schizont, as calculated by dividing the median #nuclei per well by the median #schizonts per well. 5Fold-
increase in number of nuclei per infected human hepatocyte from day 2 to day 6 after infection,  
as calculated by dividing the median #nuclei per schizont at day 6 after infection by that at day 2.
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Correlations between the in vitro human hepatocyte invasion 
assay and in vivo parasite dynamics
Given that identical sporozoite batches were used for both the human hepatocyte invasion 
assays and human infections in the CHMI-a study, we queried whether sporozoite infectivity 
in vitro might be predictive of blood-stage infection in vivo. The magnitude of the first wave 
of parasitemia emerging from the liver in study subjects inoculated with each strain (Table 1) 
appeared to correlate with the infectivity of sporozoites of that strain in the human hepatocyte 
invasion assay in vitro (Table 2) (Pearson’s R = 0.994, P = 0.068, n = 3 strains). Furthermore, a 
strong negative association existed between sporozoite infectivity in vitro and the prepatent 
period of that strain in vivo (R = −1.0, P = 0.005).
Discussion
Here, we systematically assessed the dynamics of the obligate liver stage of human malaria 
infection, from mosquito bite to the emergence of blood-stage parasites, by using three different 
clinical isolates of P. falciparum and directly linking data on sporozoite infectivity in an in vitro 
human hepatocyte invasion model with in vivo measurements of parasitemia in subjects 
undergoing CHMI.
Both in vitro and in vivo findings support the notion that a substantially greater initial burden 
of blood-stage parasites is released from the livers of subjects infected with the NF135.C10 or 
NF166.C8 P. falciparum strains than from those infected with the NF54 strain. This in turn has 
significant effects on the subsequent course of blood-stage infection, with total parasite numbers 
more quickly reaching levels detectable by thick smear microscopy, shortening the prepatent 
period by several days. The difference in parasite burden between strains in vivo was even 
greater than the differences in invasion and development observed in vitro, a phenomenon that 
may be partially explained by suboptimal conditions for sporozoite invasion and development 
in vitro as compared to in vivo. In support of this explanation, the diameter of the NF54 strain 
liver-stage schizonts in our human hepatocyte cultures in this study (Table 2), as well as in a 
previous study (10),was 1.5- to 5-fold smaller than those measured in vivo in two humanized 
mouse models [the fumarylacetoacetate hydrolase–deficient mouse (3) and the severe combined 
immunodeficient mouse homozygous for the urokinase-type plasminogen activator transgene 
under the albumin promoter (11)]. Measuring the size of liver-stage schizonts in these mouse 
models might reveal even bigger differences between P. falciparum isolates than those found 
here in vitro. Whereas more than a decade separates the original isolation date of each of these 
three strains of P. falciparum (table S2), the use of specific master cell banks (MCBs) for CHMI 
studies restricts the cumulative culture period for the generation of gametocytes of each strain. 
In our opinion, this is unlikely to explain the marked differences in phenotype of the strains in 
vivo with regard to liver-stage burden.
Both sporozoite infectivity (Fig. 2) and the size of mature liver-stage schizonts of strain NF135.
C10 in particular (Table 2) appeared to be greater than those for the NF54 strain, suggesting that 
two distinct mechanisms may be contributing to the greater number of merozoites released in 
vivo. In contrast, the duration of liverstage development was markedly similar between isolates 
2.
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(Fig. 1, D to F). Although the mean time to qPCR positivity was slightly longer for the NF54 strain, 
we regularly detected NF54 parasites in blood samples by day 6.5 after infection (Table 1) (12). 
The small magnitude of the first wave of NF54 parasitemia suggested that the earliest parasites 
to emerge from the liver may fall below the detection limit of the qPCR. In any case, this short 
delay in qPCR positivity (0.52 and 0.70 day relative to the NF135.C10 and NF166.C8 strains, 
respectively, across all studies, Table 1) would appear to form only a minor determinant of the 
overall delay in prepatent period (2.3 and 2.9 days, respectively; Fig. 1C).
Finally, the variability in both the timing and the magnitude of the first wave of parasitemia 
among subjects within each study group was relatively limited in comparison to the difference in 
that magnitude between groups, suggesting that innate host factors may have little influence on 
either the duration or efficiency of liver-stage development in primary P. falciparum infections 
in our study population.
Although no clear relationship has been found between salivary gland sporozoite load and 
the number of sporozoites inoculated by probing/feeding mosquitoes (13), higher salivary gland 
loads have been suggested to enhance the infectivity of sporozoites (14). However, NF54-infected 
mosquitoes used in the CHMI-a study actually contained higher salivary gland sporozoite loads 
than did NF166.C8-infected or NF135.C10-infected mosquitoes from the same colony (table S2), 
a finding that is consistent with batches of mosquitoes used for other CHMIs at our center (table 
S3). The advent of CHMIs using parenteral sporozoite inoculation allowing better control over 
the number of administered sporozoites may further help to disentangle this point.
As a direct consequence of their higher liver burden, the time frame between release of the 
first NF135.C10 and NF166.C8 parasites from the liver and the initiation of antimalarial treatment 
with atovaquone-proguanil (upon parasitemia attaining the threshold by thick smear microscopy) 
incorporated only a single erythrocytic cycle. This is insufficient to reliably determine their blood-
stage multiplication rate (5).
A possible limitation of this study is that sporozoite infectivity and the development of 
parasitemia were only assessed in malaria-naïve volunteers from malaria nonendemic countries. 
The observed infectivity between the parasite strains may be different in endemic populations 
with variable degrees of semi-immunity. Therefore, it will be of interest to compare these clones 
in CHMI in endemic settings. A further limitation is that only three P. falciparum isolates from 
different geographical backgrounds were tested for comparison in human hepatocyte cultures 
and by CHMI. It remains to be seen to what extent the three strains are representative of the 
overall diversity among the global P. falciparum population (15). Increasing the portfolio of 
P. falciparum clones for CHMI studies may provide further support for our findings. Both the 
NF135.C10 (9) and NF166.C8 strains described here were developed and characterized with 
the specific intent to increase the currently limited portfolio of P. falciparum strains available 
for heterologous challenge CHMI studies. For NF54 or its derivative clone 3D7, the minimum 
infecting dose to guarantee a 100% infection rate in malaria-naïve subjects in such CHMI studies 
is generally held to be five mosquito bites (16), 3200 cryopreserved sporozoites inoculated 
intravenously (17), or 75,000 cryopreserved sporozoites inoculated intramuscularly (18). Given 
the higher observed infectivity of NF135.C10 and NF166.C8 sporozoites, the minimum dose to 
reliably achieve 100% infection must be explored in further studies. Whereas interventions that 
target hepatocyte invasion aim at one of the two most constrained bottlenecks in the parasite’s 
life cycle (4), our data indicate that relatively limited but relevant heterogeneity does exist among 
strains with regard to sporozoite infectivity (Fig. 2), which should be taken into account when 
designing and evaluating such interventions.
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A major advantage of CHMI studies is the relatively small number of subjects required for the 
evaluation of vaccine efficacy, due to the homogeneity of the profile of parasitemia within each 
group and between homologous groups, as illustrated here by our CHMI-a and CHMI-b studies. 
Given the clear-cut difference in parasite dynamics between P. falciparum isolates, however, 
homologous challenge studies of malaria vaccines will remain insufficiently representative, 




Two CHMIs were performed using the well-established P. falciparum research strain NF54 and 
the new clones NF135.C10 and NF166.C8. The primary objective of the first study (CHMI-a) 
was to compare parasite dynamics of these isolates during infection, and that of the second 
(CHMI-b) study was to determine the proportion of subjects in each group who developed 
patent parasitemia, as described below. Secondary objectives of both studies included clinical 
parameters and further measures of parasite kinetics.
Healthy malaria-naïve adult (age 18 to 35 years) Dutch volunteers were recruited at the 
Harbour Hospital, Rotterdam, after signing informed consent. Our screening procedures have 
been described previously (19), and a complete list of inclusion/exclusion criteria is provided in 
table S5. In the first CHMI study described here (CHMI-a), 15 subjects (9 men and 6 women; table 
S1) were randomly allocated (ratio 1:1:1) to three parallel groups of n = 5, to be infected by bites 
of five mosquitoes per subject carrying, respectively, the NF54 strain of P. falciparum, the NF135.
C10 clone, or the new NF166.C8 clone. In the second study (CHMI-b), 24 subjects were randomly 
allocated (ratio 1:1:1:1:1:1) to six parallel groups of n = 4, to bites by one, two, or five mosquitoes 
carrying, respectively, either NF135.C10 or NF166.C8 strains. For comparison with CHMI-a, only 
the two CHMI-b groups exposed to the bites of five infectious mosquitoes are reported here 
(that is, eight subjects in total, of whom three were men, and five were women; table S1). Flow 
charts for both studies are shown in fig. S1. Sample sizes were chosen pragmatically, based 
on longstanding experience with NF54 and (limited) NF135.C10 data. The CHMI-a study was 
powered to detect a 0.9 log (7.9-fold) difference in parasite burden between strains.
At inclusion, subjects received a unique pseudonymized study code. Once the predetermined 
number of subjects per study was included, two departmental employees not otherwise involved 
in the study linked a random number generated in Excel to each study code and allocated 
the required number of study codes to each group, using simple ranking of the associated 
random numbers. This allocation list was provided only to insectary technicians, who prepared 
feeding cages containing the required strain and number of P. falciparum–infected mosquitoes 
and labeled these otherwise identical cages with only the respective study code. Thus, study 
subjects, clinical investigators, and laboratory personnel assessing study end points (thick smear 
microscopy and qPCR) remained blinded to group allocation throughout each study.
All subjects within each study underwent infection on the same day, and considering the 
extremely close monitoring of CHMI study subjects for safety reasons, all subjects were expected 
2.
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to complete follow-up. Data from all subjects were included in the study, and there were no 
specific rules for data exclusion, outliers, or premature cessation of data collection (other than if 
required for safety reasons after consultation with the sponsor, safety monitor, and Data Safety 
and Monitoring Board).
Culture and characterization of clinical parasite isolates
P. falciparum blood-stage parasites were introduced into semi-automated culture from peripheral 
whole-blood samples of patients with clinical malaria and used to generate infective Anopheles 
stephensi mosquitoes, as described before (20). The origins of NF54 and NF135 strains of P. 
falciparum have been described previously (8, 9). The NF166 strain of P. falciparum originated 
in 2010 as a clinical isolate (parasitemia 0.5 to 1%) from a child who had recently visited Guinea 
(West Africa). The clone NF166.C8 was obtained by limiting dilution culturing and established as 
a stable producer of fertile gametocytes and subsequently oocysts in infected mosquitoes (table 
S2). To minimize a potential confounding effect, gametocytes used to infect mosquitoes for our 
CHMI studies are generated following a strict culture procedure. When a cryopreserved aliquot 
of any isolate from our MCB is thawed and brought into culture, new aliquots of the culture are 
frozen down again for future use after the first four rounds of subculture. The remaining culture is 
then maintained for the generation of gametocytes, generally between the 15th and 25th rounds 
of subculture. Because in vitro parasites lose their ability to generate gametocytes beyond ±25 
rounds of subculture, such cultures are discontinued. The MCB of NF54 was generated from the 
estimated 10th to 15th subculture since its original isolation in the 1970s. For NF135, the MCB was 
generated from the sixth subculture since isolation, and for NF166 from the fourth subculture.
The identities of NF54, NF135.C10, and NF166.C8 were defined by assessing the polymorphic 
regions of three P. falciparum antigenic genes by PCR in a method adapted from Snounou et al. 
(21). Briefly, parasite DNA was isolated using QIAamp DNA Blood Mini Kit (Qiagen) and amplified 
with GoTaq G2 Flexi Polymerase (Promega) using specific primers for the polymorphic repetitive 
RII region of P. falciparum GLURP (22); the K1, MAD20, and R033 allelic variants of block 2 of 
MSP1 (23); and the IC1 and FC27 variants of block 3 of
MSP2 (24) (all primers from Invitrogen); 18S ribosomal DNA was used as a loading control. 
The sensitivity of NF166.C8, NF135.C10, and NF54 to dihydroartemisinin (Sigma-Tau), chloroquine 
diphosphate salt (Sigma-Aldrich), mefloquine, proguanil (British Pharmacopoeia), atovaquone 
(GlaxoSmithKline), and lumefantrine (Novartis) was tested by the Malaria SYBR Green I-Based 
Fluorescence Assay in triplicate experiments (25). See also table S2 and fig. S2.
Controlled human malaria infections
Mosquitoes in small cages were allowed to feed for 10min on the forearms of study subjects. All 
blood-engorged mosquitoes were dissected to confirm sporozoite carriage. Where necessary, 
study subjects were exposed to additional mosquitoes until precisely the predetermined number 
of infective bites was achieved. From day 5 after infection, subjects were seen twice daily as 
outpatients. Solicited and unsolicited adverse events and vital parameters were recorded at 
each visit and venous whole blood was drawn for thick blood smear, qPCR (see below), safety 
parameters, and exploratory assays. Adverse events were graded as mild (not interfering with), 
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moderate (interfering with), or severe (prohibiting daily activities). Respective grading of fever 
was 37.5° to 38.0°C, 38.0° to 39.0°C, and > 39.0C°. Adverse events were recorded by clinical 
investigators as being probably, possibly, or unlikely related to study procedures.
In CHMI-a, subjects were treated with a standard regimen of atovaquone-proguanil 
(Malarone, 1000/400 mg daily for 3 days) upon their first positive thick blood smear (defined as 
≥2 parasites per 225 high-powered fields, equating to 0.5 ml of whole blood examined). In CHMI-
b, subjects were treated with the same regimen as soon as two consecutive whole-blood samples 
were positive by qPCR (defined as > 500 parasites/ml, calibrated against a daily standard curve 
of known parasite concentrations). The change in methodology between studies was proposed 
(12) and implemented to minimize potential safety risks upon a request by Netherlands’ Central 
Committee on Human Research (CCMO), following concerns over a cardiac SAE possibly related 
to CHMI in an earlier study (26). Sequential daily thick smears/qPCRs were continued after 
treatment in each subject until complete clearance of blood-stage parasites. CHMI-a whole-
blood samples were also retrospectively analyzed by qPCR. These studies were approved by 
Netherlands’ CCMO (NL41004.078.12 and NL48704.000.14).
Quantitative real-time fluorescence polymerase chain reaction
P. falciparum parasitemia was quantified by qPCR as described before (27) with some 
modifications. Briefly, isolated DNA was resuspended in 100 ml of H2O, using 5 µl as template 
and the TaqMan MGB probe AAC AAT TGG AGG GCA AG-FAM. Samples for post hoc analysis 
were stored at −80°C. For each sample (including standard curve dilutions), two qPCR replicates 
were performed; if these values differed by >5%, then the sample was remeasured a third time. 
In addition, all samples were spiked with heterologous DNA as an extraction control; if the qPCR 
value of the extraction control differed by > 5% from the running average of all other samples, 
then the extraction process for that sample was repeated. Quantification of P. falciparum nuclei 
in wells of the human hepatocyte infectivity assay was performed using the same qPCR.
Primary human hepatocyte infectivity assay
In vitro sporozoite infectivity assays in human hepatocytes were performed, as described 
previously (6), at two different laboratories. Briefly, fresh primary hepatocytes derived from 
patients undergoing elective (partial) hepatectomy were plated in 96-well plates (50,000 cells 
per well). Two to five days after plating the human hepatocytes, sporozoites were dissected 
from the salivary glands of 80 to 110 infected mosquitoes per P. falciparum strain and added 
to the human hepatocyte wells in triplicate. In the first in vitro experiment (experiment A), 
sporozoites were harvested from the exact same batches of mosquitoes used on the same day 
to infect human subjects in CHMI-a; 40,000 sporozoites were added per human hepatocyte well. 
In subsequent in vitro experiments (B1 and B2), sporozoites were harvested from mosquitoes 
fed on independent gametocyte cultures used to subsequently infect subjects in CHMI-b, and 
50,000 sporozoites were added per well. After 2 to 6 days, the number of human hepatocytes 
in each well harboring viable parasites was assessed by intracellular staining with anti–P. 
falciparum HSP-70 rabbit polyclonal antibody (SPC-186C/D, StressMarq Biosciences) followed 
by fluorescence microscopy; no instances of >1 invaded sporozoite per human hepatocyte were 
2.
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observed. Discrimination between sporozoite invasion of/adherence to human hepatocytes was 
achieved by staining with fluorescent monoclonal antibodies against circumsporozoite protein 
(CSP) before cell permeabilization (28); the proportion of adherents (that is, HSP-70+CSP+-double 
positive, noninvaded parasites) was generally <5% at day 2 after infection and consistently 
<0.5% at day 6 after infection. The diameter of n = 19 to 49 liver-stage schizonts per strain was 
measured at day 2 and day 6 after infection by fluorescence microscopy and digital image analysis 
(LeicaDMI6000B). Total numbers of parasite nuclei per well were determined by qPCR in separate 
triplicate wells after discarding the culture supernatant. It was technically infeasible to perform 
both microscopy and qPCR on the same wells. The median number of merozoites per liver-
stage schizont was calculated for each strain as follows: ([median #parasite nuclei in triplicate 
wells] − [median #adhered (noninvaded) parasites in triplicate wells])/([median #infected human 
hepatocytes in triplicate wells]). Investigators carrying out the in vitro hepatocyte infectivity 
assay were blinded as to the strain of the sporozoites.
Statistical analysis
Differences in continuous variables between groups of study subjects were compared by one-way 
ANOVA/Tukey’s post hoc test (CHMI-a, three groups), unpaired t test (CHMI-b, two groups), or 
one-sample t test (CHMI-b, two groups when all values for one group were identical). Differences 
in categorical variables between groups were compared by χ2/Fisher’s exact test. Differences 
in in vitro invasive capacity between isolates were compared by repeated-measures ANOVA/
Tukey’s post hoc test (three groups). Correlations between in vitro and in vivo variables were 
assessed by Pearson’s test on the mean value of each variable per strain; where appropriate, 
variables were first log-transformed. Two-sided P < 0.05 was considered statistically significant 
in all tests. Parasite densities below the lower quantification limit of the qPCR (35 parasites/ml 
in CHMI-a and 50 parasites/ml in CHMI-b) were plotted at 0.5× the log value of that limit. The 
magnitude of the initial wave of parasitemia emerging from the liver was defined as the highest 
parasite density measured by qPCR per subject between day 6.5 and 8.0 after infection.
Acknowledgments
We thank the subjects who participated in the two CHMI studies described here. We are 
indebted to N. Molhoek, M. IJsselstijn, S. Goeijenbier, and K. Teelen for logistical support and to 
R. Siebelink-Stoter for parasite culture. We thank J. Klaassen, A. Pouwelsen, L. Pelser-Posthumus, 
and J. Kuhnen for assistance in generating infectious mosquitoes and the technicians of the 
laboratory of the Harbour Hospital and the Department of Medical Microbiology of the Erasmus 
MC for reading thick smears and performing qPCRs. We are grateful to B. Krenning for assistance 
in the cardiac screening of study subjects and to E. van Gorp for acting as safety monitor. H. de 
Wilt supplied fresh liver tissue from patients undergoing elective (partial) hepatectomy. These 
studies are registered with ClinicalTrials.gov with registration numbers NCT01627951 (29) and 
NCT02149550 (30).
Marijke Langenberg BNW proef V3.indd   36 27-04-21   08:54
37
Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers
References
1. R. Amino, S. Thiberge, B. Martin, S. Celli, S. Shorte, 
F. Frischknecht, R. Ménard, Quantitative imaging 
of Plasmodium transmission from mosquito to 
mammal. Nat. Med. 12, 220–224 (2006).
2. M. M. Mota, G. Pradel, J. P. Vanderberg, J. 
C. R. Hafalla, U. Frevert, R. S. Nussenzweig, 
V. Nussenzweig, A. Rodríguez, Migration of 
Plasmodium sporozoites through cells before 
infection. Science 291, 141–144 (2001).
3. A. M. Vaughan, S. A. Mikolajczak, E. M. Wilson, M. 
Grompe, A. Kaushansky, N. Camargo, J. Bial, A. Ploss, 
S. H. I. Kappe, Complete Plasmodium falciparum 
liver-stage development in liver-chimeric mice. J. 
Clin. Invest. 122, 3618–3628 (2012).
4. R. E. Sinden, A biologist’s perspective on 
malaria vaccine development. Hum. Vaccines 
6, 3–11 (2010).
5. M. Roestenberg, S. J. de Vlas, A.-E. Nieman, 
R. W. Sauerwein, C. C. Hermsen, Efficacy of 
preerythrocytic and blood-stage malaria 
vaccines can be assessed in small sporozoite 
challenge trials in human volunteers. J. Infect. 
Dis. 206, 319–323 (2012).
6. A. Siau, O. Silvie, J.-F. Franetich, S. Yalaoui, 
C. Marinach, L. Hannoun, G.-J. van Gemert, 
A. J. F. Luty, E. Bischoff, P. H. David, G. 
Snounou, C. Vaquero, P. Froissard, D. Mazier, 
Temperature shift and host cell contact up-
regulate sporozoite expression of Plasmodium 
falciparum genes involved in hepatocyte 
infection. PLOS Pathog. 4, e1000121 (2008).
7. L. Dembélé, J.-F. Franetich, A. Lorthiois, A. Gego, 
A.-M. Zeeman, C. H. M. Kocken, R. Le Grand, 
N. Dereuddre-Bosquet, G.-J. van Gemert, R. 
Sauerwein, J.-C. Vaillant, L. Hannoun, M. J. 
Fuchter, T. T. Diagana, N. A. Malmquist, A. 
Scherf, G. Snounou, D. Mazier, Persistence and 
activation of malaria hypnozoites in long-term 
primary hepatocyte cultures. Nat. Med. 20, 
307–312 (2014).
8. H. A. Delemarre-van de Waal, F. C. de Waal, A 
2d patient with tropical malaria contracted in a 
natural way in the Netherlands. Ned. Tijdschr. 
Geneeskd. 125, 375–377 (1981).
9. A. C. Teirlinck, M. Roestenberg, M. van de 
Vegte-Bolmer, A. Scholzen, M. J. L. Heinrichs, 
R. Siebelink-Stoter, W. Graumans, G.-J. van 
Gemert, K. Teelen, M. W. Vos, K. Nganou-
Makamdop, S. Borrmann, Y. P. A. Rozier, M. A. A. 
Erkens, A. J. F. Luty, C. C. Hermsen, B. K. L. Sim, 
L. van Lieshout, S. L. Hoffman, L. G. Visser, R. 
W. Sauerwein, NF135.C10: A new Plasmodium 
falciparum clone for controlled human malaria 
infections. J. Infect. Dis. 207, 656–660 (2013).
10. D. Mazier, R. L. Beaudoin, S. Mellouk, P. Druilhe, 
B. Texier, J. Trosper, F. Miltgen, I. Landau, C. 
Paul, O. Brandicourt, M. Gentilini, Complete 
development of hepatic stages of Plasmodium 
falciparum in vitro. Science 227, 440–442 
(1985).
11. S. Morosan, S. Hez-Deroubaix, F. Lunel, L. 
Renia, C. Giannini, N. Van Rooijen, S. Battaglia, 
C. Blanc, W. Eling, R. Sauerwein, L. Hannoun, J. 
Belghiti, C. Brechot, D. Kremsdorf, P. Druilhe, 
Liver-stage development of Plasmodium 
falciparum in a humanized mouse model. J. 
Infect. Dis. 193, 996–1004 (2006).
12. J. Walk, R. Schats, M. C. C. Langenberg, I. 
J. Reuling, K. Teelen, M. Roestenberg, C. 
C. Hermsen, L. G. Visser, R. W. Sauerwein, 
Diagnosis and treatment based on quantitative 
PCR after controlled human malaria infection. 
Malar. J. 15, 398 (2016).
13. J. C. Beier, J. R. Davis, J. A. Vaughan, B. H. 
Noden, M. S. Beier, Quantitation of Plasmodium 
falciparum sporozoites transmitted in vitro by 
experimentally infected Anopheles gambiae 
and Anopheles stephensi. Am. J. Trop. Med. Hyg. 
44, 564–570 (1991).
2.
Marijke Langenberg BNW proef V3.indd   37 27-04-21   08:54
38
CHAPTER 2
14. C. B. Pumpuni, C. Mendis, J. C. Beier, Plasmodium 
yoelii sporozoite infectivity varies as a function 
of sporozoite loads in Anopheles stephensi 
mosquitoes. J. Parasitol. 83, 652–655 (1997).
15. T. Mita, T. Jombart, Patterns and dynamics of 
genetic diversity in Plasmodium falciparum: 
What past human migrations tell us about 
malaria. Parasitol. Int. 64, 238–243 (2015).
16. M. Roestenberg, G. A. O’Hara, C. J. A. Duncan, 
J. E. Epstein, N. J. Edwards, A. Scholzen, A. J. 
A. M. van der Ven, C. C. Hermsen, A. V. S. Hill, 
R. W. Sauerwein, Comparison of clinical and 
parasitological data from controlled human 
malaria infection trials. PLOS ONE 7, e38434 
(2012).
17. B. Mordmuller, C. Supan, K. L. Sim, G. P. 
Gómez-Pérez, C. L. Ospina Salazar, J. Held, 
S. Bolte, M. Esen, S. Tschan, F. Joanny, C. 
Lamsfus Calle, S. J. Z. Lohr, A. Lalremruata, 
A. Gunasekera, E. R. James, P. F. Billingsley, 
A. Richman, S. Chakravarty, A. Legarda, J. 
Muñoz, R. M. Antonijoan, M. R. Ballester, S. L. 
Hoffman, P. L. Alonso, P. G. Kremsner, Direct 
venous inoculation of Plasmodium falciparum 
sporozoites for controlled human malaria 
infection: A dose-finding trial in two centres. 
Malar. J. 14, 117 (2015).
18. G. P. Gómez-Pérez, A. Legarda, J. Muñoz, B. K. 
L. Sim, M. R. Ballester, C. Dobaño, G. Moncunill, 
J. J. Campo, P. Cisteró, A. Jimenez, D. Barrios, B. 
Mordmüller, J. Pardos, M. avarro, C. J. Zita, C. 
A. Nhamuave, A. L. García-Basteiro, A. Sanz, M. 
Aldea, A. Manoj, A. Gunasekera, P. F. Billingsley, 
J. J. Aponte, E. R. James, C. Guinovart, R. M. 
Antonijoan, P. G. Kremsner, S. L. Hoffman, P. L. 
Alonso, Controlled human malaria infection by 
intramuscular and direct venous inoculation 
of cryopreserved Plasmodium falciparum 
sporozoites in malaria-naïve volunteers: Effect 
of injection volume and dose on infectivity 
rates. Malar. J. 14, 306 (2015).
19. E. M. Bijker, G. J. H. Bastiaens, A. C. Teirlinck, 
G.-J. van Gemert, W. Graumans, M. van de 
Vegte-Bolmer, R. Siebelink-Stoter, T. Arens, 
K. Teelen, W. Nahrendorf, E. J. Remarque, W. 
Roeffen, A. Jansens, D. Zimmerman, M. Vos, B. 
C. L. van Schaijk, J. Wiersma, A. J. A. M. van der 
Ven, Q. de Mast, L. van Lieshout, J. J. Verweij, 
C. C. Hermsen, A. Scholzen, R. W. Sauerwein, 
Protection against malaria after immunization 
by chloroquine prophylaxis and sporozoites is 
mediated by preerythrocytic immunity. Proc. 
Natl. Acad. Sci. U.S.A. 110, 7862–7867 (2013).
20. T. Ponnudurai, A. H. Lensen, G. J. A. van Gemert, 
M. P. E. Bensink, M. Bolmer, J. H. Meuwissen, 
Infectivity of cultured Plasmodium falciparum 
gametocytes to mosquitoes. Parasitology 98 
(Pt. 2), 165–173 (1989).
21. G. Snounou, X. Zhu, N. Siripoon, W. Jarra, S. 
Thaithong, K. N. Brown, S. Viriyakosol, Biased 
distribution of msp1 and msp2 allelic variants 
in Plasmodium falciparum populations in 
Thailand. Trans. R. Soc. Trop. Med. Hyg. 93, 
369–374 (1999).
22. M. B. Borre, M. Dziegiel, B. Høgh, E. Petersen, 
K. Rieneck, E. Riley, J. F. Meis, M. Aikawa, K. 
Nakamura, M. Harada, A. Wind, P. H. Jakobsen, 
J. Crowland, S. Jepsen, N. H. Axelsen, J. 
Vuust, Primary structure and localization 
of a conserved immunogenic Plasmodium 
falciparum glutamate rich protein (GLURP) 
expressed in both the preerythrocytic and 
erythrocytic stages of the vertebrate life cycle. 
Mol. Biochem. Parasitol. 49, 119–131 (1991).
23. L. H. Miller, R. J. Howard, R. Carter, M. F. Good, 
V. Nussenzweig, R. S. Nussenzweig, Research 
toward malaria vaccines. Science 234, 1349–
1356 (1986).
24. J. A. Smythe, R. L. Coppel, K. P. Day, R. K. 
Martin, A. M. Oduola, D. J. Kemp, R. F. Anders, 
Structural diversity in the Plasmodium 
falciparum merozoite surface antigen 2. Proc. 
Natl. Acad. Sci. U.S.A. 88, 1751–1755 (1991).
Marijke Langenberg BNW proef V3.indd   38 27-04-21   08:54
39
Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers
25. J. D. Johnson, R. A. Dennull, L. Gerena, M. 
Lopez-Sanchez, N. E. Roncal, N. C. Waters, 
Assessment and continued validation of the 
malaria SYBR green I-based fluorescence assay 
for use in malaria drug screening. Antimicrob. 
Agents Chemother. 51, 1926–1933 (2007).
26. M. P. A. van Meer, G. J. H. Bastiaens, M. 
Boulaksil, Q. de Mast, A. Gunasekera, S. L. 
Hoffman, G. Pop, A. J. A. M. van der Ven, R. 
W. Sauerwein, Idiopathic acute myocarditis 
during treatment for controlled human malaria 
infection: A case report. Malar. J. 13, 38 (2014).
27. E. M. Bijker, R. Schats, J. M. Obiero, M. C. Behet, 
G.-J. van Gemert, M. van de Vegte-Bolmer, W. 
Graumans, L. van Lieshout, G. J. H. Bastiaens, K. 
Teelen, C. C. Hermsen, A. Scholzen, L. G. Visser, 
R. W. Sauerwein, Sporozoite immunization of 
human volunteers under mefloquine prophylaxis 
is safe, immunogenic and protective: A double-
blind randomized controlled clinical trial. PLOS 
ONE 9, e112910 (2014).
28. B. C. L. van Schaijk, C. J. Janse, G.-J. van Gemert, 
M. R. van Dijk, A. Gego, J.-F. Franetich, M. 
van de Vegte-Bolmer, S. Yalaoui, O. Silvie, 
S. L. Hoffman, A. P. Waters, D. Mazier, R. 
W. Sauerwein, S. M. Khan, Gene disruption 
of Plasmodium falciparum p52 results in 
attenuation of malaria liver stage development 
in cultured primary human hepatocytes. PLOS 





31. D. F. Verhage, D. S. C. Telgt, J. T. Bousema, C. 
C. Hermsen, G. J. A. van Gemert, J. W. M. van 
der Meer, R. W. Sauerwein, Clinical outcome 
of experimental human malaria induced by 
Plasmodium falciparum-infected mosquitoes. 
Neth. J. Med. 63, 52–58 (2005).
32. M. Roestenberg, M. McCall, J. Hopman, J. 
Wiersma, A. J. F. Luty, G. J. van Gemert, M. 
van de Vegte-Bolmer, K. Teelen, T. Arens, L. 
Spaarman, Q. de Mast, W. Roeffen, G. Snounou, 
L. Rénia, Andre van de Ven, C. C. Hermsen, 
R. Sauerwein, Protection against a malaria 
challenge by sporozoite inoculation. N. Engl. J. 
Med. 361, 468–477 (2009).
33. M. Roestenberg, A. C. Teirlinck, M. B. McCall, 
K. Teelen, K. N. Makamdop, J. Wiersma, T. 
Arens, P. Beckers, G. van Gemert, M. van de 
Vegte-Bolmer, A. J. van der Ven, A. J. F. Luty, 
C. C. Hermsen, R. W. Sauerwein, Long-term 
protection against malaria after experimental 
sporozoite inoculation: An open-label follow-up 
study. Lancet 377, 1770–1776 (2011).
34. E. M. Bijker, A. C. Teirlinck, R. Schats, G.-J. 
van Gemert, M. van de Vegte-Bolmer, L. van 
Lieshout, J. IntHout, C. C. Hermsen, A. Scholzen, 
L. G. Visser, R. W. Sauerwein, Cytotoxic markers 
associate with protection against malaria in 
human volunteers immunized with Plasmodium 
falciparum sporozoites. J. Infect. Dis. 210, 
1605–1615 (2014).
35. E. M. Bijker, R. Schats, L. G. Visser, R. W. 
Sauerwein, A. Scholzen, Ex vivo lymphocyte 
phenotyping during Plasmodium falciparum 
sporozoite immunization in humans. Parasite 
Immunol. 37, 590–598 (2015).
36. G. J. H. Bastiaens, M. P. A. van Meer, A. 
Scholzen, J. M. Obiero, M. Vatanshenassan, 
T. van Grinsven, B. K. L. Sim, P. F. Billingsley, 
E. R. James, A. Gunasekera, E. M. Bijker, G.-J. 
van Gemert, M. van de Vegte-Bolmer, W. 
Graumans, C. C. Hermsen, Q. de Mast, A. J. 
van der Ven, S. L. Hoffman, R. W. Sauerwein, 
Safety, immunogenicity, and protective efficacy 
of intradermal immunization with aseptic, 
purified, cryopreserved Plasmodium falciparum 
sporozoites in volunteers under chloroquine 
prophylaxis: A randomized controlled trial. Am. 
J. Trop. Med. Hyg. 94, 663–673 (2016).
2.




Figure S1. Study flow charts. A. CHMI-a (recruitment started August 2012, completed September 2012; 
day of infection 25-09-2012; final day of follow-up 30-10-2012); B. CHMI-b (recruitment started August 
2014, completed October 2014; day of infection 07-10-2014; final day of follow-up 11-11-2014). Note: 
for comparison with CHMI-a, only the results of the two CHMI-b groups exposed to the bites of five 
infectious mosquitoes are presented in this paper.
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Figure S2. Genetic characterization of P. falciparum isolates. PCRs for 18S rDNA, GLURP, the K1, 
MAD20 & R033 allelic variants of MSP1 and the IC1 & FC27 variants of MSP2 were performed on the P. 
falciparum isolates NF54, NF166.C8 & NF135.C10. Note: NF54 and NF166.C8 failed to produce any MSP1 
MAD20 band. M – 100bp marker.
Table S1. Study demographics.
NF54 NF135.C10 NF166.C8
CHMI-a
gender (male / total) 5 / 5 2 /5 2 / 5
age (median [range]) 19 [18-21] 22 [18-27] 24 [18-35]
CHMI-b1
gender (male / total) 0 / 4 3 / 4
age (median [range]) 22.5 [19-27] 24 [19-25]
1Data only shown for the two CHMI-b groups exposed to bites of five infectious mosquitoes.
2.
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Table S2. Characteristics of P. falciparum isolates used in CHMI studies.
NF54 NF135.C10 NF166.C8
Country of origin Netherlands  
(West Africa)
Cambodia Guinea
Year of isolation 1979 1993 2010
Drug sensitivity (IC50):
Chloroquine (nM) 8.8 96 9.9
Mefloquine (nM) 19 37 11
Atovaquone (nM) 1.2 0.94 0.37
Proguanil (µM) 0.57 169 0.29
Dihydroartemisinin (nM) 0.36 0.19 0.05
Lumefantrine (nM) 94 122 49
Parasite batches used in 
individual CHMIs: CHMI-a CHMI-b CHMI-a CHMI-b CHMI-a CHMI-b
No. sub-cultures since 
thawing of Master Cell 
Bank aliquot
23 - 17 21 18 17
proportion of oocyst-
infected mosquitoes
10/10 - 10/10 10/10 10/10 10/10
mean oocyst count/
mosquito (n=10)
20.1 - 15.6 32.5 15.7 15.2
proportion of sporozoite-
infectious mosquitoes
9/10 - 9/10 10/10 10/10 10/10
mean sporozoite count/
mosquito (n=10)
101x103 - 69x103 69x103 40x103 51x103
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Table S3. Overview of all comparable CHMI studies performed at our center.
Study# (ref#) Year Treatment 
threshold1









12 (31) 2000 TBS (NS) 5 - - N/A N/A N/A
22 (31) 2001 TBS (NS) 5 - - N/A N/A N/A
32 (31) 2002 TBS (NS) 5 - - N/A N/A N/A
42 (31) 2003 TBS (NS) 5 - - N/A N/A N/A
5 (32) 2007 TBS 5 - - 31,500 - -
63 2008 TBS 18 - - 72,800 - -
7 (33) 2009 TBS 5 - - 88,000 - -
8 (9) 2010 TBS 4 3 - 69,000 12,500
9 (34) 2011 TBS 5 - - 79,500 - -
10 (19) 2011 TBS 5 - - 100,000 - -
11 (29) 2012 TBS 4 - - 98,250 - -
12 (CHMI-a)4 2012 TBS 5 5 5 101,250 69,000 40,000
13 (35) 2012 TBS - 5 - - 38,250 -
14 (36) 2012 TBS 5 - - 75,800 - -
15 (36) 2013 qPCR 4 - - 98,000 - -
16 (CHMI-b)4 2014 qPCR - 4 4 - 69,000 51,000
17 2015 qPCR 5 - - 74,000 - -






Total 90 22 14
1In initial studies at our centre, subjects were treated upon positive thick blood smear (TBS), whereas in more 
recent studies treatment was initiated upon positive quantitative PCR (qPCR). The lower detection threshold 
of the latter results in shorter pre-patent periods, lower parasitaemia at time of treatment and hence 
improved tolerability & safety for study subjects. In the very earliest studies, the methodology for performing 
thick blood smear analysis was not yet standardised (NS), which can result in subtly different detection 
thresholds between subjects and between studies. For meta-analysis of pre-patent periods and of highest 
parasite densities (usually at time of treatment), we have thus limited comparisons to those 10 studies (#5-
14, including n = 56 NF54, n = 13 NF135.C10 and n = 5 NF166.C8 subjects) in which standardised thick blood 
smears were used to initiate treatment. For meta-analysis of time to first qPCR positivity and magnitude of 
the first wave of parasitaemia to emerge from the liver, all 18 studies are included.
2In the very earliest studies at our centre, subjects were exposed to the bites of between 4-7 P. falciparum 
NF54-infected mosquitoes; in all subsequent studies listed, all subjects were exposed to the bites of precisely 
5 mosquitoes infected with the given isolate. No statistically significant difference was observed in the height 
of the first wave of parasitaemia in these first four studies compared to all later studies involving NF54.
3Subjects were immunised with a candidate malaria vaccine prior to CHMI, but where wholly unprotected 
against challenge.
4Studies for which directly-linked in vitro data on sporozoite invasion are available (boldface), as presented in 
this manuscript.
5Subjects were infected in two groups, for which two separate batches of P. falciparum-infected mosquitoes 
were used.
2.
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table S4b. Adverse events by severity grade during CHMI-b9
NF135.C10 (n=4) NF166.C8 (n=4)
Subjects1 Duration2 Grade3 Subjects1 Duration2 Grade3
All adverse events
Fever 4 0.7 [0.2-1.9] 2 [1-3] 1 1.0 . 2 .
Headache 3 1.3 [0.0-3.6] 1 [1-2] 3 1.8 [0.3-2.9] 2 [1-3]
Malaise/fatigue 4 2.7 [1.4-3.6] 1 [1-2] 3 3.9 [0.7-8.3] 2 [1-2]
Myalgia 3 1.9 [1.0-3.3] 1 [1-2] 2 0.7 [0.6-0.7] 1 [1-1]
Arthralgia 1 1.0 . 1 . - - -
Nausea6 4 0.7 [0.0-1.6] 1 [1-2] 1 0.2 . 1 .
Chills/rigors 3 1.3 [0.8-2.0] 2 [1-2] 3 0.7 [0.1-1.3] 1 [1-2]
Diarrhoea - - - - - -
Abdominal pain6 2 1.1 [0.1-2.1] 1 [1-1] 1 1.4 . 1 .
Unsolicited7 2 (2) 4.0 . 1 [1-1] 2 (4) 2.4 [0.0-8.3] 1 [1-2]
Any8 4 (27) 1.4 [0.0-4.0] 1 [1-3] 4 (18) 1.8 [0.0-8.3] 1 [1-3]
Grade 3 AEs
Fever 1 1.9 . 1 2.9 .
Any8 1 (1) 1.9 . 1 (1) 2.9 .
1Number of subjects per group experiencing adverse event. Multiple similar events/episodes per subject were 
counted as one, with cumulative duration and maximum gradation recorded. For Unsolicited and Any adverse 
events, total numbers of events/episodes per group are shown in parentheses.
2In days; data represent mean [range] per group.
3AE gradation: 1=mild, 2=moderate, 3=severe; Fever gradation respectively: 37.5-38.0°C, 38.0-39.0°C, >39.0°C; 
data represent medians [range].
4Two NF135.C10 subjects and two NF166.C8 subjects (those with grade 3 symptoms) held persisting fever 
across the third and final day atovaquone-proguanil treatment, which subsequently resolved spontaneously.
5Mean difference in duration of malaise/fatigue: 2.6 [95% CI 0.0 to 5.1] days between NF54 and NF135.C10 (P < 
0.05); 2.6 [95% CI 0.0 to 5.1] days between NF54 and NF166.C8 (P < 0.05); 0.0 [95% CI -2.6 to 2.5] days between 
NF135.C10 and NF166.C8 (P > 0.05); all comparisons by one-way ANOVA/Tukey’s post-hoc test.
6Gastro-intestinal complaints, including nausea (but not vomiting), diarrhoea and abdominal pain were mainly 
experienced following intake of atovaquone-proguanil.
7Unsollicited adverse events in CHMI-a included 5 episodes of common cold, 2 of tender submandibular 
swelling, 1 of cold sore, 2 of anorexia, 1 of gastric reflux, 2 of syncope, 1 of hyperventilation syndrome, 1 of 
blurry vision, 1 of mild oedema orbitae and 1 of lumbago. In CHMI-b, there was 1 episode of atypical chest 
pain, 1 of dizziness, 1 of syncope, 1 of a minor transport accident, 1 of influenza-like illness (ongoing at the 
final day of follow-up) and 1 subject developed haematomas in both anticubital fossae.
8No other statistically significant difference in frequency, duration or gradation of any adverse events was 
observed between the three groups.
9Data only shown for the two CHMI-b groups exposed to bites of five infectious mosquitoes.
2.
Marijke Langenberg BNW proef V3.indd   45 27-04-21   08:54
46
CHAPTER 2
Table S5. Inclusion and exclusion criteria for CHMI studies.
CHMI-a Inclusion criteria
1. Males and females aged 18-35 years
2. In general good health based on history, physical examination and basic haematology and 
biochemistry
3. Negative pregnancy test for females
4. Use of adequate contraception for females
5. Signed informed consent, based on a thorough understanding of the concept and 
procedures of the study
6. Volunteer agrees to allow informing his/her general practitioner about participation and 
agrees to sign a request for medical information from the GP concerning any contra-
indications for participation in the study
7. Willingness to undergo a Pf sporozoite challenge
8. Agreement to stay in a hotel close to the trial center during part of the study (day 5 until 
three days post-treatment)
9. Reachable (24/7) by mobile telephone during the whole study period
10. Available to attend all study visits
11. Agreement to refrain from blood donation to Sanquin or for other purposes, during the 
course of the study and thereafter following Sanquin guidelines.
12. Willingness to undergo an HIV, HBV and HCV screening test
13. Negative urine toxicology screening test at the screening visit and on the day before 
challenge
14. Willingness to take a curative regimen of Malarone®
Exclusion criteria
1. History of malaria
2. Plans to travel outside of the Netherlands during the study period
3. Previous participation in any malaria vaccine study and/or positive serology for P. 
falciparum
4. Symptoms, physical signs or laboratory values suggestive of systemic disorders, including 
but not limited to renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, 
psychiatric and other conditions, which could compromise the health of the volunteer 
during the study or interfere with the interpretation of the study results
5. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
6. Clinically significant ECG abnormalities at screening, or history of arrhythmia’s or prolonged 
QT-interval
7. Positive family history of cardiac disease in 1st or 2nd degree relatives < 50 years old
8. An estimated ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the 
Systematic Coronary Risk Evaluation (SCORE) system
9. Body Mass Index (BMI) below 18 or above 30 kg/m2
10. Any clinically significant deviation from the normal range in haematological or biochemical 
blood tests or urine analysis
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Table S5. Continued.
11. Positive HIV, HBV or HCV screening tests
12. Participation in any other clinical study within 30 days prior to the onset of the study or 
during the study period
13. Pregnant or lactating women
14. Volunteers unable to give written informed consent
15. Volunteers unable to be closely followed during the study period for social, geographic or 
psychological reasons
16. Previous history of drug or alcohol abuse interfering with normal social function in the 
period of one year prior to study onset
17. A history of psychiatric disease or convulsions
18. Known hypersensitivity to anti-malarial drugs
19. History of severe reactions or allergy to mosquito bites
20. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying 
drugs within three months prior to study onset (inhaled and topical corticosteroids are 
allowed) or during the study period
21. Contra-indications for Malarone® use, including treatment taken by the volunteers that 
interferes with Malarone®
22. Any confirmed or suspected immunosuppressive or immunodeficient condition, including 
asplenia
23. Co-workers of the departments of Medical Microbiology of the UMC St Radboud, the 
department of Internal Medicine of the Havenziekenhuis or the department of Medical 
Microbiology & Infectious Diseases of the Erasmus MC
24. A history of sickle cell, thalassaemia trait or G6PD deficiency
CHMI-b Inclusion criteria
1. Subject is aged ≥ 18 and ≤ 35 years and in good health.
2. Subject has adequate understanding of the procedures of the study and agrees to abide 
strictly thereby.
3. Subject is able to communicate well with the investigator, is available to attend all study 
visits, lives in proximity to the trial centre (<10 km) or (if >10km) is willing to stay in a hotel 
close to the trial centre during part of the study (day 5 post-infection until three days post-
treatment). Furthermore the subject will remain within the Netherlands during the study 
period and is reachable (24/7) by mobile telephone throughout the entire study period.
4. Subject agrees to inform his/her general practitioner and (if applicable) medical specialist 
about participation in the study and to sign a request to release by the GP any relevant 
medical information concerning possible contra-indications for participation in the study.
5. Subject agrees to refrain from blood donation to Sanquin or for other purposes throughout 
the study period and for a defined period thereafter according to current Sanquin 
guidelines.
6. For female subjects: subject agrees to use adequate contraception and not to breastfeed 
for the duration of study.
7. Subject has signed informed consent.
2.





1. Any history, or evidence at screening, of clinically significant symptoms, physical signs 
or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, 
pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, 
haematological, infectious, immunodeficient, psychiatric and other disorders, which 
could compromise the health of the volunteer during the study or interfere with the 
interpretation of the study results. These include, but are not limited to, any of the 
following:
1.1 Body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening
1.2 A heightened risk of cardiovascular disease, defined as: an estimated ten year risk of fatal 
cardiovascular disease of ≥5% at screening, as determined by the Systematic Coronary Risk 
Evaluation (SCORE); history, or evidence at screening, of clinically significant arrhythmia’s, 
prolonged QT-interval or other clinically relevant ECG abnormalities; or a positive family 
history of cardiac events in 1st or 2nd degree relatives <50 years old.
1.3 Functional asplenia, sickle cell trait/disease, thalassaemia trait/disease or G6PD deficiency.
1.4 History of epilepsy in the period of five years prior to study onset, even if no longer  
on medication.
1.5 Positive HIV, HBV or HCV screening tests.
1.6 Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other immune modifying 
drugs within three months prior to study onset (inhaled and topical corticosteroids and 
oral anti-histamines exempted) or expected use of such during the study period.
1.7 History of malignancy of any organ system (other than localized basal cell carcinoma of the 
skin), treated or untreated, within the past 5 years
1.8 Any history of treatment for severe psychiatric disease by a psychiatrist in the past year.
1.9 History of drug or alcohol abuse interfering with normal social function in the period of one 
year prior to study onset, or positive urine toxicology test for cocaine or amphetamines at 
screening or prior to infection.
2. For female subjects: positive urine pregnancy test at screening or prior to infection.
3. Any history of malaria, positive serology for P. falciparum, or previous participation in any 
malaria (vaccine) study.
4. Known hypersensitivity to or contra-indications (including co-medication) for use of 
atovaquone-proguanil (Malarone®) or artemether-lumefantrine (Riamet®), or history of 
severe (allergic) reactions to mosquito bites.
5. Receipt of any vaccinations in the 3 months prior to the start of the study or plans to 
receive any other vaccinations during the study period or up to 8 weeks thereafter.
6. Participation in any other clinical study in the 30 days prior to the start of the study or 
during the study period.
7. Being an employee or student of the department of Medical Microbiology of the 
Radboudumc, the department of Internal Medicine or Laboratory of the Havenziekenhuis 
or the department of Medical Microbiology & Infectious Diseases of the Erasmus MC.
8. Any other condition or situation that would, in the opinion of the investigator, place 
the subject at an unacceptable risk of injury or render the subject unable to meet the 
requirements of the protocol.
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Controlled human malaria infections (CHMIs) with Plasmodium falciparum (Pf) parasites are well-
established. Exposure to five Pf (NF54)-infected Anopheles mosquitoes results in 100% infection 
rates in malaria-naïve volunteers. Recently, Pf clones NF135.C10 and NF166.C8 were generated 
for application in CHMIs. Here, we tested the clinical infection rates of these clones, using graded 
numbers of Pf-infected mosquitoes. In a double-blind randomized trial, we exposed 24 malaria-
naïve volunteers to bites from one, two, or five mosquitoes infected with NF135.C10 or NF166.
C8. The primary endpoint was parasitemia by quantitative polymerase chain reaction. For both 
strains, bites by five infected mosquitoes resulted in parasitemia in 4/4 volunteers; 3/4 volunteers 
developed parasitemia after exposure to one or two infected mosquitoes infected with either 
clone. The prepatent period was 7.25 ± 4.0 days (median ± range). There were no serious adverse 
events and comparable clinical symptoms between all groups. These data confirm the eligibility 
of NF135.C10 and NF166.C8 for use in CHMI studies.
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Introduction
Controlled human malaria infections (CHMIs) are a well-accepted tool used since the 1980s for 
the exploration of immunology and pathophysiology of malaria infections and for evaluation 
of candidate vaccines and drugs.1 The majority of studies have been conducted with 3D7 and 
its parental strain NF54.1 Most volunteers have been infected using five laboratory-reared 
Plasmodium falciparum (Pf)–infected Anopheles mosquitoes, which reproducibly result in 
optimal infection rates in malaria-naïve volunteers.2,3 Reducing the number of NF54 or 3D7 Pf-
infected mosquitoes to one or two reduces the infection rate.4,5
Given the diversity of Pf isolates in the field, the value of CHMI trials can be increased by 
expanding the portfolio with Pf clonal isolates from different geographical origins.6 The Pf isolate 
NF54 most likely originates from Africa.7 The more recently generated clones are NF135.C10 and 
NF166.C8, originating from Cambodia and Guinea, respectively. Initial studies with NF135.C10 
and NF166.C8 show that these clones are safe and give high infection rates with five infectious 
mosquitoes (80% [8/10] and 100% [5/5], respectively).8,9 However, these clones show more 
effective hepatocyte invasion and liver merozoite development as compared with NF54, which 
results in higher first peak of parasitemia and shorter prepatent period.10 In order to establish 
an NF135.C10 or NF166.C8 CHMI model with comparable parasite dynamics as obtained in 
NF54-infected volunteers, the objective of the current study was to compare infection rates and 
dynamics of parasitemia as well as clinical manifestations using one, two or five NF135.C10- or 
NF166.C8-infected mosquitoes.
Materials and Methods
The study is a single-center, double-blind, randomized trial. The flowchart, screening procedures, 
and inclusion and exclusion criteria were described previously.10 Briefly, 24 healthy male and 
female volunteers, aged 18–35 years, were randomly assigned to six groups and exposed to 
bites from five mosquitoes of which five, two, or one were infected with either NF135.C10 or 
NF166.C8. Uninfected mosquitoes were added to preserve blinding of all trial personnel except 
the staff members preparing and aliquotting infected mosquitoes.
Anopheles stephensi mosquitoes were reared and infected according to standardized 
protocols.11,12 The average number of sporozoites per mosquito used in this study was 69,000 
for NF135.C10 and 51,000 for NF166.C8. Mosquito feeding was allowed for 10 minutes and 
infectivity of mosquitoes was assessed after feeding by dissecting salivary glands for the presence 
of sporozoites. Feeding was repeated until the predefined number of infected bites was reached. 
Eight volunteers needed two sessions, one needed three sessions (all in the five- or two-mosquito 
bite groups).
After CHMI, volunteers were followed-up twice daily from day 5 post-infection until two 
consecutive blood samples were positive by quantitative polymerase chain reaction (qPCR) 
(≥500parasites/mL), or, when they remained negative, until day 13. At this point, volunteers 
were treated with atovaquone/proguanil and followed on days 1, 2, 3, and 7 after treatment 
3.
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and on day 35 post-infection. Follow-up was prolonged if volunteers remained qPCR-positive or 
symptomatic. Throughout the study, high-sensitive troponin T, lactate dehydrogenase (LDH), and 
platelet counts were measured as safety parameters. The first peak of parasitemia was calculated 
as the geometric mean of Pf parasites per milliliter between day 6.4 and 8.4.13
The trial was registered at www.clinicaltrials.gov, identifier NCT02149550. Ethical approval from 
the Central Committee on Research Involving Human Subjects (NL48704.000.14) was obtained.
All statistical analyses were performed with IBM SPSS statistics for Windows (Version 23.0; 
IBM Corp., Armonk, NY). Mean prepatent period, first peak of parasitemia, and the frequency 
of adverse events (AEs) between the groups were assessed by using unpaired t‑test, one-way 
analysis of variance (ANOVA), or their nonparametric variants. Adverse events were reported 
as mild (grade 1), moderate (grade 2), or severe (grade 3).
Results
In total, 20 of 24 volunteers developed parasitemia; all volunteers exposed to five infected 
mosquitoes and 3/4 volunteers exposed to one or two infected mosquitoes with either strain 
(Table 1).
The prepatent period in the NF135.C10 groups ranged from 7 to 9 days and did not differ 
significantly between the dosage groups (median [range] five mosquitoes: 7.5 [7.0–9.0] versus 
two mosquitoes: 9.0 [7.5–9.0] versus one mosquito: 7.0 [7.0–7.0]; P = 0.06, Table 1).
Figure 1. Comparison of one, two, and five NF135.C10-infected mosquito bites (A). Kinetics of 
parasitemia in Pf/mL (log) at days post-controlled human malaria infection until qPCR positive (two 
consecutive samples > 500 Pf/mL). Data represent the geometric means and error bars. (B). Number of 
graded adverse events (AE) per volunteer. Symbols represent individual volunteers, and horizontal lines 
and whiskers represent median and range, respectively. Pf = Plasmodium falciparum.
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Table 1. The number of volunteers developing parasitemia and the prepatent period in days after infection 
with graded numbers of NF135.C10- or NF166.C8- infected mosquitoes
No. of infectious bites
Five, two, 
or one
Five Two One P value






































There was no difference in first peak of parasitemia in parasites/mL (geometric mean (GM) [95% 
confidence interval (CI)] five mosquitoes: 2.9 [1.8–4.0], versus two mosquitoes: 2.4 [1.0–3.8], 
versus one mosquito: 3.0 [2.3–3.7]; P = 0.32) (Figure 1A). All parasitemic volunteers experienced 
one or more AEs. When comparing subjects challenged with either five, two, or one NF135.
C10-infected mosquitoes, there were no differences in the total number of grade 1, 2, or 3 
AEs (P = 0.81, P = 0.60, and P = 0.87, respectively) (Figure 1B), or the number of solicited AEs 
(headache, nausea, malaise, chills and myalgia, data not shown). A few unsolicited AEs were 
reported, two or three per group, all grade 1.
For the NF166.C8 clone, no significant difference was found in the prepatent period between 
the three dosage groups either (median [range] five mosquitoes: 7.0 [7.0–7.0] versus two 
mosquitoes: 7 [7.0–11.0] versus one mosquito: 9.0 [7.5–9.0]; P = 0.09, Table 1). In contrast to 
NF135.C10, the first peak of parasitemia was significantly higher in volunteers bitten by higher 
numbers of NF166.C8-infected mosquitoes (GM [95% CI] five mosquitoes: 3.8 [3.3–4.2], versus 
two mosquitoes: 2.4 [−0.9 to 5.6], versus one mosquito: 2.2 [1.7–2.7]; P = 0.04, Figure 2A). 
There were no differences in the number of grade 1, 2, or 3 AEs (P = 0.11, P = 0.33, and P = 0.90, 
respectively) (Figure 2B), nor in the number of solicited AEs between the volunteers challenged 
with either five, two, or one NF166.C8-infected mosquitoes (data not shown). A few unsolicited 
AEs were reported, four or six per group, all grade 1.
When comparing all subjects who developed parasitemia with either strain, the prepatent 
period was similar for NF135.C10 and NF166.C8 (median [range] 7.5 [7.0–9.0] versus 7.0 [7.0–
11.0]; P = 0.65 see Table 1) as was the height of the first peak of parasitemia (GM [95% CI] NF135.
C10: 2.8 [2.4–3.2] parasites/mL versus NF166.C8: 2.9 [2.1–3.6]; P = 0.48). In addition, there were 
no significant differences in the number of grade 1, grade 2, or grade 3 AEs between the two 
strains (P = 0.91, P = 0.07, P = 0.96).
3.
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Figure 2. Comparison of one, two, and five NF166.C8-infected mosquito bites (A). Kinetics of 
parasitemia in Pf/mL (log) at days post-controlled human malaria infection until qPCR positive (two 
consecutive samples > 500 Pf/mL). Data represent the geometric means and error bars. Significant 
difference in first peak of parasitemia (geometric mean of day 6.4–8.4) between five, two, or one 
infected mosquito bites, P = 0.04 (B). Number of graded adverse events (AEs) per volunteer. Symbols 
represent individual volunteers, and horizontal lines and whiskers represent median and range, 
respectively. Pf = Plasmodium falciparum.
Upon antimalarial drug treatment, LDH was elevated (> 248 U/L, max 499 U/L) in 10 (50%) 
malaria-positive volunteers. Platelets were decreased (< 150 × 109/L, min 85 × 109/L) in 11/20. 
There was no relation with the Pf-clone used or the number of bites, and these changes in 
safety parameters were deemed clinically insignificant. The changes normalized by the end of 
the study. Throughout the trial hs-troponin T remained lower than 14.0 ng/L in all volunteers.
Discussion
This study shows that CHMI with five bites of NF135.C10- or NF166.C8-infected mosquitoes 
results in 100% patent parasitemia, which is comparable with the outcomes of previous CHMIs 
with NF54, 3D7, or 7G8.3,14,15 Lowering the number of infectious bites of both test clones to one 
or two bites reduced the patency to 75% (3/4 individuals infected), which is similar to previous 
trials with 3D7-or NF54-infected mosquitoes showing parasitemia in 40-60% of the cases.4,5
The kinetics of emerging NF135.C10 parasitemia remained relatively similar irrespective of the 
number of infected mosquitoes used. Theoretically, a relation with the number of infectious 
mosquito bites could be expected, as seen in NF166.C8. However, the variance in first peak of 
parasitemia in NF135.C10 was large, and these small groups did not allow to find differences. 
Parasite release from the liver may be subject to variation in sporozoite numbers delivered by 
the blood-feeding mosquitoes. We previously estimated from CHMI studies that on average 
21 sporozoites per mosquito infect hepatocytes, whereas others estimated a release in the 
range of 1–369 per mosquito.16,17 In addition, the probability of infection decreases with a lower 
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sporozoite load (0–1,000) per mosquito.18 However, in our studies mosquitoes are infected with 
>25,000 sporozoites/mosquito where no such relation exists.19
Differences in patency between one, two, or five infected bites suggest there is a strain-
independent threshold to be overcome before successful infection occurs which can 
stochastically result in zero successful events. Such bottlenecks may include the frequency of 
mosquito probing, the number of sporozoites entering the blood stream, and the number that 
invade hepatocytes. After hepatocyte invasion, the efficiency of parasite multiplication
may differ between strains with a potential higher first peak of parasitemia and 
correspondingly shorter prepatent periods for NF135.C10 and NF166.C8. This difference in 
multiplication inside hepatocytes is unlikely related to differences in fitness of these clones, as 
the IC50 of CSP-antibodies blocking in vitro hepatocyte development is comparable.9
Data from this and other studies with NF135.C10- and NF166.C8-infected volunteers showed that 
there is no increase in the number or severity of AEs compared with NF54-infected volunteers, 
despite the higher first peak of parasitemia.10 The prevalence and severity of AEs will likely 
further reduce if antimalarial treatment is initiated upon more stringent qPCR cut-off values.20
In conclusion, this study with limited numbers of volunteers per group shows that bites of 
five mosquitoes of NF135.C10 and NF166.C8 of either clone consistently gives 80–100% patent 
parasitemia in the three studies performed with these heterologous clones. In future CHMI 
studies using clones NF135.C10 and NF166.C8 and lower numbers of mosquito bites may 
suffice to achieve blood-stage dynamics which are more similar to NF54, albeit reaching lower 
infection rates.
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Abstract
Immunization with attenuated Plasmodium sporozoites can induce protection against malaria 
infection, as shown by Plasmodium falciparum (Pf) sporozoites attenuated by radiation in 
multiple clinical trials. As alternative attenuation strategy with a more homogeneous population 
of Pf sporozoites (PfSPZ), genetically engineered Plasmodium berghei sporozoites (SPZ) lacking 
the genes b9 and slarp induced sterile protection against malaria in mice. Consequently, PfSPZ-
GA1 Vaccine, a Pf identical double knockout (PfΔb9Δslarp), was generated as a genetically 
attenuated malaria parasite vaccine and tested for safety, immunogenicity, and preliminary 
efficacy in malaria-naïve Dutch volunteers. Dose-escalation immunizations up to 9.0 × 105 
PfSPZ of PfSPZ-GA1 Vaccine were well tolerated without breakthrough blood-stage infection. 
Subsequently, groups of volunteers were immunized three times by direct venous inoculation 
with cryopreserved PfSPZ-GA1 Vaccine (9.0 × 105 or 4.5 × 105 PfSPZ, N = 13 each), PfSPZ Vaccine 
(radiation-attenuated PfSPZ, 4.5 × 105 PfSPZ, N = 13), or normal saline placebo at 8-week 
intervals, followed by exposure to mosquito bite controlled human malaria infection (CHMI). 
After CHMI, 3 of 25 volunteers from both PfSPZ-GA1 groups were sterilely protected, and the 
remaining 17 of 22 showed a patency ≥9 days (median patency in controls, 7 days; range, 7 to 
9). All volunteers in the PfSPZ Vaccine control group developed parasitemia (median patency, 9 
days; range, 7 to 12). Immunized groups exhibited a significant, dose-related increase in anti-Pf 
circumsporozoite protein (CSP) antibodies and Pf-specific interferon-γ (IFN-γ)–producing T cells. 
Although no definite conclusion can be drawn on the potential strength of protective efficacy of 
PfSPZ-GA1 Vaccine, the favorable safety profile and induced immune responses by PfSPZ-GA1 
Vaccine warrant further clinical evaluation.
CHAPTER 4
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Introduction
A recent resurgence in Plasmodium falciparum (Pf) malaria cases after years of control 
underscores the need for a highly efficacious vaccine for elimination (1). The Pf circumsporozoite 
protein (CSP) subunit vaccine RTS,S/AS01E (Mosquirix, GlaxoSmithKline) is the only malaria 
vaccine to move beyond phase 3 clinical trials, although it provides only short-term and partial 
clinical vaccine efficacy (2).
In the past decade, there has been a growing interest in attenuated whole Pf sporozoite 
(PfSPZ) vaccines based on the idea that this whole-organism immunization will be able to induce 
the protection needed against the breadth of antigens present in the parasite. The first approach 
to immunizing humans with radiation-attenuated PfSPZ was developed almost 50 years ago (3) 
and has now been translated to a vaccine, consisting of radiation-attenuated, metabolically 
active, aseptic PfSPZ that meet regulatory standards for direct venous inoculation (DVI). This 
product, Sanaria PfSPZ Vaccine, has shown an excellent safety profile in 1595 subjects aged 5 
months to 65 years in 20 clinical trials in the United States, Europe, and Africa (4–6). Furthermore, 
it has provided protection against controlled human malaria infection (CHMI) and malaria 
infections in the field (4, 7, 8).
Radiation induces random DNA damage in the parasite genome, generating a heterogeneous 
nonreplicating population of PfSPZ. These PfSPZ invade hepatocytes, partially develop, and then 
arrest at an early stage in the liver (9). As an alternative to radiation-based attenuation, genetic 
modification generates a homogeneous formulation of PfSPZ, which stop development in the 
liver at a well-defined point (10). In rodent models, immunization with genetically attenuated 
malaria SPZ can induce similar, or even greater, protective immunity compared to radiation-
attenuated malaria SPZ (11). The intrinsic and irreversible nature of the genetic attenuation 
greatly reduces safety risks during manufacturing of PfSPZ. Consequently, several liver-arresting 
genetically attenuated Pf parasites have been generated (12–14), two of which have been tested 
for safety in volunteers by mosquito bite (13, 15).
We engineered attenuated PfSPZ by deletion of two genes encoding slarp and b9, each 
governing independent and critical processes for successful liver-stage development (12). Pf 
double-knockout (PfΔb9Δslarp) SPZ were capable of invading primary human hepatocytes 
in vitro, but arrested growth early after invasion and were not detected at days 2 to 7 after 
infection, similar to PfSPZ Vaccine. PfΔb9Δslarp parasite development was fully abrogated in 
the liver of humanized mice (12). SPZ of the equivalent rodent Plasmodium berghei–attenuated 
parasite (PbΔb9Δslarp) also showed aborted liver-stage development while retaining the capacity 
to induce fully protective immunity in both the BALB/c and C57BL/6 mouse models (12). These 
preclinical data justified formulation and clinical assessment of PfΔb9Δslarp.
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Figure 1. Study flow chart. Manufacture of aseptic, purified, and cryopreserved PfΔb9Δslarp PfSPZ 
(Sanaria PfSPZ-GA1 Vaccine) was performed in compliance with Good Manufacturing Practice (16). 
We report the first-in-human evaluation of PfSPZ-GA1 Vaccine (NCT0316121). We tested safety and 
immunogenicity of PfSPZ-GA1 Vaccine and subsequently examined the protective vaccine efficacy 
against a homologous CHMI with wild-type (WT) Pf (NF54) and compared this to a previously tested 
regimen of PfSPZ Vaccine.
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Results
Study population
In total, 124 malaria-naïve adults were screened for participation in the study from 1 May to 28 
November 2017. Nineteen volunteers were selected as volunteers in the safety dose-escalation 
stage A of the study, and 48 were selected for the immunogenicity and preliminary efficacy stage 
B. In addition, six backup volunteers were enrolled in stage B to replace any dropouts before 
immunization. One volunteer withdrew informed consent after the second immunization in 
stage B of the trial for reasons unrelated to the trial; all others completed follow-up (Fig. 1). In 
total, 34 of 67 (51%) were males. Mean age of the volunteers was 23 years old (SD, 4; range, 
18 to 34), and mean body mass index (BMI) was 23.5 kg/m2 (SD, 3.0; range, 18 to 30) (Table 1).
Volunteers in stage A were immunized once with escalating doses up to 9.0 × 105 PfSPZ of PfSPZ-
GA1 Vaccine, whereas in stage B volunteers were randomized double blind to receive three 
doses of 4.5 × 105 or 9.0 × 105 PfSPZ of PfSPZ-GA1 Vaccine, 9.0 × 105 PfSPZ of PfSPZ Vaccine, or 
saline placebo at 8-week intervals.
Table 1. Volunteer demographics.
STAGE A STAGE B Total
Group A1 Group A2 Group A3
Number of volunteers 3 3 13 48 67
Age (years) Mean 23 25 23 23 23
SD 3 3 5 3 4
Median 23 26 23 23 23
Min, Max 20, 26 20, 29 18, 34 18, 33 18, 34
Sex Male 1 2 5 26 34
Female 2 1 8 22 33
BMI Mean 25.3 23.9 23.6 23.3 23.5
SD 0.7 2.7 2.9 3.1 3.0
Median 25.1 24.9 23.6 22.5 23.4
Min, Max 25, 26 18, 26 19, 29 18, 30 18, 30
Safety results
No serious adverse events occurred during this trial. None of the blood samples taken for blood-
stage infection at any time point after DVI of 1.35 × 105, 4.5 × 105, or 9.0 × 105 PfSPZ of PfSPZ-
GA1 Vaccine in stage A and after any of three immunizations with 4.5 × 105 or 9.0 × 105 PfSPZ 
of PfSPZ-GA1 Vaccine in stage B were positive for parasite DNA. Blood samples were tested 
for erythrocytic-stage parasites by quantitative polymerase chain reaction (qPCR) every day 
from day 6 to day 21 after immunization and on day 28 in stage A and on day 14 after each 
immunization in stage B (Fig. 2).
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All immunizations with PfSPZ-GA1 Vaccine and PfSPZ Vaccine were well tolerated, and there were 
no significant differences in incidence or severity of adverse events between vaccine and placebo 
groups in stage B. A total of 66 related adverse events were reported after immunization (table 
S1). DVI was successful after a single needle stick in 93% of injections (151 of 162 injections), 
and after three attempts, all but one DVI was successful. Volunteers reported no or mild pain 
during injection; only one volunteer reported severe pain once for a few seconds during needle 
insertion. Bruising after DVI was the most commonly reported local adverse event, occurring in 
7 of 67 (10%) of volunteers. Headache and fatigue/malaise were the most frequently reported 
systemic adverse events (reported by 31 and 14 volunteers, respectively) in both intervention 
and placebo groups, of which three events were severe. One severe unsolicited adverse event 
probably related to immunization occurred when a volunteer experienced a vasovagal reaction 
during immunization. There were no clinically significant laboratory abnormalities.
The most common adverse events after CHMI with Pf WT NF54 were headache (52% of 
volunteers) and fatigue (51%). One volunteer (placebo group) reported severe chills 2 days 
after atovaquone/proguanil treatment for blood test–positive Pf malaria. Two volunteers 
(placebo group and PfSPZ Vaccine group) reported severe dizziness on the first and third day of 
atovaquone/proguanil treatment. All adverse events resolved without sequelae.
There were two cases of mild (grade 1) highly sensitive troponin T elevation to a maximum 
of 19 ng/ml (reference, <14 ng/ml) 10 to 12 days after CHMI at the time when blood samples 
were positive for Pf by qPCR: one (9.0 × 105 PfSPZ of PfSPZ-GA1 Vaccine group) deemed probably 
related and one (4.5 × 105 PfSPZ of PfSPZ-GA1 Vaccine) deemed possibly related to CHMI. Both 
volunteers were asymptomatic, and electrocardiogram did not show abnormalities. Both 
volunteers were treated with atovaquone/proguanil on the first day of troponin elevation, at 
which time blood samples were positive for Pf. The highly sensitive troponin T concentration 
decreased to normal range within a day, and volunteers experienced no sequelae.
Protective efficacy against CHMI
To obtain a preliminary measure of PfSPZ-GA1 vaccine efficacy (VE), the immunized volunteers in the 
stage B study underwent CHMI with Pf NF54 WT parasites by mosquito bite 3 weeks after the final 
immunization. The volunteers were monitored on a daily basis, and blood samples were tested for 
the presence of parasites by qPCR (Fig. 2). Although the primary endpoint of proportion protected 
was not significantly different between any vaccine groups and the placebo control group, all vaccine 
groups showed a significant delayed time to positive qPCR as compared to the placebo (Fig. 3; log-
rank test, P = 0.0003). All volunteers in the placebo group developed parasitemia, with a median 
of 7 days after CHMI (seven volunteers at day 7, one at day 8, and one at day 9). All 13 volunteers 
immunized with the control 4.5 × 105 PfSPZ of PfSPZ Vaccine developed parasitemia, with a median 
delay of 2 days (median, 9; range, 7 to 12 days, compared with placebo Mann-Whitney, P = 0.0078). 
After CHMI, 3 of 25 volunteers from both PfSPZ-GA1 groups were sterilely protected. Immunization 
with 4.5 × 105 PfSPZ of PfSPZ-GA1 Vaccine resulted in 11 of 12 volunteers developing blood-stage 
parasitemia, with a median delay of 2 days (median, day 9; range, 7 to 12 days, compared with 
placebo Mann-Whitney, P = 0.0005). In the highest-dose PfSPZ-GA1 group, 11 of 13 volunteers 
became qPCR positive, with a median 4-day delay (median prepatent period, 11 days; range, 7 to 
12 days, compared with placebo Mann-Whitney, P = 0.0018). This study was not powered to detect 
significant differences in time to positive qPCR between vaccine groups.
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Figure 2. Study design. In stage A study, volunteers were immunized by direct venous inoculation (DVI) 
with either 1.35 × 105, 4.5 × 105, or 9.0 × 10 PfSPZ of PfSPZ-GA1 Vaccine (n = 3, 3, or 13, respectively; 
green circle), after which blood samples were taken on a daily basis from day 6 until day 21 (black circles). 
At day 28 (blue circle), all volunteers were treated with a curative regimen of atovaquone/proguanil. 
Final visits were at days 35 and 100. In stage B study, four groups of volunteers were immunized three 
times (green circles) with either 4.5 × 105 (n = 13) or 9.0 × 105 PfSPZ (n = 13) of PfSPZ-GA1 Vaccine or 
4.5 × 105 PfSPZ of PfSPZ Vaccine (n = 13) or saline placebo (n = 9) by DVI, with blood samples 
taken for blood-stage parasitemia at day 14 after every immunization. CHMI by mosquito bite 
with WT Pf NF54 (red circle) was performed 3 weeks after the final immunization, after which 
daily follow-up was performed from day 139 to day 154. All volunteers received curative 
treatment with atovaquone/proguanil (blue circle) and came for three final follow-up visits.  
Figure 3. Parasitemia after CHMI. (A) Kaplan-Meier showing number of volunteers without blood-stage 
parasitemia as measured by qPCR between 0 to 28 days after CHMI (log-rank, P = 0.0003) and (B) days until 
patency [qPCR > 100 p/ml, for the 9.0 × 105 PfSPZ-GA1 Vaccine (dark green), 4.5 × 105 PfSPZ-GA1 Vaccine 
(green), 4.5 × 105 PfSPZ Vaccine (blue), and placebo group (black)]. Lines indicate median. (B) shows 
significance by Mann-Whitney test: *P < 0.05 and **P < 0.01.
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Figure 5. Relationship between immune parameters and protection. (A) Relationship between anti-
PfCSP antibody titers (lines indicate geomean), % of (B) IFN-γ–producing CD4+, or (C) CD8+ T cells (lines 
indicate median and interquartile ranges) and the protection status of volunteers. Protection grouped 
by day of positive qPCR (patency) ≤8 or >8 or “sterile” if qPCR negative until day 28. One-way ANOVA, 
P = 0.05. (D) Correlation of anti-PfCSP antibody titer 14 days after the final immunization with prepatent 
period. Pearson correlation P = 0.02 and r = 0.32.
Immunogenicity
All immunized groups showed a significant increase in antibody titers against PfCSP between pre-
immunization and pre-CHMI time points (P < 0.0001, paired t test overall; Fig. 4A). Immunization 
with 4.5 × 105 PfSPZ of PfSPZ Vaccine and PfSPZ-GA1 Vaccine induced similar anti-PfCSP antibody 
titers, whereas immunization with 9.0 × 105 PfSPZ of PfSPZ-GA1 Vaccine produced significantly 
higher anti-PfCSP titers [Fig. 4A; one-way analysis of variance (ANOVA) Tukey post hoc mean 
difference, 5573; 95% confidence interval (CI), 332 to 30,823; P = 0.04].
Peripheral blood cells from all immunized groups exhibited a significant increase in CD4+ and 
CD8+ T cells producing interferon-γ (IFN-γ) upon stimulation with Pf-infected red blood cells after 
three immunizations (PfRBC; Fig. 4, D and E; P < 0.03) as compared to baseline. In total, 35 and 
32% of all immunized volunteers were IFN-γ responders for CD4+ or CD8+ T cells, respectively, 
with 46% of volunteers showing an increase in at least one subset.
To examine whether there was an association between an increase in antibody or cellular 
responses and protection, data from immunized individuals were segregated on the basis of 
protection status (Fig. 5A). The anti-PfCSP antibody titers correlated significantly with time until 
4.
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positive qPCR-based blood-stage patency (Pearson correlation r = 0.32; 95% CI, −0.01 to 0.59; 
P = 0.02, R2 = 0.1; Fig. 5D). However, cellular responses did not correlate with protection (one-
way ANOVA for patency ≤8 days, >8 days, and full protection, P = 0.05).
We thus demonstrate that immunization with three doses of 4.5 × 105 PfSPZ of PfSPZ 
Vaccine and PfSPZ-GA1 induced similar anti-PfCSP antibody responses and that there was a 
dose-dependent increase in anti-PfCSP responses after immunization with 9.0 × 105 PfSPZ of 
PfSPZ-GA1. Moreover, anti-PfCSP antibody responses correlated with protection.
Discussion
Here, we report the first-in-human administration and efficacy data of the live, injectable, 
nonreplicating, genetically attenuated PfSPZ, PfSPZ-GA1 Vaccine. PfSPZ-GA1 Vaccine was 
safe and well tolerated, and no blood-stage infections were observed in 45 volunteers after 
97 injections, totaling more than 6 × 107 PfSPZ administered by DVI. PfSPZ-GA1 Vaccine was 
immunogenic and induced both antibody and CD4+ and CD8+ T cell responses, with a potency 
analogous to the comparator PfSPZ Vaccine. Homologous CHMI through the bites of WT (Pf 
NF54)–infected mosquitoes 3 weeks after the last immunization resulted in three fully protected 
individuals and delays in time to patency in 17 of 25 volunteers at both dosages of PfSPZ-GA1 
Vaccine. The delay in time to patency correlated with increased anti-PfCSP antibody responses.
This study shows that an injectable, double gene deletion attenuated parasite vaccine is safe 
and immunogenic in humans. Previously, two genetically attenuated parasites (GAPs) have 
undergone safety evaluation in healthy volunteers in an experimental setting through the bites 
of infected Anopheles mosquitoes (13, 15). One GAP, lacking the two genes p52 and p36, showed 
a blood-stage infection in a single volunteer after being exposed to 200 infectious bites (15). 
The breakthrough blood parasites were confirmed as having the p52 and p36 gene deletion 
genotype, indicating that deletion of these two genes was not sufficient to result in a complete 
growth arrest in the liver stage. This same incomplete attenuation phenotype (at high infection 
doses) had also been observed in rodent malaria parasites lacking the same genes (17). In a 
subsequent study, another GAP was analyzed, which additionally included a deletion of the slarp 
gene, also referred to as sap1. This triple-knockout GAP (PfΔp52Δp36Δsap1) was administered 
to healthy volunteers through the bites of 150 to 200 infectious Anopheles mosquitoes, and no 
breakthrough blood infections were observed (13). No protective efficacy studies of the triple-
knockout GAP have been reported yet. In contrast to PfΔp52Δp36Δsap1, PfSPZ-GA1 Vaccine was 
administered as an injectable vaccine.
We found a delay in patency up to day 12 after CHMI as compared to a 7- to 9-day patency in 
controls, reflecting a 2-log reduction in parasites released from the liver in volunteers vaccinated 
with both doses of PfSPZ-GA1. However, the interpretation of the vaccine efficacy data is 
complicated by the unexpected low efficacy of the PfSPZ Vaccine reference group. The dose of 
the control PfSPZ Vaccine was chosen on the basis of a previous study in which three doses of 
4.5 × 105 PfSPZ of PfSPZ Vaccine by DVI protected 13 of 15 volunteers from mosquito bite CHMI 
3 weeks after the last immunization (18). The same dose was selected for PfSPZ-GA1 in group 
1 to enable a comparison of the two vaccines’ immunogenicity. As anticipated when designing 
the trial, the PfSPZ Vaccine group allows us to put the vaccine efficacy results in perspective of 
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previous trials with the PfSPZ Vaccine as reference. This difference in vaccine efficacy of PfSPZ 
Vaccine between the study in the United States and our study may be explained by either (i) 
differences in the stringency of the CHMI or (ii) differences in the immunogenicity of PfSPZ 
Vaccine in the two studies. With regard to the first possibility, both studies used mosquito 
bite–based CHMI at 3 weeks after the last immunization. Mosquito bite CHMI is more similar to 
natural infections as it includes the possibly relevant SPZ skin stage, where antibodies against SPZ 
may have an effector function (19, 20). However, in the Epstein et al. study (18), the 3D7 clone of 
the NF54 strain of Pf was used in the CHMI, whereas in this study we used the NF54 strain of Pf, 
which is not clonal. Small genotypic differences between these two strains have been identified 
(21), but it remains unclear whether these are relevant and result in differences in prepatent 
period as observed in independent clinical trials (22). Unfortunately, direct comparisons have 
not been performed. Because PfSPZ-GA1 was created in an NF54 background, we would expect 
the NF54 CHMI to be more homologous as compared to the 3D7 CHMI. In addition, the primary 
parasitological outcome variable differed between the trials (qPCR in The Netherlands and 
thick smear in the United States), so prepatent periods cannot be directly compared, making 
it difficult to assess challenge stringency. However, for both strains, five mosquito bites are 
needed to achieve a virtually 100% infection rate and ultimately cannot account for the lower 
than expected vaccine efficacy. Thus, we do not think that differences in stringency of CHMI can 
explain the difference in VE between the two studies. Moreover, we have broad experience with 
this mosquito bite CHMI model, including studies in which we show 100% vaccine efficacy by the 
chemoprophylaxis with SPZ approach against homologous Pf NF54 CHMI (23–25).
Both PfSPZ Vaccine and PfSPZ-GA1 Vaccine were immunogenic and induced anti-PfCSP 
antibodies and PfRBC-specific T cells. There was a positive association between anti-PfCSP 
antibodies and the protection status of the volunteers as measured by prepatent period. 
However, less than half of volunteers had significant induction of T cell responses, and CD8+ 
responses were inverse related to prepatency. Whether this reflects a compartmental shift of 
CD8+ T cells to nonlymphoid tissues, as observed in animal models (26), will require further study. 
This is in contrast with other PfSPZ Vaccine studies (7, 8), in which typically most volunteers show 
induction of CD4+ T cell responses, although CD8+ T cell responses have been variable. Possibly 
a difference in the in vitro cell stimulus (PfRBC versus PfSPZ) could also explain this difference, 
and therefore, in future studies with GAP vaccines, it would be of importance to also compare 
these two stimuli. However, anti-PfCSP antibody titers in our study were also significantly lower 
than those found in the Epstein et al. study (18) after immunization with PfSPZ Vaccine using 
the same schedule and dose of 4.5 × 105 PfSPZ (median level [net optical density (OD), 1.0] at 2 
weeks after the third dose of 19,044 versus 5465).
On the basis of these data, we consider a lower vaccine immunogenicity of PfSPZ Vaccine 
compared to the Epstein et al. study (18) to be a likely explanation for the decreased vaccine 
efficacy of PfSPZ Vaccine observed in our study. However, the true cause of the decreased 
immunogenicity remains unclear. Retrospective evaluation did not reveal any procedural 
complications or deviations from established protocols in vaccine transport, storage, or 
administration. In addition, the trial in our study was performed in two centers, with different 
teams performing vaccine preparation and administration and yet both showed similar 
immunogenicity results. Vaccine lot–specific problems also do not seem a likely explanation, 
given experiences in other sites with parallel trials. Although we observed that PfSPZ-GA1 Vaccine 
appeared to be as immunogenic as PfSPZ Vaccine, at an equivalent dose, the unexpected low 
vaccine efficacy of the PfSPZ Vaccine comparator limits our ability to draw firm conclusions on 
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the VE of PfSPZ-GA1 Vaccine. However, given the suboptimal vaccine efficacy of PfSPZ-GA1, the 
next-generation genetically attenuated PfSPZ vaccines should aim at enhanced potency either 
by increasing dose or potentially through an arrest later in the liver stage.
An alternative to Pf gene deletion mutants as whole SPZ vaccine is the use of Plasmodium 
species that are nonpathogenic for humans expressing selected Pf target proteins. Transgenic 
murine P. berghei SPZ expressing the Pf CSP were recently tested in a clinical trial for safety, 
immunogenicity, and protective efficacy against a CHMI (27).
This study demonstrates that a genetically attenuated, live parasite vaccine, PfSPZ-GA1, 
can be safely administered to malaria-naïve volunteers by DVI. Genetically attenuated PfSPZ have 
advantages over other whole PfSPZ vaccination strategies, because they can improve the safety 
and consistency of manufacturing. Although the potential protective efficacy of PfSPZ-GA1 Vaccine 
cannot be fully appreciated in this trial, the data show clear immunogenicity combined with a 
favorable safety and tolerability profile. The current trial underscores the clinical potential of 
genetically attenuated vaccines, boosting further development of such malaria vaccine strategies.
Materials and Methods
Study design
The study was designed as a multicenter phase 1, open-label, dose-escalating trial to assess 
safety, tolerability, and immunogenicity of PfSPZ-GA1. In the initial, open-label safety stage of the 
trial (stage A), single escalating doses of PfSPZ-GA1 were administered by DVI to three groups of 
healthy adults at the Leiden University Medical Center (LUMC). Group A1 (n = 3) was inoculated 
with 1.35 × 105 PfSPZ of PfSPZ-GA1 Vaccine, group A2 (n = 3) was inoculated with 4.5 × 105 PfSPZ 
of PfSPZ-GA1 Vaccine, and group A3 (n = 13) was inoculated with 9.0 × 105 PfSPZ of PfSPZ-GA1 
Vaccine. For this initial proof-of-concept study, a dose of 1.35 × 105 PfSPZ of PfSPZ-GA1 Vaccine 
was chosen because this is the lowest dose at which PfSPZ Vaccine has shown to induce protective 
immunity (18), whereas after three doses of 9.0 × 105 PfSPZ Vaccine >90% VE was to be expected. 
This is based on a study where three doses of 4.5 × 105 PfSPZ induced >80% protection (18). In 
the follow-on efficacy stage of the trial (stage B), a total of 48 volunteers were included at LUMC 
(n = 24) and Radboud University Medical Center (RUMC) (n = 24), with double-blind randomization 
over four study groups according to a randomization list prepared by the study head pharmacist. 
Randomization was stratified per study site. The investigator, site personnel, and the sponsor were 
masked to treatment assignment. The site pharmacist or qualified employees were not masked 
and prepared the assigned vaccines. Groups 1 and 2 received three immunizations with PfSPZ-
GA1 Vaccine at doses of 9.0 × 105 (n = 13) and 4.5 × 105 (n = 13) PfSPZ. Group 3 received three 
immunizations with the control PfSPZ Vaccine at a dose of 4.5 × 105 PfSPZ (n = 13), and group 4 
was injected three times with normal saline as placebo (n = 9). All immunizations in stage B were 
administered at 8-week intervals. Three weeks after the final immunization, all stage B volunteers 
were exposed to five bites of Pf NF54–infected Anopheles stephensi mosquitoes according to 
previously described procedures to assess vaccine efficacy (28). The primary objective of the study 
was to investigate the safety and tolerability of PfSPZ-GA1 Vaccine, by analysis of (i) the presence of 
blood-stage parasites after inoculation and (ii) the frequency and magnitude of adverse events. A 
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secondary objective was the VE of PfSPZ-GA1 Vaccine against mosquito bite CHMI with Pf NF54 SPZ, 
as assessed by the presence or absence of parasitemia after CHMI. The presence of blood-stage 
parasites after inoculation with PfSPZ-GA1 Vaccine and the frequency and magnitude of adverse 
events after immunization were primary endpoints. The presence of blood-stage parasites after 
immunization was a stopping criterium.
We calculated a sample size of 13 immunized subjects per group and 9 infectivity controls for 
the first CHMI to show with a power of 80% that a 50% blood-stage parasite positive rate in the 
immunized group and 100% in the control group are significantly different (α < 0.05, two-tailed), 
assuming that one subject drops out from the immunized group (final N = 12).
The clinical trial was conducted under a U.S. Food and Drug Administration (FDA) 
Investigational New Drug (IND) application and was approved by the central committee for 
research involving human subjects in The Hague [Centrale Commissie Mensgebonden Onderzoek 
(Central Committee on Research Involving Human Subjects) (CCMO; NL56657.000.16)]. It was 
performed in The Netherlands under a license from the Dutch Ministry of Infrastructure and 
Environment (Ministerie van Infrastructuur en Milieu) for deliberate release of genetically 
modified organisms (IM-MV 15-004 and IM-MV 15-009). The study was registered at 
ClinicalTrials.gov (NCT03163121). Primary data are reported in data file S1.
Production of PfSPZ-GA1
The genetically attenuated Pf NF54 parasite, PfΔb9Δslarp (12), lacks two genes, b9 and slarp, 
which are vital for liver-stage development (12). Master and working cell banks were generated 
from the clone Pf NF54 parasite, PfΔb9Δslarp, filed under an FDA Master File and IND application, 
resulting in the product referred to as PfSPZ-GA1 Vaccine. PfSPZ-GA1 parasites were tested 
sensitive to the anti-malarial drugs chloroquine, mefloquine, artemether/lumefantrine, 
atovaquone/proguanil, and pyrimethamine.
Manufacture of PfSPZ-GA1 Vaccine bulk product followed the identical manufacturing 
schema of PfSPZ (NF54) Vaccine (16) except for several tests of vialed final products that were 
specific to PfSPZ-GA1 Vaccine. These tests included a PCR test for identity that confirmed the 
genetic signature of PfΔb9Δslarp (12), the potency assay that documented 3-day parasites that 
were developed in HCO4 cells in vitro, and the 6-day safety assay that confirms the absence 
of late-stage developing parasites in vitro. The manufacturing process generated aseptic A. 
stephensi mosquitoes that were infected with PfΔb9Δslarp (12). PfSPZ were harvested, purified, 
vialed, cryopreserved, and shipped in liquid nitrogen vapor phase at −150° to −196°C. On the day 
of administration, vials of PfSPZ-GA1 Vaccine were thawed and diluted using phosphate-buffered 
saline and 25% human serum albumin (CSL Behring) to the correct dose in a sterile environment.
Participants
A total of 67 healthy malaria-naïve male and female volunteers aged 18 to 35 years were recruited 
for the study. All included volunteers were in good health as assessed by medical history, physical 
examination, general chemistry and hematology evaluation, and an electrocardiogram. All 
included volunteers provided informed consent, and females were counseled to use adequate 
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contraception. A detailed list of inclusion and exclusion criteria is provided in the Supplementary 
Materials.
Procedures
Volunteers were immunized by a trained nurse administering 0.5 ml of the vaccine by DVI 
through a 25-gauge needle. Volunteers were observed for 30 min after every immunization. 
Local adverse events and pain scores were assessed immediately. In stage A, volunteers visited 
the trial facility daily from day 6 to day 21 after every immunization to report adverse events 
and to collect blood samples for assessment of parasites by qPCR. During the immunization 
period, all volunteers were treated with a curative regiment of atovaquone/proguanil when 
qPCR was positive for malaria or at day 28 after immunization. Complete blood counts and 
general chemistry laboratories were performed on days 6, 14, 21, 30, and 35 after immunization. 
Platelet counts, lactate dehydrogenase, and highly sensitive troponin T tests were performed 
daily to detect possible myocarditis in an early stage, in line with previously established 
protocols (29, 30). Blood samples for immunological assays were taken at baseline and at days 
6, 14, 21, 28, 35, 100, and 188. In stage B of the clinical trial, visits were on day 14 after every 
immunization and the day before immunization for safety assessments. Three weeks after the 
third and final immunization, volunteers were exposed to the bites of five mosquitoes infected 
with the homologous Pf NF54 strain (CHMI). All mosquitoes were checked for a blood meal 
and infectivity by dissection (28). Further details on the CHMI with Pf are reported in table 
S2. After CHMI, volunteers visited the trial center on a daily basis from day 6 to day 21. All 
volunteers were treated with a curative regimen of atovaquone/proguanil if they were qPCR 
positive or, alternatively, at day 28 after CHMI. Final visits took place at days 35, 100, and 188 
after CHMI. Blood samples for immunological analysis were taken before and 14 days after each 
immunization, before CHMI, and at days 6, 14, 21, 35, 100, and 188 after CHMI.
Adverse events
Solicited and unsolicited adverse events after DVI were recorded at every visit until 35 days after 
immunization. Solicited local adverse events were tenderness, induration, bruising/extravasated 
blood, erythema, swelling, pain, and pruritis. Solicited systemic adverse events were fever, rash, 
urticaria, pruritis, edema, headache, fatigue, malaise, chills, myalgia, and arthralgia. All volunteers 
were instructed to fill out a diary card, listing daily temperature and any adverse events up to 
day 35 after immunization. Causality of all adverse events was assessed by the investigators as 
definitely related, probably related, possibly related, unlikely related, or not related to the study 
procedures. In dichotomous analysis, the latter two were regarded as “unrelated” and the first 
three categories as “related.” All adverse events were graded as mild (grade 1), moderate (grade 
2), severe (grade 3), or serious (grade 4). Review of all safety data by an independent safety 
monitoring committee was performed at 28 days after each immunization in stage A, before 
continuing dose escalation to the next group and on day 28 after CHMI in stage B.
Marijke Langenberg BNW proef V3.indd   74 27-04-21   08:54
75
A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1
Blood-stage parasitemia
To examine whether PfSPZ-GA1 were fully attenuated and incapable of establishing a blood-
stage infection, blood samples were monitored for parasites by qPCR (31). Blood samples were 
considered negative if no signal was detected in 50 cycles or the Pf load was <100 Pf/ml. Any 
sample with a load of >100 Pf/ml was considered positive. Parasite densities were determined 
with the use of a trendline of standardized control samples between 20 and 106 Pf/ml.
Immunology
Exploratory endpoints included immune responses after immunization with PfSPZ-GA1 Vaccine. 
Antibodies were detected by enzyme-linked immunosorbent assay (ELISA) against PfCSP (32). 
Cellular immune responses were analyzed using peripheral blood mononuclear cell (PBMC) 
samples obtained 1 day before the first immunization and 21 days after the third immunization. 
Cells were isolated using heparin cell preparation tubes according to previously published 
protocols (32). After thawing, cells were stimulated, as described previously (33). In short, PBMCs 
were cultured at 2.5 × 106 cells/ml in a final volume of 200µl per well in RPMI 1640 (Dutch 
Modification; Gibco) with gentamicin (5 mg/ml; Centraform), 100 mM pyruvate (Gibco), 200 
mM GlutaMAX (Gibco), and 10% heat-inactivated pooled human A+ serum (Sanquin, Nijmegen, 
The Netherlands). Cells were stimulated with purified NF54 schizonts (PfRBC) or uninfected 
red blood cells (uRBC) at a concentration of 2.5 × 106 RBC/ml for 24 hours. Brefeldin A (10 µg/
ml; Sigma-Aldrich) and monansin (2 µM; eBioscience) were added during the last 4 hours of 
stimulation. Cells were stained with fixable viability dye labelled with eFlour780 (eBioscience), 
CD3–phycoerythrin (PE)–Dazzle549 (BioLegend; clone OKT3), CD4–fluorescein isothiocyanate 
(FITC) (BioLegend; clone OKT4), CD8-Alexa Fluor 700 (BioLegend; clone HIT8A), pan-γδTCR-PE 
(Beckman Coulter; clone IMMU510), and CD56 peridinin chlorophyll protein (PerCP)–Cy5.5 
(BioLegend; clone HCD56) for 30 min at 4°C. Cells were subsequently permeabilized using 
Foxp3 fixation/permeabilization buffer (eBioscience) and stained for intracellular cytokines with 
IFN-γ–PE-Cy7 (BioLegend; clone 4S.B3), interleukin-2 (IL-2)–BrilliantViolet510 (BioLegend; clone 
MQ1-17H12), and tumor necrosis factor–α (TNF-α)–Alexa Fluor 647 (BioLegend; clone MAb11). 
Analysis was performed using a Gallios flow cytometer (Beckman Coulter) and FlowJo software 
(version 10.0.8 for Apple OS). Background cytokine production after stimulation with uRBC was 
subtracted from PfRBC responses. On an individual level, we defined IFN-γ responders as those 
volunteers with a percentage increase in IFN-γ–producing cells greater than twice the SD of all 
pre-immunization samples.
Statistical analysis
Adverse events were evaluated by tabulating according to intention to treat analysis. The 
proportion of volunteers in each group who reported mild, moderate, or severe adverse events 
was calculated, and analysis was primarily descriptive. The secondary endpoint of the study was 
the presence of parasitemia (by qPCR) after CHMI with the (WT) Pf NF54 strain in stage B of the 
study. Differences between groups were evaluated by log-rank test.
4.
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Differences in immunological parameters between groups were assessed by comparing mean 
values between the groups using one-way ANOVA when comparing several groups or a two-tailed 
Student’s t test or nonparametric equivalents. Paired tests were used if pre-exposure values 
were compared with post-exposure values, and unpaired tests were used if comparisons were 
made between groups. For discrete variables, the χ2 test or Fisher’s exact test was used (two-
tailed). All statistical analyses were performed with SPSS version 23.
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Supplementary
Inclusion and exclusion criteria
Inclusion criteria
1. Subject is aged ≥ 18 and ≤ 35 years and in good health.
2. Subject has adequate understanding of the procedures of the study and agrees to abide 
strictly thereby.
3. Subject is able to communicate well with the investigator, is available to attend all study visits.
4. Furthermore, the subject will remain within the Netherlands or within reasonable travelling 
distance from the Radboudumc from day -1 till day +28 after each parasite exposure. After CHMI, 
subjects have to be reachable by phone (24/7) from day -1 until day 35.
5. Subject agrees to inform his/her general practitioner (GP) about participation in the study 
and to sign a request to release by the GP, and medical specialist when necessary, any relevant 
medical information concerning possible contra-indications for participation in the study.
6. Subject agrees to refrain from blood donation to Sanquin or for other purposes throughout 
the study period and for a defined period thereafter according to Sanquin guidelines (3 years 
minimum, depending on serology).
7. Non-pregnant, non-lactating females of reproductive potential (i.e., have a uterus and are 
neither surgically sterilized nor post-menopausal) should agree to use adequate contraception 
and not to breastfeed for the duration of study.
8. Subject agrees to refrain from intensive physical exercise (disproportionate to the subjects’ 
usual daily activity or exercise routine) for twenty-one days following each immunization and 
during the malaria challenge period.
9. Subject has signed informed consent.
Exclusion criteria
1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or 
abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, 
renal, hepatic, neurological, dermatological, endocrine, malignant, hematological, infectious, 
immune-deficient, psychiatric or other disorders, which could compromise the health of the 
volunteer during the study or interfere with the interpretation of the study results. These include, 
but are not limited to, any of the following:
a. Body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening
b. A heightened risk of cardiovascular disease, defined as:
4.
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i. An estimated ten-year risk of fatal cardiovascular disease of ≥5% at screening, as determined 
by the Systematic Coronary Risk Evaluation (SCORE);
ii. History, or evidence at screening, of clinically significant arrhythmia’s, prolonged QT-interval 
or other clinically relevant ECG abnormalities; or
iii. a positive family history of cardiac events in first or second degree relatives (according to the 
system used in medical genetics) <50 years old.
c. Functional asplenia, sickle cell trait/disease, thalassemia trait/disease or G6PD deficiency.
d. History of non-febrile seizure at any time prior to study onset, even if no longer on medication.
e. Positive HIV, HBV or HCV screening tests.
f. Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other immune modifying 
drugs within three months prior to study onset (excluding inhaled and topical corticosteroids 
and incidental use of oral anti-histamines) or expected use of such during the study period.
g. History of malignancy of any organ system (other than localized basal cell carcinoma of the 
skin), treated or untreated, within the past five years.
h. Any history of treatment for severe psychiatric disease by a psychiatrist in the past year.
i. History of drug or alcohol abuse interfering with normal social function in the period of one 
year prior to study onset, positive urine toxicology test for cocaine or amphetamines at screening 
or prior to infection or positive urine toxicology test for cannabis prior to infection.
2. For female subjects: breastfeeding, or positive urine pregnancy test at screening or prior to 
immunization or prior to CHMI.
3. Any history of malaria, positive serology for P. falciparum, or previous participation in any 
malaria (vaccine) study or CHMI.
4. Known hypersensitivity to or contra-indications (including co-medication) for use of 
atovaquone/proguanil or artemether/lumefantrine, or history of severe (allergic) reactions to 
mosquito bites.
5. Receipt of any vaccinations in the 3 months prior to the start of the study or plans to receive 
any other vaccinations during the study period or up to 8 weeks thereafter.
6. Participation in any other clinical study in the 30 days prior to the start of the study or during 
the study period.
7. Being an employee or student of the department of Medical Microbiology or Infectious 
Diseases of the Radboudumc or the LUMC.
8. Any other condition or situation that would, in the opinion of the investigator, place the subject 
at an unacceptable risk of injury or render the subject unable to meet the requirements of the 
protocol or would compromise the integrity of the data.
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Table S1. Number and severity of adverse events after immunization. Number of volunteers reporting 
solicited local and systemic adverse events possibly, probably or definitely related to immunization. 
Percentages are given between parenthesis. Data collected until 35 days after each immunization. No 
rash, induration, edema, chills or arthralgia were reported. 
PfSPZ-GA1 Vaccine PfSPZ Vaccine Placebo
1.35x105 4.5x105 9.0x105 4.5x105




Tenderness 1 0 (0) 0 (0) 2 (8) 1 (8) 0 (0)
Bruising 1 1 (33) 0 (0) 3 (12) 3 (23) 0 (0)
Erythema 1 0 (0) 0 (0) 0 (0) 0 (0) 1 (11)
Swelling 1 0 (0) 0 (0) 1 (4) 2 (15) 0 (0)
Pain 1 0 (0) 0 (0) 2 (8) 1 (8) 1 (11)






Fever 1 0 (0) 1 (6) 1 (4) 1 (8) 0 (0)
2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
3 0 (0) 1 (6) 0 (0) 0 (0) 0 (0)
Headache 1 0 (0) 5 (31) 11 (42) 4 (31) 3 (33)
2 1 (33) 1 (6) 2 (8) 2 (15) 1 (11)
3 0 (0) 0 (0) 0 (0) 1(8) 0 (0)
Fatigue/malaise 1 1 (33) 2 (13) 3 (12) 2 (15) 1 (11)
2 0 (0) 1 (6) 1 (4) 0 (0) 1 (11)
3 0 (0) 0 (0) 1 (4) 0 (0) 1 (11)
Myalgia 1 0 (0) 0 (0) 1 (4) 0 (0) 0 (0)
2 0 (0) 0 (0) 2 (8) 0 (0) 1 (11)
3 0 (0) 1 (6) 0 (0) 0 (0) 0 (0)
Table S2. Bite numbers used for CHMI for the different study arms. Mosquitoes were 100% infected with 




Number of Infected 
bites median (range)
Number of Uninfected 
bites median (range)
PfSPZ-GA1 9 x105 1 (1-3) 5 0 (0-2)
PfSPZ-GA1 4.5 x105 1 (1-2) 5 0 (0-2)
PfSPZ Vaccine 4.5 x105 1 (1-2) 5 0 (0-1)
Placebo 1 (1-2) 5 0 (0-3)
4.
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Abstract
To accelerate the development of novel vaccines for schistosomiasis, we set out to develop a 
human model for Schistosoma mansoni infection in healthy volunteers. During natural infections, 
female schistosomes produce eggs that give rise to morbidity. Therefore, we produced single-
sex, male Schistosoma mansoni cercariae for human infection without egg production and 
associated pathology. Cercariae were produced in their intermediate snail hosts in accordance 
with the principles of good manufacturing practice (GMP). The application of GMP principles to 
an unconventional production process is a showcase for the controlled production of complex 
live challenge material in the European Union or under Food and Drug Administration guidance.
Schistosomiasis ranks among the leading neglected tropical diseases in terms of disability-
adjusted life years, with roughly 252 million people infected worldwide [1]. Schistosoma mansoni 
and Schistosoma haematobium are responsible for the majority of cases [2]. Morbidity in 
schistosomiasis is caused by the inflammatory response to tissue-deposited eggs, which induce 
granulomas and fibrosis that can lead to portal hypertension or bladder cancer [2].
Current schistosomiasis control programs rely on the mass administration of praziquantel, but 
transmission of schistosomes persists, primarily because of high reinfection rates [3]. Alternative 
tools to break transmission and eliminate schistosomiasis are urgently needed. The development 
of a highly efficacious vaccine would be a major asset to schistosomiasis control programs.
Vaccination studies in mice and nonhuman primates prove that immunity to schistosomes 
can be induced by repeated exposure to radiation-attenuated cercariae [4, 5]. Based on such 
landmark studies, stage-specific antigens have been identified that reduce the worm burden by 
>40% [6]. Currently there are 4 vaccine candidates in the clinical stage of development (Sh28GST, 
Sm-TSP-2, Sm14, and Smp80) [6, 7]. Typically, these vaccine candidates undergo phase 1 testing 
for safety, after which efficacy needs to be demonstrated in large-scale field trials in schistosome-
endemic areas. To obtain an estimate of the vaccine induced protective efficacy, trials of long 
duration and/or large population size are necessary.
To decrease the risk of downstream efficacy failure, healthy volunteers have been 
deliberately exposed to infectious agents to test malaria, dengue, and influenza vaccines [8]. 
Such controlled human infection (CHI) trials provided early efficacy estimates that were used 
to guide further clinical development. The availability of a CHI model for schistosome infection 
could revolutionize the development of schistosomiasis vaccines.
To ensure the safety of participants in a human schistosome infection trial, a challenge 
inoculum should be available that complies with regulatory requirements for human use and 
cannot induce egg-associated morbidity. We therefore took an important conceptual step 
to produce single-sex, male, schistosome cercariae in accordance with good manufacturing 
practice (GMP) principles. This process for producing live parasites, which complies with the 
highly demanding regulatory environment in place currently, is a showcase for the production 
of complex live challenge material in the European Union (EU) or under Food and Drug 
Administration guidance.
CHAPTER 5
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Methods
Production Principles
Manufacture of single-sex cercariae for the purpose of controlled human schistosome infections 
was performed within the quality control and quality assurance system of the Interdivisional 
GMP facility of Leiden University Medical Center (LUMC). The product was characterized as 
an auxiliary medicinal product (EU regulation 536/2014) or previously as a noninvestigational 
medicinal product according to the definition of EU clinical trial directive 2001/20/EC. The 
principles of GMP as outlined in European Commission directive 2003/94/ EC were used in the 
production process wherever possible.
 
Figure 1. Schematic representation of the production process.
5.
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Cercariae were produced in a biosafety level 3 laboratory environment with controlled humidity, 
temperature, and pressure. The production process (Figure 1) was standardized in 34 standard 
operating procedures, which were kept in the institutional document management system. 
A product dossier was created according to section 2.7 of EC CT-1 guideline 2010/C 82/01 for 
pharmacological products. All disposables, reagents, solvents, culture media, and starting 
materials were released for use by the quality control (QC) officer and the qualified person 
(QP) responsible for advanced cell therapy medicinal products. All manufacturing steps and 
batch numbers of all used materials were entered and logged in real time in a GMP-compliant 
digital database, using a portable tablet. The use of a tablet facilitated communication 
between manufacturers and QC officers without breaching hygienic procedures established 
for containment of the biosafety level 3 environment. A separate read-only account was held 
by the QC officer and the QP. Monitored data were locked by the QP to prevent editing. All QC 
testing was independently analyzed by the QC officer, and thereafter the product was released 
by the QP for use.
Figure 2. A. Percentages of uninfected, dead, and infected Biomphalaria glabrata snails with either male 
or female cercariae after single-miracidium infection. B. Number of cercariae produced by each snail for 
each weekly shedding episode, starting from week 5 after infection. C. Number of male or female cercariae 
from shedding episode 1 or 2. D. Results from sex-specific polymerase chain reaction analysis, shown as the 
difference in cycle threshold (ΔCt) between the ITS2 gene and the W1 repeat, in 47 cercarial samples from 
preclinical production.
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Origin of Snails and Parasites
The S. mansoni Puerto Rico strain used for production was obtained together with its 
Biomphalaria glabrata snail host by Prof C. F. A. Bruijning in 1955 (Prof A. M. Deelder, personal 
communication). This isolate has been maintained in laboratory culture in the LUMC by routine 
passaging of the schistosomes through laboratory hamsters and/or mice as the definitive host 
and laboratory-cultured B. glabrata as the intermediate host. Adult worms were genetically 
characterized to confirm their origin (Supplementary Materials).
Production of Cercariae
S. mansoni miracidia were obtained by light-induced hatching of S. mansoni eggs isolated from 
an infected hamster [9]. After infection by a single miracidium [10], B. glabrata snails of the same 
batch (ie, infection day) were housed and labeled individually, and they shed cercariae after 5 
weeks. Cercariae were counted, and their viability was determined by calculating the percentage 
of the counted larvae that were moving.
Identity and Sex Confirmation
The identity and sex of cercariae were determined by a purpose-made multiplex real-time 
polymerase chain reaction (PCR) targeting Schistosoma-specific ITS2 sequences [11], as well 
as the S. mansoni W1 repeat [12] (Supplementary Materials). The W1 copy number is much 
lower in male as compared to female schistosomes [13]. Using DNA of duplicate cercaria samples 
unequivocally resulted in an ITS2 cycle threshold (Ct) between 15 and 30. Sex was determined on 
the basis of the difference in Ct between W1 and ITS2, with males having a ΔCt of >10, and females 
having a ΔCt of <4. Sensitivity of the quantitative PCR was confirmed in samples containing only 1 
cercaria (mean ITS2 Ct, 23). To validate the PCR finding, the sex of single-sex cercaria samples was 
confirmed by assessment of the morphology of adult worms after hamster infection.
Bioburden Testing
The bioburden in shed waters was determined at the ISO-15189–certified clinical medical 
microbiology laboratory of the LUMC (Supplementary Materials). Aeromonas species, 
Staphylococcus aureus, β-hemolytic streptococci, and Pseudomonas aeruginosa were defined 
as pathogenic bacteria potentially causing skin infections upon transfer with cercariae. Cultures 
were optimized for detection of these bacteria. To reduce the bioburden, snails were kept in 
an environment containing 2 mg/L ciprofloxacin and 4 mg/L gentamicin for 24 hours before 
clinical use.
One week before use, the bioburden in shed water was assessed before and after antibiotic 
treatment. After shedding for clinical use, cercariae were counted, their viability was recorded, 
and doses were prepared by 2 persons separately.
5.





In preparation for the production of clinical trial material, 24 preclinical batches of miracidium-
infected snails were produced, averaging 12 snails per batch. Of those 294 snails, 246 (84%) 
were still alive at week 5. In total, 47 snails (19%) shed cercariae, of which 25 (53%) were male 
(Figure 2A).
Viability of cercariae was always very high (>90% in all batches), but the number of cercariae 
per shed varied considerably per snail and over time. At week 5, snails shed approximately 3500 
cercariae (geometric mean [GM], 3416 cercariae; 95% confidence interval [CI], 2386–4889), 
decreasing to 1261 cercariae (95% CI, 704–2259) at week 7 (P < .0001, by the Mann-Whitney U 
test; Figure 2B). The number of cercariae per shed was not affected by the cercarial sex (P = .6, 
by the Mann- Whitney U test; Figure 2C). On the basis of these data, cercariae from shedding 
episode 2 were preferably selected for clinical use.
Sex Identification by Quantitative PCR
Sex and identity were unequivocally confirmed in all cercarial samples (Figure 2D). Samples 
obtained from snails shedding mixed male and female cercariae always showed ΔCt values 
similar to those containing females only (ΔCt W1-ITS2 range, 2.83–4.88 for mixed-sex cercariae 
and 2.24–3.11 for female cercariae). Samples containing only male cercariae always showed 
different ΔCt values (range, 11.83 to undetectable). Thus, the ΔCt difference of >6 between male 
and female cercarial samples ensured that male sex could always be confirmed with certainty.
Bioburden
All samples that underwent bioburden testing were found to contain Aeromonas veronii biovar 
sobria susceptible to ciprofloxacin, gentamicin, and trimethoprim-sulfamethoxazole. No other 
pathogenic bacteria were cultured. Because Aeromonas species are incidentally reported as 
causative agents of skin infections, production snails were pretreated with antibiotics before 
clinical use of cercariae. After this treatment, all samples were free of Aeromonas species. 
After antibiotic treatment, waterborne bacteria such as Chryseobacterium species and 
Stenotrophomonas maltophilia, which are not known to cause infections in healthy volunteers, 
persisted.
In-Process Testing and Release
S. mansoni miracidia and hamsters were defined as starting materials and were released by the 
QC officer. Based on the critical steps in the production process, 3 in-process tests were defined: 
(1) confirmation of single-miracidium infection of snails by a second person, (2) daily examination 
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of snail viability, and (3) determination of the number and viability of cercariae after the first 
shedding episode (ie, >100 and >90%).
A 2-step release procedure was established, with a conditional release procedure 
immediately after dose preparation, followed by a final release procedure when bioburden 
tests were completed 3 days later. Criteria for conditional release were based on (1) absence 
of potentially pathogenic bacteria after antibiotic treatment of 2 snails from the same batch, 
(2) identity confirmation of cercarial species and male sex by quantitative PCR, (3) absence of 
potentially pathogenic bacteria resistant to ciprofloxacin and gentamicin, and (4) presence of 
>100 cercariae with >90% viability.
The shelf life of the product at 28°C was determined at 2 hours, when 96% (95% confidence 
interval [CI], 91%–100%) of cercariae were confirmed viable by microscopy. At 4 hours viability 
was more variable (mean, 96%; 95% CI, 81%–100%), and at 24 hours viability had dropped to 
14% (95% CI, 4%–24%).
Discussion
In summary, we were able to establish a rigorous production process for male S. mansoni 
cercaria that complied with current regulatory standards for human use. Despite the complex, 
unconventional production process that includes a snail host, production was in accordance 
with the principles of GMP, with clearly defined release criteria, which were supervised by a QC 
officer and a QP responsible for advanced cell therapy medicinal products.
CHI trials are increasingly used for the down selection of novel drugs or vaccines [8]. 
However, specific guidelines regarding the production of challenge material are often lacking. 
Whereas the Food and Drug Administration states that stage-appropriate GMP is required, 
European Medicines Agency guidelines for auxiliary medicinal products state that full GMP 
may not be required, but deviations must be justified [14]. In this specific case, the production 
process in snails is exceptional and requires thorough risk analysis and intense collaboration of 
pharmacists, clinicians, and technicians. Paramount to the safety of volunteers in a controlled 
human schistosome trial is the ability to determine cercaria sex so that egg-induced pathology 
cannot occur. To this end, we have developed technologies and procedures to ensure unique 
identification and tracking of individual snails.
To confirm the identity and sex of cercariae, we established a sensitive and specific multiplex 
real-time PCR. We confirmed high variability in the copy numbers of the female-specific W1 
repeat in male cercariae, corroborating previous data [13]. Nevertheless male cercariae could be 
confidently distinguished from female or mixed-sex cercarial samples, based on a large difference 
in Ct between male and female/mixed-sex samples. Should the production of female cercariae 
be necessary in the future, multiple individual cercariae from 1 snail should be tested to confirm 
cercarial sex.
We fully characterized the bioburden associated with the snail microbiome. We focused on 
excluding microbiological contaminants that might confer a risk of adverse events when applied 
to cercaria-penetrated skin. We believe that the current remaining nonpathogenic bioburden 
does not pose any risk for volunteers. In addition, the rearing of sterile snails has not been 
5.
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reported previously and might be biologically challenging, owing to increasing evidence that the 
microbiome is particularly essential for the well-being of nonvertebrates [15].
Both the B. glabrata snails and the S. mansoni parasites have been kept in the laboratory 
for >60 years. Although the origin of the isolates lacked a full historical paper trail, the main 
advantage of such an old and highly established laboratory culture is the naivety to praziquantel, 
excluding possible resistance this drug. Nevertheless, for clinical use, extensive follow-up is 
needed to ensure full cure after praziquantel administration. We performed genotyping 
to confirm the parasite strain as S. mansoni from Puerto Rico. Future efforts will focus on 
establishing a master and working bank of parasites, although cryopreservation of schistosome 
cercariae, miracidia, or eggs has not been performed and may be challenging.
In conclusion, through an interdisciplinary approach, we were able to achieve highly controlled 
production of viable male S. mansoni cercariae. Following these efforts, the next steps will be the 
use of cercariae for infection of healthy volunteers in a proof-of-concept clinical trial to find a safe 
and infectious dose. Establishing a CHI model for schistosomiasis will be a game-changing step to 
accelerate the development of novel vaccines and drugs for this devastating disease.
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Genomic DNA was extracted from pooled worms using the DNeasy tissue kit (QIAgen) according 
to the manufacturer’s protocol. The mitochondrial cox1 region was PCR amplified and sequenced 
as described in Webster et al., 2013 [1]. The sequences were compared to the S. mansoni cox1 
database to find the closest identity, which was a 99% match to Genbank Accession: HE601612 
(Mitochondrial genome of S. mansoni Puerto Rico).
Sex-identity Schistosoma multiplex qPCR
DNA from at least 50 cercariae was isolated with the QIAamp DNA mini kit spin columns (QIAgen, 
Hilden, Germany) and diluted 1:100. The multiplex PCR amplified a 77-bp fragment from the 
Schistosoma-specific ITS2 sequences (with primers Ssp48F, Ssp124R and probe Ssp78T) [2] and a 
121-basepair fragment from the female specific Schistosoma mansoni W1 repeat (with primers 
SmW1-238F, SmW1-358R and probe SmW1-291T (Biolegio, Netherlands)) [3]. Amplification was 
performed in 20 µl PCR mix and 5 µl of cercarial DNA. Table 1 shows the concentrations of the 
PCR mix used with the sequences of all primers and double-labelled probes. The CFX real-time 
detection system (Bio-Rad laboratories) was used with amplification program of 15 min at 95°C 
followed by 50 cycles of 15s at 95°C, 30s at 60°C, and 30s at 72°C. Negative and positive (mixed, 
male and female) control samples were included.
Table 1. PCR mix and primer/probe sequences of the sex-identity Schistosoma multiplex PCR.
Components Concentration Per sample  Sequence
H20 2,73
MgCl2  25 mM 3,50
BSA  5 mg/ml 0,50
Primer Ssp48F 25 µM 0,06 5’-GGTCTAGATGACTTGATTGA GATGCT-3’
Primer Ssp124R 25 µM 0,06 5’-TCCCGAGCGTGTATAATGTC ATTA-3’
Probe Ssp78T 10 µM 0,13 FAM-5’-TGGGTTGTGCTCGAGT CGTGGC-3’-BHQ1
Primer SmW1-238F 25 µM 0,20 5’-TGTTTGTGGATGCGATGGTG-3’
Primer SmW1-358R 25 µM 0,20 5’-TGTGCACAAGCAACGATTCC-3’
Probe SmW1-291T 10 µM 0,13 YAK-5’-GCGATGATGCATTAGG GTGTGTGGT-3’-BHQ1
HotStarTaq Master Mix 12,50
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Bioburden testing
Shed water was plated on Trypcase Soy Agar with 5% sheep blood, Cystine lactose electrolyte 
deficient agar, Columbia agar with colistin and nalidixic acid, Xylose Lysine Desoxycholaat Agar 
(Biomerieux, Marcy-l’Étoile, France) and Cefsulodin Irgasan Novobiocine agar (Media Products, 
Groningen, The Netherlands) and incubated aerobically for 48 hours at 35°C. Plates were checked 
daily for the growth of bacteria. Identification was performed by MALDI TOF mass spectrometry 
(MALDI Biotyper, Bruker Daltonik GmbH, Bremen, Germany) and susceptibility testing in a Vitek 
2 instrument (Biomerieux) or, in case of streptococci by disk diffusion (Oxoid, Thermofisher, 
Landsmeer, The Netherlands).
5.
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Katayama syndrome is a self-limited illness that occurs several weeks after infection with 
schistosome larvae (cercariae). Its symptoms are typical of an acute inflammatory response.
Objective
To provide insight into the cause of Katayama syndrome.
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Case Report
We exposed 2 human participants to male cercariae of Schistosoma mansoni in an experimental 
infection that met all applicable laws and regulations, was approved by the Ethical Research 
Committee of Leiden University Medical Center (study P16.111), and was registered at 
ClinicalTrials.gov (NCT02755324).
The first patient was a healthy 24-year-old medical student with a history of hay fever and 
mild atopic dermatitis. We exposed her to 30 male cercariae of S. mansoni on her lower arm for 
30 minutes. She felt itching and developed a typical localized cercarial rash that lasted 2 weeks. 
Four weeks after exposure, she started having fever, night sweats, myalgia, and headache, but 
no cough. Her temperature increased above 38.5 °C for 10 days (Figure, top). At that time, her 
complete blood count showed lymphocytopenia without eosinophilia, but her eosinophil count 
increased 1 week later (Figure, bottom). A chest radiograph was normal, and bacterial blood and 
urine cultures were negative. Serum aminotransferase levels increased to 4 times the upper limit 
of detection. We found no acute viral infections in serologic studies or in repeated molecular 
diagnostic tests on throat swabs. At week 6, the patient’s fever decreased to between 37.5 and 
38.0 °C in the evenings; she had night sweats for 3 weeks and reported fatigue, malaise, and 
mild to severe headaches for a total of 8 weeks. These symptoms were relieved by intermittent 
acetaminophen and nonsteroidal anti-inflammatory drugs and did not require corticosteroids.
Figure. Highest temperature recorded by the physician or trial participant (top) and eosinophil count 
(bottom). The horizontal dashed line represents normal body temperature.
6.
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The second patient was a healthy 26-year-old psychology student who also had a history of 
hay fever and mild atopic dermatitis. We exposed her to 30 male cercariae of S. mansoni on 
her lower arm for 30 minutes. She developed nonitching cercarial dermatitis that lasted 6 
weeks. Four weeks after exposure, she reported fever and severe headaches for 2 days (Figure, 
top). Molecular diagnostic tests could not identify viral infections on a throat swab. After the 
patient’s fever abated, she had mild headaches for 5 days. One week after onset of symptoms, 
her complete blood count showed eosinophilia (Figure, bottom) and she reported periorbital 
edema of the left eye. We treated her with cetirizine for 2 days, and the edema resolved.
All symptoms eventually subsided, and both patients recovered completely. At the end of 
the study (week 12), we treated them with praziquantel, 40 mg/kg of body weight, as part of 
the study protocol.
Table. Quantitative Data of the Anti–Adult Worm IgM (IFA) and Anti-Egg IgG (EIA) in Serum and of the 
Parasite Antigen Detection Assays for CCA in Urine and CAA in Serum.
Test week
0 4 5 6 7 8 12
Patient 1
Schistosoma serology
 IFA* <1:16 1:32 1:256 1:1024 >1:1024 >1:1024 >1:1024
 EIA† <1:32 <1:32 - - - - <1:32
Parasite antigen
 Urine POC-CCA Negative Trace - - - Trace Negative
  Serum UCP-LF CAA Negative Trace Positive Positive Positive Positive Positive
Patient 2
Schistosoma serology
 IFA* <1:16 <1:16 1:64 1:1024 >1:1024 >1:1024 >1:1024
 EIA† <1:32 <1:32 - - - - <1:32
Parasite antigen
 Urine POC-CCA Negative Trace - - - Trace Negative
  Serum UCP-LF CAA Negative Negative Negative Positive Positive Positive Positive
EIA = enzyme immunoassay; IFA = immunofluorescent assay; POC-CCA = point-of-care–circulating 
cathodic antigen; UCP-LF CAA = upconverting phosphor-lateral flow circulating anodic antigen. *Cutoff, 
1:16. †Cutoff, 1:32.
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Discussion
Both participants developed Katayama syndrome, as evidenced by typical illness at the 
expected time after exposure without detectable viral or bacterial pathogens (1). In addition, 
both were diagnosed with schistosomiasis by parasite antigen testing in serum (upconverting 
phosphorlateral flow circulating anodic antigen) and had antiworm IgM antibodies detectable 
by immunofluorescent assay 1 week after the onset of fever (Table) (2, 3). Selection of male 
cercariae by molecular tests for the experimental infection ensured that Schistosoma egg 
production would not occur (4). In addition, the monosexual infection was supported by the 
absence of IgG antibody responses to egg antigens on enzyme immunoassay (Table) and the 
lack of detectable Schistosoma DNA in feces (3).
Katayama syndrome has been described as an immune complex–mediated hypersensitivity 
response to schistosomes or their eggs in previously unexposed persons (1). The antigens that 
trigger the syndrome are unknown. Our cases prove that it can occur in the absence of eggs 
and suggest that newly expressed antigens on developing worms may be the cause. The classic 
type 1 immunologic responses in Katayama syndrome (for example, urticaria; angioedema; and 
particularly periorbital edema, which occurred in one participant) suggest that worm-specific IgE 
has a role in this process. These IgE-mediated conditions often respond well to antihistamines 
and corticosteroids (5).
Katayama syndrome can be remarkably heterogeneous in terms of clinical signs and 
symptoms (1). Because symptoms are generally mild, transient, and nonspecific, the diagnosis 
is easily overlooked. Our cases show that both eosinophilia and seroconversion may become 
apparent after severe symptoms have subsided, that Katayama syndrome can be diagnosed as 
early as 5 weeks after exposure, and that it is not necessarily related to egg deposition.
6.




1. Ross AG, Vickers D, Olds GR, Shah SM, McManus 
DP. Katayama syndrome. Lancet Infect Dis. 
2007;7:218-24. [PMID: 17317603]
2. Corstjens PL, Nyakundi RK, de Dood CJ, Kariuki 
TM, Ochola EA, Karanja DM, et al. Improved 
sensitivity of the urine CAA lateral-flow assay 
for diagnosing active Schistosoma infections by 
using larger sample volumes. Parasit Vectors. 
2015;8:241. [PMID: 25896512] doi:10.1186/
s13071-015-0857-7
3. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, 
Knopp S. New diagnostic tools in schistosomiasis. 
Clin Microbiol Infect. 2015;21:529-42. [PMID: 
25843503] doi:10.1016/j.cmi.2015.03.014
4. Janse JJ, Langenberg MCC, Kos-Van Oosterhoud 
J, Ozir-Fazalalikhan A, Brienen EAT, Winkel 
BMF, et al. Establishing the production of 
male Schistosoma mansoni cercariae for a 
controlled human infection model. J Infect 
Dis. 2018;218:1142-6. [PMID: 29905805] 
doi:10.1093/infdis/jiy275
5. Rocha MO, Greco DB, Pedroso ER, 
Lambertucci JR, Rocha RL, Rezende DF, et 
al. Secondary cutaneous manifestations of 
acute schistosomiasis mansoni. Ann Trop Med 
Parasitol. 1995;89:425-30. [PMID: 7487229]
Marijke Langenberg BNW proef V3.indd   106 27-04-21   08:54
107
Katayama syndrome without Schistosoma mansoni eggs
6.
Marijke Langenberg BNW proef V3.indd   107 27-04-21   08:54
Marijke Langenberg BNW proef V3.indd   108 27-04-21   08:54
CHAPTER 2










*These authors contributed equally
Science Translational Medicine 2017 Jun 21;9(395)
CHAPTER 7
A controlled human 
Schistosoma mansoni infection 
model to advance novel drugs, 
vaccines and diagnostics
Marijke C. C. Langenberg, Marie-Astrid Hoogerwerf*, 
Jan Pieter R Koopman*, Jacqueline J. Janse, 
Janneke Kos-van Oosterhoud, Carola Feijt, Simon P. 
Jochems, Claudia J. de Dood, Roos van Schuijlenburg, 
Arifa Ozir-Fazalalikhan, Mikhael D. Manurung, Erliyani Sartono, 
Martha T. van der Beek, Béatrice M. F. Winkel, 
Petra H. Verbeek-Menken, Koen A. Stam, Fijs W. B. van Leeuwen, 
Pauline Meij, Angela van Diepen, Lisette van Lieshout, 
Govert J. van Dam, Paul L. A. M Corstjens, Cornelis H. Hokke**, 
Maria Yazdanbakhsh**, Leo G. Visser**, Meta Roestenberg
Nature Medicine, 2020 Mar; 26(3):326-332




Schistosomiasis treatment relies on the use of a single drug, praziquantel, which is insufficient 
to control transmission in highly endemic areas1. Novel medicines and vaccines are urgently 
needed2,3. An experimental human model for schistosomiasis could accelerate the development 
of these products. We performed a dose-escalating clinical safety trial in 17 volunteers with male 
Schistosoma mansoni cercariae, which do not produce eggs (clinicaltrials.gov NCT02755324), at 
the Leiden University Medical Center, the Netherlands. The primary endpoints were adverse 
events and infectivity. We found a dose-related increase in adverse events related to acute 
schistosomiasis syndrome, which occurred in 9 of 17 volunteers. Overall, 5 volunteers (all 3 of 
the high dose group and 2 of 11 of the medium dose group) reported severe adverse events. 
Worm-derived circulating anodic antigen, the biomarker of the primary infection endpoint, 
peaked in 82% of volunteers at 3–10 weeks following exposure. All volunteers showed IgM and 
IgG1 seroconversion and worm-specific cytokine production by CD4+ T cells. All volunteers were 
cured with praziquantel provided at 12 weeks after exposure. Infection with 20 Schistosoma 
mansoni cercariae led to severe adverse events in 18% of volunteers and high infection rates. This 
infection model paves the way for fast-track product development for treatment and prevention 
of schistosomiasis.
Marijke Langenberg BNW proef V3.indd   110 27-04-21   08:54
111
A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics
Introduction
Worldwide, 290 million people are infected with schistosomes, mainly Schistosoma haematobium 
and Schistosoma mansoni4. The endemicity is determined by the presence of the fresh water 
snail intermediate host. Snail-derived cercariae penetrate the human skin and migrate into the 
vascular system, where mature male and female worms mate and produce ~300 eggs per day. 
S. mansoni eggs provoke inflammatory responses, which can lead to liver cirrhosis and portal 
hypertension5.
Current treatment and control of schistosomiasis relies on the use of a single drug, 
praziquantel. Mass drug administration with praziquantel does not protect from reinfection1 
and thus provides insufficient control in highly endemic areas, creating the need for a vaccine2.
Several schistosome antigens have been put forward as possible S. mansoni vaccine 
candidates, of which three are in clinical development: Sm-TSP-2, rSm14/GLA-SE and Sm-
p806–8. These candidates aim for >40% reduction in worm load for World Health Organization 
endorsement9, but higher levels are preferred10,11. To obtain efficacy data, large phase II and 
III field trials in Schistosoma-endemic areas are needed12. In addition, increasing concerns of 
praziquantel resistance create a need for anti-schistosomal drug development3. Controlled 
human infection (CHI) trials can select drug and vaccine candidates early in clinical development 
and help prevent late clinical failure12. We thus aimed to develop a schistosome CHI model to 
aid vaccine and drug development and better characterize human anti-schistosome immune 
responses.
Between September 2016 and January 2018, 35 healthy adult volunteers were screened, 
of which 17 were included in the trial and completed follow up (Fig. 1). Baseline demographics 
between dose groups were comparable (Supplementary Tables 1 and 2).
Volunteers were exposed to 10, 20 or 30 cercariae in water on the forearm skin for 30 min, 
after which they were followed bi-weekly for adverse events and infectivity. After exposure, 
water was pipetted off the skin and inspected for remaining cercariae. We found tails of roughly 
half the number of the cercariae that they were exposed to, with clear differences between 
exposure groups (r = 0.70, P = 0.002; Supplementary Table 1).
Results
Safety
The majority of volunteers (15 of 17, 88%) experienced pruritus during or after exposure, but no 
topical treatment was required (Supplementary Table 3). All but one volunteer (16 of 17, 94%) 
developed a mild local cercarial dermatitis within 2 d after exposure (Fig. 2a–c), which lasted 
longer in higher dose groups (10 cercariae: median 1 week (range 1–2); 20 cercariae: 3 weeks 
(1–9); 30 cercariae: 6 weeks (2–7), r = 0.45, P = 0.07).
7.
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Figure 1. Study flow diagram. The inclusion and exclusion of volunteers. The first group (n = 3 
volunteers) was exposed to 10 cercariae and the second group (n = 3 volunteers) to 30 cercariae. 
Thereafter the dose was de-escalated to 20 cercariae for the third group (n = 3 volunteers) and validated 
in a fourth group (n = 8 volunteers). In total eight volunteers served as backup for included volunteers in 
case an included volunteer might drop out before exposure to cercariae.
There were no serious adverse events (AEs) (an event that is life-threatening or requires 
hospitalization), but nine severe related AEs (resulting in the inability to perform daily activity) 
were reported in volunteers from the 20 (n = 2) or 30 cercariae (n = 3) group. Seven of these 
severe AEs were symptoms of an acute schistosomiasis syndrome (n = 5). In the 30 cercariae 
group all volunteers (n = 3) experienced severe AEs, starting 2.5 to 5.0 weeks after exposure (Fig. 
2d–f) as follows: headache (n = 2), fever (n = 2), syncope (n = 1), nausea (n = 1) and elevated liver 
enzymes (n = 1) (Supplementary Table 3). In one volunteer this episode was followed by mild 
to moderate headaches, malaise, fatigue and nocturnal sweats for up to 6 weeks as previously 
described13, but steroid treatment was declined. Given the burden of these prolonged symptoms 
of an acute schistosomiasis syndrome (Katayama symptoms), defined as moderate to severe 
symptoms of malaise, fatigue, fever, night sweats, flu-like symptoms or headache, between 2 to 
7 weeks after exposure, the dose was de-escalated to 20 cercariae. Subsequently, 2 of 11 (18%) 
volunteers reported one severe symptom of an acute schistosomiasis syndrome (headache, 
nocturnal fever and sweats).
In addition to these five volunteers with severe AEs there were four volunteers, all exposed 
to 20 cercariae, with moderate symptoms of an acute schistosomiasis syndrome (flu-like 
symptoms, n = 3; and malaise, n = 2). Eight volunteers did not experience any symptoms of an 
acute schistosomiasis syndrome.
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Figure 2. Adverse events. a–c, Pictures of volunteers with the most pronounced cercarial dermatitis 
taken 5 d after infection from the group infected with 10 cercariae (a), 20 cercariae (b) or 30 cercariae 
(c). d–f, The average number of related AEs per volunteer at each week for volunteers exposed to 10 
cercariae (d), 20 cercariae (e) or 30 cercariae (f). For each AE the highest grading score is plotted. White 
bar, mild AE; light gray bar, moderate AE; dark gray bar, severe AE.
Figure 3. Pre-patent period and serum CAA levels. a, The time to patency (serum CAA level > 1 pg ml−1) 
in weeks per dose group (log-rank test, P = 0.21). b, The serum CAA levels for individual volunteers in pg 
ml−1 (top) and the median serum CAA levels and interquartile range for groups infected with 10, 20 or 
30 cercariae (bottom). The gray, yellow and blue lines represent data of individual volunteers or groups 
exposed to 10 (n = 3), 20 (n = 11) or 30 (n = 3) cercariae respectively.
7.




Eosinophils increased in 11 of 17 (65%) volunteers peaking between week 2 and 8 after infection 
(0.1–8.4 × 109 l−1; Extended Data Fig. 1). Eosinophils were not related to the dose or symptoms 
(Extended Data Fig. 2a).
Infection rates by antigen detection assays
Both worm-excreted circulating anodic antigen (CAA) and circulating cathodic antigen (CCA) 
were measured to determine the presence and degree of infection. In two of three volunteers 
exposed to 10 cercariae the serum CAA was higher than 1 pg ml−1. In the higher dose groups, 9 
out of 11 (82%) volunteers exposed to 20 cercariae and all volunteers exposed to 30 cercariae 
crossed this threshold. The time to patency was comparable between these groups (range 3–8 
weeks, Fig. 3a).
Cercarial dose and serum CAA levels were related (10 cercariae median at week 7–12: 0.4 
pg ml−1 (range 0.3–0.8); 20 cercariae: 1.2 pg ml−1 (0.3–1.9); and 30 cercariae: 3.6 pg ml−1 (2.0–
6.5), r = 0.70, P = 0.002) (Fig. 3b). The volunteer experiencing the most severe AEs had at least 
sevenfold higher serum CAA levels (maximum 49.9 pg ml−1) than other volunteers. There was 
no significant correlation between serum CAA levels and symptoms of an acute schistosomiasis 
syndrome (Extended Data Fig. 2b) or eosinophils (data not shown).
Urine CAA levels were variable (Extended Data Fig. 3a,b), but correlated with serum CAA 
(r = 0.58, P < 0.0001). The point-of-care rapid test for CCA (POC-CCA) was positive in 12% (2 
of 17) of volunteers within 12 weeks after exposure and did not correlate with serum or urine 
CAA levels.
Praziquantel treatment
After a single 40 mg kg–1 dose of praziquantel treatment 12 weeks after exposure, serum CAA 
levels dropped below the detection limit in 8 out of 14 (57%) positive volunteers. The remaining 
43% of volunteers were treated again with praziquantel, after which all remained undetectable 
until 1 year after exposure (Extended Data Fig. 4a–c).
Serology
All volunteers showed seroconversion of IgM against adult worms by immunofluorescence assay 
(IFA) (Fig. 4a,b). Seroconversion became apparent at week 4 in two volunteers and by week 6 
in all. In addition, seven volunteers showed anti-soluble egg antigen (SEA) IgG seroconversion 
respectively at week 4 (1 of 16), week 12 (1 of 16) or week 20 (5 of 16). The absence of eggs was 
confirmed by a negative feces Schistosoma PCR at week 12 in all volunteers.
All volunteers showed an increase in adult worm antigen (AWA)-specific total IgG over time, 
with seroconversion above 2× s.d. of all baseline values in 12 of 16 volunteers at week 20. These 
responses were primarily IgG1, with seroconversion in all volunteers by week 16 (Fig. 4c,d). 
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Figure 4. Humoral immune response. a, IgM against adult worm antigens over time. The gray, yellow 
and blue lines represent data of individual volunteers exposed to 10 (n = 3), 20 (n = 10) or 30 (n = 3) 
cercariae respectively and the darker lines represent the median of each group. b, IFA showing reactivity 
of volunteer IgM antibodies to Rossman-fixed S. mansoni adult worm sections (right) and pre-exposure 
negative serum (left). T, tegument; G, gastrodermis. c, AWA-specific total IgG for individual volunteers 
over time. d, AWA-specific IgG1 for individual volunteers over time. The gray circles, yellow triangles 
and blue squares represent data of individual volunteers exposed to 10 (n = 3), 20 (n = 10) or 30 (n = 3) 
cercariae respectively.
There was a clear dose response in AWA-specific total IgG and IgG1 levels (IgG week 20: r = 0.70, 
P = 0.003; IgG1 week 16: r = 0.56, P = 0.02), and a trend toward higher IgG1 levels and symptoms 
of an acute schistosomiasis syndrome (P = 0.08) (Extended Data Fig. 2c). No changes over time 
were found in total IgE or AWA-specific IgE and IgG4 compared to baseline (data not shown).
Cytokines
Cytokine and chemokine measurements in serum revealed increases in innate chemokines 
interferon (IFN)-γ- inducible protein (IP)-10 (Fig. 5a,b) and macrophage inflammatory protein 
(MIP)-1β (Fig. 5c), the latter of which was significantly higher in volunteers with symptoms of an 
acute schistosomiasis syndrome (P = 0.01 at week 8, Fig. 5d). There were no detectable changes 
in the other circulating chemokines or cytokines measured in serum (data not shown).
7.
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Figure 5. Cytokine responses. a, Ex vivo IP-10 over time for individual volunteers (dotted line) and 
the mean of each group (line). b, IP-10 levels at week 8 in volunteers with (yes, n = 8) or without (no, 
n = 8) symptoms of an acute schistosomiasis syndrome (two-sided Mann–Whitney U-test, P = 0.16). 
c, Ex vivo MIP-1β over time for individual volunteers (dotted line) and the mean of each group (line). 
d, MIP-1β levels at week 8 in volunteers with (yes, n = 8) or without (no, n = 8) symptoms of an acute 
schistosomiasis syndrome at week 4 (two-sided Mann–Whitney U-test, P = 0.01). e, The percentage 
of IFN-γ-producing CD4+ T cells (P = 0.01), Th2 cytokine (IL-4, IL-5 and IL-13)-producing CD4+ T cells 
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(P = 0.004), FOXP3+CD25+CD4+ T cells (P = 0.49) and IL-10-producing CD4+ T cells (P = 0.91) over time for all 
volunteers (n = 16), showing average of all volunteers at each week and fitted linear regression line with 
95% confidence interval (linear mixed model with two-sided Student’s t-test, using the Satterthwaite’s 
degrees of freedom method). f, The percentage of IFN-γ-producing CD4+ T cells (P = 0.28), Th2 cytokine 
(IL-4, IL-5 and IL-13)-producing CD4+ T cells (P = 0.01), FOXP3+CD25+CD4+ T cells (P = 0.02) and IL-10-
producing CD4+ T cells (0.56) in volunteers with (yes, n = 8) or without (no, n = 8) symptoms of an acute 
schistosomiasis syndrome. In all boxplots, the lower and higher hinge are respectively the first and third 
quartiles and the middle line is the median (second quartile). The whiskers extend from the hinge to the 
largest value no further than 1.5× the interquartile range or distance between the first and third quartile. 
The largest and lowest visible points beyond the whiskers extend this range and can then be considered, 
respectively, the maxima and minima.
Cellular immunology
Overall, the frequency of antigen-specific IFN-γ (P = 0.01) and Th2 cytokine (interleukin (IL)-4, 
IL-5 and IL-13, P = 0.004)-producing CD4+ T cells increased over time (Fig. 5e and Extended Data 
Fig. 5a,b), but FOXP3+CD25+CD4+ regulatory T cells (P = 0.49) or the production of the regulatory 
cytokine IL-10 (P = 0.91, Fig. 5e) did not. However, in volunteers with symptoms of an acute 
schistosomiasis syndrome, both IFN-γ and Th2 cytokine-producing CD4+ T cells and CD25+FOXP3+ 
regulatory T cells were higher at week 4 and week 8 respectively, although not significantly 
for all (P = 0.28, P = 0.01 and P = 0.02, respectively; Fig. 5f). There were no differences in IL-10-
cytokine-producing CD4+ T cells at week 4 (Fig. 5f). At all timepoints 17% of IFN- γ+CD4+ T cells 
also produced IL-2.
Data integration
To understand which immunological and microbiological datasets were associated with the 
occurrence of symptoms of an acute schistosomiasis syndrome, we performed data integration 
using parallel generalized canonical correlation and partial least squares discriminant analysis. 
Eosinophil data decreased model accuracy and were thus removed (Extended Data Fig. 6a,b). At 
baseline, 9 of 16 (56.3%) participants were accurately predicted by the model with leave-one-
out cross-validation, which increased to 13 of 16 (81.3%) correct classifications at week 12 and 
further to 15 of 16 (93.8%) when data from all timepoints were included (Fig. 6a,b). Thus, the 
model was able to accurately classify participants by the presence of an acute schistosomiasis 
syndrome. Permutation analysis confirmed that symptoms were strongly associated with the 
measured immunological and microbiological parameters over the infection course (n = 1,000; 
99.6th percentile, Extended Data Fig. 6c). We identified Th2 cytokines at week 4 and FOXP3 
regulatory T cells at weeks 12 and 16, MIP-1β at weeks 8 and 12 and levels of serum CAA at week 
9 as important features elevated in symptomatic participants by leave-one-out cross-validation 
(Fig. 6c). Levels of Th2 cytokines upon stimulation at week 4 correlated with serum CAA at week 
9, whereas concentrations of MIP-1β in plasma correlated with FOXP3 regulatory T cell numbers 
(Extended Data Fig. 6d).
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Figure 6. Immunological and microbiological data integration. Cellular, antibody, antigen and Luminex 
data were combined with generalized canonical correlation analysis and simultaneously associated with 
presence of symptoms through discriminant analysis. a, Proportion of correct predictions of each model 
assessed using leave-one-out cross-validation. Gray bars indicate data from one specific timepoint and 
orange bars indicate the model, including all data across timepoints. The number of correct predictions 
is indicated above each bar. b, Individual predictions across folds for the full model per dataset, including 
majority vote, with weighing to break ties. Each symbol represents one prediction, with volunteers in 
columns and datasets in rows. Filled circles indicate a correct prediction and open circles a false prediction. 
Volunteers with (red, n = 8) or without (green, n = 8) symptoms of acute schistosomiasis syndrome are 
indicated, as are the number of correct predictions per dataset. c, Consensus features selected in at least 
25% of the folds are indicated and ranked by frequency of presence among folds. The number after each 
feature indicates the week of measurement. The z score-normalized levels of the seven features present  
in at least 75% of the folds are indicated in the heat map, where each column corresponds to one volunteer. 
Missing data points from one asymptomatic participant are depicted in white.
Discussion
This pilot study shows that experimental exposure to 20 male cercariae results in a detectable 
and well-tolerated S. mansoni infection in 82% of volunteers. This infection rate resembles that 
of other human infection models14. All volunteers were cured after 1–2 doses of praziquantel.
The dose-escalating design of the study revealed a concomitant increase in AEs. The occurrence 
of a severe acute schistosomiasis (Katayama) syndrome in one volunteer prompted us to lower 
the dose. At a dose of 20 cercariae, 2 of 11 volunteers reported severe AEs, which is comparable 
with other human infection models. For example, in experimental malaria infections, volunteers 
generally experience three to four AEs, of which one would be severe for several days15. In 
typhoid infections ~50% of volunteers report severe symptoms and 55% experiences fever16 and 
in cholera infection studies 40% of volunteers experience 1.6–8.0 liters of diarrhea17. We thus 
conclude that 20 cercariae may be the optimal dose that was both well tolerated and detectable. 
A relationship between dose and symptoms, as suggested by epidemiological data18, cannot be 
Marijke Langenberg BNW proef V3.indd   118 27-04-21   08:54
119
A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics
statistically confirmed with the current number of volunteers. Regardless of dose, all symptoms 
had resolved without sequelae at 12 weeks.
The follow up of volunteers in our study unequivocally showed that anti-adult worm IgM 
(100% seroconversion by week 6) or serum CAA (10 of 17 positive by week 6) are the earliest 
diagnostic markers currently available. This is in accordance with previous studies in travelers19–21. 
We found levels of serum CAA comparable to those in low endemic settings22. In nonhuman 
primate models these levels reflect 5–24 cercariae reaching adulthood8,23. Although serum CAA 
levels were more stable compared to urine CAA, the higher volume input of urine allows for 
more sensitive detection24. As suggested in previous studies, the urine POC-CCA rapid test was 
not suitable to detect very low intensity infection25. The main advantage of measuring serum 
CAA levels, as opposed to antibody detection, is the potential to follow up after treatment and 
confirm cure. In doing so, we found low cure rates with a single dose of 40 mg kg−1 praziquantel. 
Although a 60 mg kg−1 dose seemed more effective, the subsequent changes in pharmacokinetic 
and pharmacodynamic parameters need to be evaluated to conclude this with certainty. Because 
of the synchronous development of adult worms and the absence of reinfection in our model, 
the CHI design allows for screening of existing and new (stage-specific) anthelmintics.
The controlled schistosome infection model presented here clearly differs from infections in 
endemic settings, where doses are not controlled and infection occurs repeatedly. In addition, 
the single-sex infection lacks production of eggs that drive chronic regulatory and modified 
Th2 responses26. The presence of IgG to soluble egg antigen, indicates cross-reactive epitopes 
between eggs and worms. The induction of chemokines IP-10 and MIP-1β aligned with the 
increase in both antigen-specific CD4+ T cell IFN-γ and Th2 cytokine production, respectively. The 
IFN-γ production contrasts with predominantly Th2 profiles in epidemiological studies, which 
may be driven by egg-related responses26. Although we detected increases in FOXP3+CD25+CD4+ T 
cells, these mainly occurred in symptomatic volunteers and were found at a later timepoint than 
IFN-γ- or Th2 cytokine-producing T cells. This would be in line with the induction of regulatory 
T cells to prevent deleterious immune responses27, different from the chronic regulation 
found in endemic infections. These important differences in antigen exposure and subsequent 
immunological responses between single-sex infections and endemic chronic egg production 
may limit the use of the model to study anti-fecundity effects. However, the immunological 
observations from our model are comparable to acute infection models in travelers and baboons, 
where a mixed Th1 and Th2 response also dominates28,29. Integrated data analysis revealed that 
acute schistosomiasis symptoms were particularly associated with antigen-specific Th2 cytokine 
production and circulating MIP-1β and IgM production, but could not be predicted at baseline. 
In contrast to volunteers with symptoms, those without symptoms predominantly showed IgG1 
antibody responses. Similarly to what has been performed for other infectious diseases30, a trial 
with repeated controlled infections could address whether these IgM or IgG1 antibodies have 
a protective effect. Currently, the clinical and immunological data from baseline alone cannot 
predict who will become symptomatic. However, the analysis of longitudinal responses reveals a 
clear profile predicting presence or absence of symptoms in 15 out of 16 participants. Unraveling 
the interplay between symptoms, immune responses and resistance to schistosome reinfection 
provides an opportunity for identification of new antigens for vaccine development31.
Immunological models for protection against S. mansoni were developed in rodents and 
nonhuman primates by repeated exposure to radiation attenuated cercariae23,32. In humans, 
three candidate S. mansoni vaccines are currently in clinical development6. A phase I study with 
rSm14/GLA-SE showed a good safety profile and immunogenicity7. Phase I safety results for Sm-
7.
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TSP-2 are expected soon (ClinicalTrials.gov identifier: NCT02337855), while Sm-p80 is currently 
entering phase I testing on the basis of promising efficacy data in baboons8. The limited funding 
opportunities and large sample size required for phase III testing preclude testing of all three 
candidates in phase III trials. Despite the differences between chronic S. mansoni infection in 
the field and the controlled human S. mansoni infection, the model provides an opportunity to 
obtain preliminary efficacy data on these vaccines and reduce the costs by allowing selection of 
the most promising candidates, which may be co-formulated to maximize benefit12.
Future vaccine studies aim at a 75% infection reduction in worm burden and egg output10. As 
there is a clear relationship between worm burden and serum CAA levels24,33, we propose that 
the reduction in worm burden can be determined by measuring the median serum CAA level 
between week 7–12. Assuming an 80% power and α = 0.05, this would require a group size of 11 
individuals per arm. Currently the main limitation of our model is the use of male schistosomes 
only. Consequently vaccine targets that are more commonly expressed on females, such as the 
Sm-p80 vaccine candidate8, cannot be fully evaluated. A female worm infection model would 
be of value to dissect mechanisms of action and sex-specificity of vaccines.
We conclude that this controlled human S. mansoni infection model results in an 82% 
infection rate with few severe side effects at a dose of 20 cercariae. In addition, this model 
provides insight into the onset of symptoms of a schistosome infection, the ensuing immune 
response and the performance of diagnostic tests over time. Notably, this model paves the way 
for cost-effective and rapid proof-of-concept testing of new vaccines and drugs.
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Methods
Study design
This phase I trial (ClinicalTrials.gov identifier: NCT02755324) was an open-label dose-escalation 
study at the Leiden University Medical Center (LUMC).
Male cercariae were produced as previously reported34. The initial dose was 10 cercariae (n = 3), 
which was escalated to 30 (n = 3) and subsequently de-escalated to 20 cercariae (n = 3) on the 
basis of AEs. The 20 cercariae infection was then validated in another group (n = 8). The viability 
of cercariae was confirmed by imaging of cercariae penetrating skin explants35. The cercariae 
were applied to the volunteer’s forearm in 0.5–1 ml of water for 30 min, the number of remaining 
cercariae were counted by microscopy. Volunteers were observed for 30 min after exposure.
Volunteers were followed bi-weekly between week 0–24 and on week 52. During each visit, 
AEs were recorded. Symptoms of an acute schistosomiasis syndrome were defined as moderate 
to severe symptoms of malaise, fatigue, fever, night sweats, flu-like symptoms or headache, 
between 2–7 weeks after exposure. Safety reports were reviewed regularly by an external safety 
monitor, who advised on dose escalation. Blood and urine samples were collected at all visits.
The pre-patent period was defined as the time until serum CAA levels were above 1.0 pg ml−1 
24. At week 12 all volunteers were treated with 40 mg kg−1 praziquantel in two doses. A second 
regimen of 60 mg kg−1 praziquantel in two doses was provided if serum CAA levels persisted 3–6 
weeks after treatment. Cure was defined as serum CAA levels ≤0.5 pg ml−1.
The study was approved by the LUMC Institutional Medical Ethical Research Committee 
(Institutional Review Board P16.111). It was performed according to the European Clinical Trial 
Directive 2001/20/EC, in accordance with ICH-GCP guidelines and the Declaration of Helsinki36,37.
Informed consent procedure
Healthy 18–45-year-old Schistosoma-naïve volunteers were screened by medical history, 
general physical examination and safety laboratory tests. Informed consent was obtained from 
all volunteers.
Through advertisements, volunteers provided their email address and received written 
information. When they so wished, volunteers could schedule a screening visit at least 3 d after 
having received the information. They were then requested to complete an application form, 
which included a questionnaire regarding their health.
During the 1.5–2-h screening visit, the study purpose and procedures were explained and 
questions answered. The possible AEs and right of withdrawal were explained to the volunteers. 
The informed consent form was signed and a full physical exam was performed. All volunteers 
were required to consent to an HIV, hepatitis B (HBV) and hepatitis C (HCV) serological screening, 
urine toxicology and (for females), a pregnancy test at screening.
At the infection day (14 d to 23 weeks after screening), informed consent was reconfirmed, 
and a final check of inclusion and exclusion criteria was performed, including a focused 
physical exam. Volunteers were exposed to male Schistosoma mansoni cercariae after baseline 
assessment and safety laboratory tests.
7.
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The first volunteer was included on 27 October 2015 and the last volunteer was included on 1 
February 2018.
All three volunteers gave permission to use the photographs (Fig. 2a–c) taken of their skin 
after cercarial exposure for publication.
Inclusion and exclusion criteria
Inclusion criteria
•  Volunteer is aged ≥ 18 and ≤ 45 years and is in good health.
•  Volunteer has adequate understanding of the procedures of the study and agrees to abide 
strictly thereby.
•  Volunteer is able to communicate well with the investigator and is available to attend all 
study visits.
•  Volunteer will remain within Europe (excluding Corsica) during the study period and is reachable 
by mobile telephone from week 3 to week 12 of the study period.
•  Volunteer agrees to refrain from blood donation to Sanquin or for other purposes throughout 
the study period.
•  For females: volunteer agrees to use adequate contraception and not to breastfeed for the 
duration of study.
• Volunteer has signed informed consent form.
Exclusion criteria
•  Any history, or evidence at screening, of clinically significant symptoms, physical signs or 
abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, 
pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, hematological, 
infectious, immune-deficient, psychiatric and other disorders, which could compromise the 
health of the volunteer during the study or interfere with the interpretation of the study 
results. These include, but are not limited to, any of the following:
• body weight <50 kg or body mass index <18 or >30 kg m−2 at screening;
• positive HIV, HBV or HCV screening tests;
•  the use of immune-modifying drugs within 3 months before study onset (inhaled and 
topical corticosteroids and oral anti-histamines exempted) or expected use of such during 
the study period;
•  history of malignancy of any organ system (other than localized basal cell carcinoma of the 
skin), treated or untreated, within the past 5 years;
• any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
•  history of drug or alcohol abuse interfering with normal social function in the period of 1 year 
before study onset;
•  any clinically significant abnormalities (including extended QT interval) on electrocardiogram.
•  The chronic use of any drug known to interact with praziquantel, artesunate or lumefantrine 
(artesunate combined with lumefantrine served as alternative treatment of schistosomiasis 
in an earlier phase of infection) metabolism (for example, phenytoin, carbamazepine, 
phenobarbital, primidone, dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, 
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imipramine, amitriptyline, clomipramine, class IA and III anti-arrythmics, antipsychotics, 
antidepressants, macrolides, fluorquinolones, imidazole- and triazole antimycotics and anti-
histamines). Because lumefantrine may cause extension of QT-time, chronic use of drugs with 
effect on QT interval are excluded from the study.
• For female volunteers: positive urine pregnancy test at screening
• Any history of schistosomiasis or treatment for schistosomiasis
• Positive serology for schistosomiasis or elevated serum or urine CAA at baseline
•  Known hypersensitivity to or contraindications (including co-medication) for use of praziquantel, 
artesunate or lumefantrine




•  Mild (grade 1): awareness of symptoms that are easily tolerated and do not interfere with 
usual daily activity
• Moderate (grade 2): discomfort that interferes with or limits usual daily activity
•  Severe (grade 3): disabling, with subsequent inability to perform usual daily activity, resulting 
in absence or required bed rest
•  Serious AE: any untoward medical occurrence in a patient or trial participant, which does not 
have a causal relationship with the treatment, and:
 - is fatal, and/or
 - is life-threatening for the volunteer, and/or
 - makes hospital admission or an extension of the admission necessary, and/or
 - causes persistent or significant invalidity or work disability, and/or
 - manifests itself in a congenital abnormality or malformation, and/or
 -  could, according to the person that carries out the research, have developed to a 




•  Not related: a relationship to the administration of the S. mansoni male cercariae cannot be 
reasonably established; another etiology is known to have caused the AE or is highly likely to 
have caused it.
•  Unlikely related: a relationship to the administration of S. mansoni male cercariae is unlikely; 
however, it cannot be ruled out.
Related
•  Possibly related: there is a potential association between the event and administration of 
the S. mansoni male cercariae; however, there is an alternative etiology that is more likely.
7.
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•  Probably related: administration of the S. mansoni male cercariae is the most likely cause; 
however, there are alternative reasonable explanations, even though less likely.
•  Definitely related: administration of the S. mansoni male cercariae is the cause; another 
etiology causing the adverse event is not known.
Parasitological assays
CAA was measured in serum and urine by the previously described upconverting phosphor 
lateral flow (UCP-LF CAA) assay24,38. The presence of urine CCA was determined by the POC-CCA 
(Rapid Medical Diagnostics). The Schistosoma PCR on feces was performed according to previous 
descriptions (ISO 15189:2012-certified)39.
Antigen detection assays
Upconverting phosphor lateral flow assay for circulating anodic antigen
Both serum and urine were analyzed for schistosome CAA using a UCP-LF CAA assay. The assay 
was performed as described previously24,38. In brief, 500 μl of serum (or 4 ml of urine) samples or 
standards were diluted 1:1 in 4% trichloro-acetic acid (TCA) (or diluted 5:1 in 12% TCA for urine 
samples) and incubated for 5 min at room temperature. Serum samples were centrifuged for 10 
min at 13,000 r.p.m. (and urine samples were centrifuged for 45 min at 4,000 r.p.m.). Then 500 
μl of supernatants of serum (or 4 ml of urine) was applied to 0.5-ml (or 4.0-ml) Amicon filtration 
devices (Amicon Ultra-0.5 (or Amicon Ultra4), Millipore) and concentrated to approximately 20 
μl by centrifugation for 25 min at 13,000 r.p.m. for serum (or 60 min at 4,000 r.p.m. for urine). 
The concentrates were diluted 1:5 in LF assay buffer and incubated in microtiter plate wells 
at 37 °C for 1 h while shaking. LF strips were inserted into the wells and incubated for 3 h or 
overnight, before being read on a modified Packard FluoroCount microtiter plate reader24. A TCA-
soluble fraction of S. mansoni adult worm antigen with known CAA concentration was used as 
a reference standard for the quantification of the antigen. Predefined cutoff values were used, 
where a serum CAA concentration above 1 pg ml−1 was defined as positive, below 0.5 pg ml−1 as 
negative and between 0.5 and 1.0 as undecisive24.
Point-of-care circulating cathodic antigen
Urine samples were tested for the presence of schistosome CCA using a commercially available 
rapid diagnostic test (POC-CCA, batch no. 170622073, Rapid Medical Diagnostics) according to 
the manufacturer’s procedure. Readings above a trace line were considered as positive.
Immune responses
Clinical diagnostics
Schistosome-specific antibodies, IgM against adult worms and anti-SEA IgG were determined 
according to ISO 15189:2012-certified routine diagnostic in-house IFA and ELISA respectively, 
which have been in use for the clinical diagnosis of schistosomiasis at the LUMC for decades40,41.
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IgM adult worm antibodies by IFA
IgM antibodies against adult worms were detected by an in-house IFA assay as previously 
described42. This IFA, as well as the ELISA described below, are currently in use at LUMC as 
the routine antibody detecting assays for the diagnosis of imported schistosomiasis and 
feature in all laboratory quality assessment requirements (ISO 15189:2012-certified), including 
successful participation in an external quality assessment scheme (UK-NEQAS). In brief, sections 
of Rossman’s fixed male adult worms were incubated with a twofold dilution series of serum 
samples starting at 1:8 dilution. Following incubation with goat anti-human IgM (u-chain specific)-
FITC antibody (Sigma-Aldrich; F5384), slides were examined using a fluorescence microscope. A 
negative control and a positive reference serum were run in parallel at each slide. The titer was 
determined as the dilution of the sample at which the fluorescence of adult worm gut epithelium 
was still visible. Samples were considered positive if titers were above 1:8. Previous studies 
showed that the IgM detected in this IFA is mainly directed against CCA42.
IgG against soluble egg antigen
IgG antibodies directed against S. mansoni SEA were detected by a previously described in-house 
ELISA with some minor modifications40. Crude SEA was prepared from S. mansoni eggs collected 
from the livers of infected hamsters43,44. A concentration of 5 μg protein ml−1 was diluted in 
100 μl of 0.1 M sodium carbonate buffer (pH 9.6) and coated overnight at 4 °C in 96-well plates 
(Polysorb NUNC). Plates were stored at −80 °C until use. After thawing, plates were washed and 
blocked in 1% BSA in PBS for 1 h at 37 °C. A dilution series of serum samples from 1:16 to 1:2,048 
in a solution with 5% FCS and 0.05% Tween in PBS were incubated for 1 h at 37 °C. Plates were 
washed and incubated for 1 h at 37 °C with mouse anti-human IgG alkaline phosphatase 1:10,000 
(Sigma-Aldrich; A2064) in 4% BSA and 0.05% Tween/PBS. Para-nitrophenyl phosphate (pNPP) 
substrate (Sigma-Aldrich; P5994) in 0.1 M diethanolamine buffer (pH 9.6) (Merck) was added for 
1 h at room temperature after washing. Plates were read with the Multiskan EX reader at 405 
nm. A negative control and a positive reference serum were run in parallel at each plate. The 
titer was determined as the dilution of the sample at which the extinction is higher or equal to 
the reference standard. Samples were considered positive if titers were above 1:16.
Experimental immunological assays
Serum was analyzed for total IgE, S. mansoni AWA-specific IgE and IgG by ELISA45–47. Data 
were expressed as arbitrary units (AU ml−1). Peripheral blood mononuclear cells (PBMCs) were 
evaluated for their phenotype and function after 24-h stimulation with crude S. mansoni AWA 
by flow cytometry.
Adult worm antigen-specific IgE, IgG, IgG1 and IgG4
S. mansoni AWA-specific IgE and IgG was measured by ELISA modified from previous protocols45,46. 
In brief, adult S. mansoni worms were collected from hamsters and crude AWA was prepared 
as described previously48. MaxiSorp plates (Nunc) were coated overnight with 5 μg ml−1 AWA 
diluted in carbonate buffer pH 9.6. After blocking with 5% BSA/PBS, the sera were diluted with 
a solution with 5% FCS and 0.05% Tween in PBS and the presence of IgG1 or IgG4 was shown by 
using horseradish peroxidase (HRP)-labeled anti-human IgG1 or HRP-labeled anti-human IgG4 
(1:3,000 dilution; Sanquin). For measuring total anti-AWA IgG antibody, alkaline phosphatase-
conjugated anti-human IgG (1:5,000 dilution; Sigma) was added, whereas for the anti-AWA IgE 
7.
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assay, the plate was incubated with biotinylated goat anti-human IgE (1:1,000 dilution; Vector 
Laboratories) followed by streptavidin HRP conjugate (1:10,000 dilution; Sanquin). IgG1 and IgG4 
assays were developed using tetramethylbenzine, stopped with 10% H2SO4 and the absorbencies 
were measured at 450 nm. For total IgG and IgE, the color was developed by addition of pNPP 
(Sigma) diluted in diethanolamine buffer and optical density was measured at 405 nm. For all four 
assays, the levels of antibody present in a given sample were expressed in AU ml−1 or International 
Units (IU ml−1) according to the standard curve of pooled sera from inhabitants of an S. mansoni 
endemic area in Ghana. The levels of antibody present in a given samples were expressed in AU 
ml−1 for total IgG, IgG1 and IgG4 or in IU ml−1 for IgE. Seroconversion was defined as antibody 
levels above 2× s.d. of the baseline.
Total IgE
Total IgE levels were measured as previously described47. Briefly, MaxiSorp plates were coated 
overnight with rabbit anti-human IgE (Dako). Plates were blocked with PBS 5% BSA followed 
by incubation of diluted samples in PBS 0.05% Tween-20. As a reference, the World Health 
Organization standard of human serum IgE (NIBSC) was used, starting at a concentration of 90 
IU ml−1. After a washing step, the plates were incubated with IgE biotinylated goat anti-human IgE 
antibody (Vector Laboratories) followed by an incubation with streptavidin alkaline phosphatase 
conjugate (Boehringer Mannheim). The color was developed by addition of pNPP (Boehringer 
Mannheim) diluted in diethanolamine buffer and optical density was measured at 405 nm. The 
results were expressed in IU ml−1. Seroconversion was defined as antibody levels above 2× s.d. 
of the baseline.
Ex vivo cytokines
Serum samples were tested for the presence of different cytokines using a commercially 
ProcartaPlex Multiplex Immunoassay (17-plex, lot 178863000, Invitrogen) according to the 
manufacturer instructions. The following cytokines were measured: IFN-α, IFN-β, IL-1β, IL-10, 
IL-12p70, IL-13, IL-15, IL-2, IL-22, IL-23, IL-4, IL-6, IP-10, MCP-1, MIP-1α, MIP-1β and TNF-α using 
the Bioplex 200 Luminex (Bio-Rad).
Cellular immunology
Between week 0 and 24 after exposure every 4 weeks, human PBMCs were isolated from 
whole blood collected in heparin. Cells of two heparin tubes were diluted at least 1:2 with HBSS 
(ThermoFisher) at room temperature. Ten milliliters of ficoll at room temperature was added, 
followed by 25 min centrifugation at 400g with low brake. Cells were collected and washed with 
HBSS, counted and frozen in 10% DMSO, in RPMI Hepes (Invitrogen), with 100 U ml−1 penicillin, 
100 μg ml−1 streptomycin, 1 mM pyruvate/2 mM glutamate and 10% FCS (Bodinco). Subsequently, 
PBMCs were thawed in RPMI Hepes, with 100 U ml−1 penicillin, 100 μg ml−1 streptomycin, 1 mM 
pyruvate/2 mM glutamate and 10% FCS and rested overnight at 37 °C with 5% CO2. Cells were 
counted and transferred to a 96-well round bottom plate (Corning) with 500,000 cells per well. 
Cells were stimulated with AWA (50 μg ml−1) for 24 h. Staphylococcal enterotoxin B (SEB) (Sigma-
Aldrich) 200 ng ml−1 was used as a positive control and RPMI Hepes (Invitrogen), with 100 U ml−1 
penicillin, 100 μg ml−1 streptomycin, 1 mM pyruvate/2 mM glutamate and 10% FCS as a negative 
control. After 4 h of incubation 5 mg ml−1 brefeldin A (Sigma) was added to SEB-stimulated wells 
and after 20 h to AWA- and medium-stimulated wells. After a total stimulation of 24 h, the cells 
were stained with Aqua (Invitrogen) and fixed with 3.9% formaldehyde (Sigma). After fixating, 
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the cells were stained with the following antibodies: CD3, CD4, IFN-γ, IL-2, Th2-cytokines (IL-4, 
IL-5, IL-13), TNF and IL-10 (Supplementary Table 4). Human FC block was used to avoid nonspecific 
interactions. The cells were measured with the FACSCanto II (BD Biosciences; Supplementary 
Fig. 1). The data were analyzed with FlowJo 10.5 software for MAC OS. The gating was placed 
with the help of fluorescence minus one controls, the medium as a negative control and SEB 
as a positive control. The leftover, aqua-stained and fixed cells were frozen in 10% DMSO, in 
RPMI Hepes (Invitrogen), with 100 U ml−1 penicillin, 100 μg ml−1 streptomycin, 1 mM pyruvate/2 
mM glutamate and 10% FCS (Bodinco) and stored at −80 °C. The cells were thawed at 37 °C 
and stained with the following antibodies: CD3, CD4, CD25, CD127 and FOXP3 (Supplementary 
Table 4). As before, human FC block was used to avoid nonspecific interactions. The cells were 
measured with the FACSCanto II (BD Biosciences; Supplementary Fig. 1). The data were analyzed 
with FlowJo 10.5 software for MAC OS. The gating was placed with help of fluorescence minus 
one controls, the medium as a negative control and SEB as a positive control.
Statistical analysis
All 17 volunteers were included in the intention-to-treat analysis (safety analysis and 
parasitological assays). One volunteer was excluded from the per-protocol analysis (all 
immunological readouts) on the basis of high baseline AWA-specific IgG and IgG1 levels. Samples 
from individual volunteers were measured once and plotted as single values.
Demographics and the presence of symptoms between groups were analyzed with a Mann–
Whitney U-test, time to patency with a log-rank test and correlations with a Spearman’s rank 
test. Changes in the frequency of cytokine-producing cells over time were analyzed using a linear 
mixed model. Time was considered as the fixed effect and the volunteer ID as a random effect 
for the intercept. P values based on Student’s t-tests were obtained using the Satterthwaite’s 
degrees of freedom method. In the cytokine boxplots, the negative values (after subtracting 
the medium condition) were set to zero to prevent a negative cytokine response. However, the 
statistical analysis was performed on the unaltered data. All statistical tests were two-tailed 
with α set at the 0.05 level.
Analyses were performed using IBM SPSS statistics for Windows, v.23.0 (IBM Corp.) and R 
(v.3.5). The R packages used were ggplot2, lme4 and lmerTest49–51.
P values were considered significant when P < 0.05.
MixOmics and data integration
Data integration was performed using the mixOmics package in R (v.6.8.0)52,53. This method 
allowed us to correlate across datasets, while associating features with outcome. Feature 
selection was performed using Lasso-like penalization for each of the datasets. The number of 
components was set at two and tuning was performed to find the minimum number of features 
needed per dataset (in a range from 1–3 per component) and the correlation between datasets 
was entered into the design matrix. The number of features included in the final model was 3, 
3, 2 and 5 for cytokines, antigens, antibodies and cellular responses, respectively. A correlation 
of 0.75 between datasets was used in the design matrix.
7.
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Extended Data Figure 1. Eosinophil counts. a-c. Eosinophil counts (x109/L) per volunteer and the median per 
group. The thin green, red, and blue lines represent data of individual volunteers infected with 10 (n = 3), 20 
(n = 11) or 30 (n = 3) cercariae respectively, while thick lines represent the median of each group.
 
 
Extended Data Figure 2. Relation between symptoms of an acute schistosomiasis syndrome and 
immunological readouts. The relation between the presence of symptoms of an acute schistosomiasis 
infection and a. the highest eosinophil count (n = 17), b. the median serum CAA level from week 7 to 12 
(n = 17), or c. the AWA specific IgG1 response at week 16 (n = 16). All using the two-sided Mann-Whitney 
U test. Individual data is presented as dots, the line represents the median, while the error bars 
represent the interquartile range of the groups.
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Extended Data Figure 3. Urine CAA levels. a. Urine CAA levels after exposure and b. after first and 
second praziquantel treatment (week 0) and at week 52 after exposure. The thin green, red, and blue 
lines represent of individual volunteers infected with 10 (n = 3), 20 (n = 11) or 30 (n = 3) cercariae 
respectively, while thick lines represent the median of each group before treatment.
Extended Data Figure 4. Serum CAA levels after treatment. a-c. Serum CAA levels in pg/ml after the first 
treatment, second treatment, and at week 52. All values below the detection threshold of 0.5 pg/mL, are 
plotted at 0.25 pg/mL. The gray, yellow and blue lines represent data of individual volunteers infected 
with 10 (n = 3), 20 (n = 11) or 30 (n = 3) cercariae respectively.
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Extended Data Figure 5. IFN-γ and TH2 cytokine producing CD4+ T-cells over time. The percentage of a. 
IFN-γ and b. Th2-cytokine producing CD4+ T-cells over time in weeks after exposure in the 10 cercariae 
(gray, n = 3), 20 cercariae (yellow, n = 10) and 30 cercariae (blue, n = 3) groups. Dotted lines are linear 
regression lines, gray areas are confidence intervals, light dots are individual data, and horizontal lines 
with dots are the average values.
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Extended Data Figure 6. Effect of eosinophil data and model performance. a. Individual predictions 
across folds for the full model per dataset including majority vote. Each symbol represents one 
prediction, with volunteers in columns and datasets in rows. Filled circles indicate a correct prediction 
and open circles a false prediction. Symptomatic and asymptomatic volunteers are indicated in red 
and the number of correct predictions per dataset is indicated. b. Mean Pearson correlation score 
between datasets using the first component of the projection onto the latent space across all folds from 
the model including all datasets. Size and color of circles reflect the mean rho value. c. Permutations 
analysis (n = 1000) with leave-one-out cross-validation on the full model using all subjects and including 
the four datasets without eosinophils. Blue and red dashed lines indicate the 99th percentile and the 
accuracy when comparing symptomatic and asymptomatic individuals (99.6%), respectively. d. Spearman 
correlation matrix of the seven consensus features selected in > 75% of folds in the leave-one-out cross-
validation. Features were clustered using hierarchical clustering with complete linkage on Euclidean 
distance. All graphs are based on n = 16.
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Supplementary table 1. Demographics and cercariae retrieved after exposure. Demographics of included 
volunteers, (median and range). The number of heads, tails and whole body cercariae retrieved from 
volunteers’ skin after infection (median and range). The 10, 20 and 30 cercariae groups were compared 










(n=3) (n=11) (n=3) (n=17)
Demographics
Gender 0.34
• Male 1 5 0 6
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Supplementary table 2. Volunteer’s age and sex. Listing of volunteer code, group allocation, cercarial 
exposure, sex and age.
Volunteer Group Cercarial exposure Sex Age
Cs1-501 group 1 10 F 20
Cs1-516 group 1 10 F 26
Cs1-753 group 1 10 M 19
Cs1-106 group 2 30 F 23
Cs1-495 group 2 30 F 21
Cs1-674 group 2 30 F 25
Cs1-069 group 3 20 F 22
Cs1-229 group 3 20 F 35
Cs1-425 group 3 20 M 20
Cs1-004 group 4 20 M 18
Cs1-102 group 4 20 F 30
Cs1-464 group 4 20 M 36
Cs1-759 group 4 20 M 25
Cs1-780 group 4 20 F 39
Cs1-832 group 4 20 F 23
Cs1-923 group 4 20 M 35
Cs1-967 group 4 20 F 45
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Supplementary table 4. The antibodies used for staining of the cells.
Antibody Label Dilution Company Cat.
IL-2 FITC 1:25 BD Biosciences 340448
IL-4 PE 1:20 BD Biosciences 340451
IL-5 PE 1:250 Biolegend 504303
IL-13 PE 1:100 Biolegend 501903
CD4 PerCP-ef710 1:400 eBioscience 46-0047
TNF PE-Cy7 1:1000 eBioscience 25-7349
IL-10 APC 1:250 BD Biosciences 554707
CD3 APC ef780 1:800 eBioscience 47-0038
IFN-γ BV421 1:1000 Biolegend 502531
CD3 FITC 1:100 BD Biosciences 555339
CD4 Pe-Cy7 1:150 BD Biosciences 557852
CD25 BV421 1:200 BD Biosciences 562442
CD127 APCe780 1:200 eBioscience 47-1278-42
FOXP3 APC 1:100 eBioscience 17-4776-42
Human FC block - 1:100 eBioscience 14-9161
Live/Dead Aqua AmCyan 1:400 ThermoFisher L34957
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Controlled human infection trials, whereby a small group of healthy participants is deliberately 
exposed to a pathogen under controlled circumstances, can provide preliminary data for 
vaccine efficacy and for the selection of the most promising candidate vaccines for field trials. 
Because of the potential harm to participants through the deliberate exposure to a pathogen, 
the use of smaller groups minimises the cumulative risk. As such, a control group that receives 
a placebo vaccine followed by controlled exposure to a pathogen should be scientifically well 
justified. As these types of trials are designed to generate consistent infection rates and thus 
comparable outcomes across populations and trial sites, data from past studies (historical data) 
could be used as a valid alternative to placebo groups. In this Personal View, we review this 
option and highlight the considerations for choosing historical data as a suitable control. For the 
widespread application of this method, responsibility for the centralisation and sharing of data 
from controlled human infection trials lies with the scientific community.
Marijke Langenberg BNW proef V3.indd   146 27-04-21   08:55
147
Are placebo controls necessary in controlled human infection trials for vaccines?
Introduction
Between 2001 and 2003, eight women with type 1 diabetes were enrolled in a trial to assess the 
safety of a single-donor islet transplantation and all achieved insulin independence in the first 
year after the procedure.1 Even though this study was not designed as a randomised controlled 
trial with a placebo group, the outcome was convincing because the treatment effect was 
clearly evident. The clinical course of type 1 diabetes in the absence of islet transplantation 
is known with certainty: patients will continue to need exogenous insulin. Although health-
care professionals are often wary of evidence from sources other than randomised controlled 
trials to infer treatment effects, there are multiple examples of convincing results without 
this randomised design. Examples in the field of infectious diseases include treatment with 
phototherapy for skin tuberculosis in the 1890s2–4 and treatment with streptomycin for 
tuberculous meningitis in the 1940s.5 Both studies had a large effect size (eg, an 80% reduction in 
deaths using sulphamidochrysoidin for puerperal sepsis),6 showing that treatment effectiveness 
can sometimes be measured reliably even in the absence of a control group.
In controlled human infection trials, susceptibility to infection after vaccination or clearance 
of the infection after taking a drug are tested in healthy individuals by exposing them to 
pathogenic microorganisms. In this Personal View, we will focus only on the design of vaccine 
trials. Most of these studies are done as randomised controlled trials in which participants are 
randomly assigned to either a vaccine or placebo group. The treatment allocation is commonly 
blinded to both the investigators and participants, and individuals in both the vaccine and 
placebo group are challenged with the infectious agent to compare the attack rates (figure 1A). 
Less frequently, an infectivity control group is used in an open-label design to establish if the 
pathogen is infectious during the procedure, rather than to measure the infection rate (figure 1B). 
In the historical control approach, data are based on results from a placebo or non-intervention 
group from previous controlled human infection studies (figure 1C).
Controlled human infection trials to test the efficacy of new interventions have increased 
in number from 15 studies in the 1950s to 140 studies from 2011 to 2017.7 The advantages 
are that they require small sample sizes (10 to 50 participants) and are designed to detect 
large effects in an homogeneous population with 100% exposure. By contrast, clinical trials in 
endemic areas are large (hundreds to thousands of participants) and have heterogeneity in pre-
exposure, infection dose, exposure timing, and incidence of exposure, resulting in lower rates of 
infection and decreased power. Controlled human infection trials can also select for products 
with the highest potential for efficacy in field studies.7,8 As a result, they will lower overall costs by 
reducing the number of products progressing to field studies. Additionally, this type of trial allows 
multiple products to be evaluated in parallel and reduces unnecessary exposure of participants 
in field trials to ineffective products. As such, controlled human infection trials are generally 
accepted as a tool to minimise the risk of late clinical failure.7
8.
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Similarly to phase 1 trials (dose-finding studies in healthy participants), controlled human 
infection studies are subject to ethical debate as they seemingly breach the so-called do no 
harm principle by exposing healthy people to risks (ie, a pathogen), with no direct benefit to the 
individual.8 Participants might be subjected to symptomatic infection, a high frequency of blood, 
urine, or stool sampling, or invasive procedures, such as bronchoscopy. Moreover, periods of 
quarantine might be required, and, in the case of a transmissible agent, there might be potential 
for third-party exposure. Although the risks to volunteers are very small, serious events have 
occurred previously.9–12 As such, the total sum of risks and the burden on participants and third 
parties should be carefully weighed against the value of science and the expected benefits to 
society.13 This concept is especially important for high risk or high burden studies, where the 
number of individuals exposed to a pathogen should be minimised. A framework has been 
proposed to ensure proper ethical justification for the inclusion of healthy volunteers;8,13,14 risk 
and burden should be reduced as much as possible and the scientific rationale should be carefully 
articulated.15 Importantly, we will argue that placebo control groups might not be necessary to 
obtain valid study results in some controlled human infection models and their inclusion should 
therefore be scientifically scrutinised and ethically justified.
Healthy volunteer controls
A healthy volunteer control group can be scientifically justified in four different scenarios: first, 
to show that the infection procedure was successful; second, if one of the secondary outcome 
measurements (eg, immunological response) is unknown and these data add indispensable 
scientific value; third, the infection rate (primary outcome measure) is unknown; and finally, 
differences between an intervention group testing a new vaccine and a placebo control group 
are expected to be small.
In the first scenario, infectivity controls provide information on the quality and procedure 
of infection. For example, clinical malaria trials used between four and six volunteers in the 
infectivity control group to prove that the exposure procedure resulted in infection.16–18 In 
these situations, the size of the control group depends on the expected infection rate, requiring 
information based on previous studies. The goal is to show that at least one healthy volunteer 
can be successfully infected. As such, the infectivity control group is usually smaller than the 
placebo control group, which will also determine the frequency of infections.
In the second scenario, when the expected infection rate (the primary outcome) is known 
from historical data, the use of a placebo control group can still be essential to determine 
secondary outcomes. For instance, to compare immune responses between people that are 
colonised and non-colonised with pneumococcus, along with vaccine efficacy, placebo control 
samples might be needed.19 In this case, previously obtained specific samples (eg, freshly 
processed samples) or data might be absent and the size of the placebo group should then be 
based on the sample size calculation of the secondary endpoint.
In the third scenario, when the infection rate is unknown, there is no other way to determine 
the efficacy of a vaccine other than to include a placebo control group. However, in established 
infection models, the procedures are typically standardised and the expected infection rate 
for placebo control groups is well known. Because of this consistency, an historical control 
8.
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group could serve as a benchmark. As an example, over 2650 volunteers worldwide have been 
experimentally exposed to malaria in controlled human infection trials, with more than 99% 
of participants developing patent parasitaemia after five bites from mosquitoes infected with 
Plasmodium falciparum.20–22 As the number of successful infections is consistent between trials, 
these data can be used for comparison as a historical control group.
In the final scenario, when the expected efficacy of a vaccine, which is often based on animal 
studies or target-product profiles, is low, the uncertainty of historical data is generally too large 
and a placebo group is needed to act as a comparator.23 This control is also required in human 
infection trials where the magnitude or precision of the treatment effect needs to be established 
with certainty. However, the group sizes are often too small to reliably determine the treatment 
effect size, and the purpose of these trials is to instead search for signals of vaccine efficacy.
Historical controls
To examine the suitability and validity of historical data for a specific controlled human infection 
model it is important that the data are based on comparable populations, the method is 
comparable, the infection rate from previous studies is reproducible, and that there are suitable 
data to provide a reliable outcome estimate.24 Although these models are designed to mimic 
naturally occurring infections, data from non-controlled epidemiological studies are generally 
unsuitable to use as historical controls because of differences and uncertainties in infection dose, 
route of infection, and population. These criteria are equivalent for the selection of historical 
data for non-controlled human infection trials.25
Population
The first variable to consider is the study population. Immunological responses to a specific 
pathogen might vary according to race, age, health status, and previous exposure. For consistent 
data and comparisons, the differences in demographics should have no effect on the infection 
rate between the historical control group and the intervention group. Demographic variation 
is often already reduced as controlled human infection studies generally have strict inclusion 
criteria, selecting for only healthy participants. Population differences were clearly shown in a 
controlled human malaria infection study in which semi-immune African participants showed 
a reduced infection rate of 64% compared with nonimmune European participants (100%),26 
underlining the need for similar population characteristics when used for comparison.
Methods
When the population is considered similar, variations in method that could influence the infection 
rate should be examined. For controlled human infection models, differences between species 
can affect outcome measures. For example, about 65% of volunteers were infected when 
given Salmonella enterica serovar Typhi at a dose of 1 × 10⁴ colony forming units (CFU) but for 
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Salmonella enterica serovar Paratyphi a dose of 1 × 10³ CFU was needed.27,28 However, with 
the Cryptosporidium model, infection with 1 × 10⁵ Cryptosporidium muris oocysts or 1 × 10⁵ 
Cryptosporidium meleagridis oocysts resulted in the same infection rate (100%).29,30 Differences 
in strains can also be important; for instance, Neisseria gonorrhoeae MS11mkC is more infectious 
than the FA1090 strain, with the estimated dose needed for 50% infection being 1·8 × 10³ 
CFU (MS11mkC) and 1·0 × 10⁵ CFU (FA1090).31 Other models use one strain only, such as for 
Haemophilus ducreyi.32
Centre clustering (eg, controlled human infection studies for one pathogen that are all done 
in one centre), between centre differences (eg, related to variations in protocols between study 
centres), seasonal variation, batch-to-batch variability, and operator effects (eg, variation in 
adverse event registration by operators) can all result in inconsistent outcomes. For controlled 
human infections of Necator americanus (hookworm), the percentage of infected volunteers 
was similar (90–100%) after controlled exposure to the same hookworm dose, but substantial 
differences in egg counts were observed (125 eggs per g vs 2400 eggs per g) and depended 
on the batch, study centre, or operator effects.33,34 In the influenza A model, infection with 1 
× 10⁷ of the A/Kawasaki/8/86 H1N1 strain resulted in variable proportions of viral shedding 
from 70–100%.35,36 This variety could be due to seasonal variation, but might also be related 
to the amount of pre-exposure among volunteers (population). These factors should be taken 
into account when a study is done in another geographical region or during a different season.
The infection dose is directly related to the primary study outcome. For example, increasing 
the dose of S. Typhi from 1 × 10⁵ to 1 × 10⁹ CFU raised the percentage of infected volunteers 
from 28% to 95%.37 For many models, the pathogen dose has been standardised and is generally 
based on an initial dose-escalation study whereby infection rates, and the risks and burden to 
the participants, are carefully balanced.
The route of infection also affects the study outcome, as each method requires a specific dose 
to obtain 100% infection rates. For example, the Plasmodium falciparum model uses controlled 
exposure through mosquito bites, intramuscular or intradermal injections, or by direct venous 
inoculation.38–40 Only one route of infection is used in most models, such as with the dengue 
virus, respiratory syncytial virus, rhinovirus, and influenza virus.41–44
The infection rate can be based on microbiological (infection model) or clinical parameters 
(disease model). Both can be used as historical data as long as the criteria to determine infection 
rate between studies are similar. A well-described disease model for Vibrio cholerae states 
that participants producing more than 3 L of diarrhoea are considered positive for cholera;45 
however, if this cut-off point varies between studies it will affect the measured infection rate. This 
difference can be seen in the enterotoxigenic Escherichia coli model, where diarrhoea is listed 
as three watery stools per 24 h or one to two loose stools in 24–48 h.46 Distinct microbiological 
outcome measures might also lead to variation, such as with the influenza model that uses 
titration on canine kidney cells, PCR, or the inoculation of embryonated eggs followed by the 
haemagglutination inhibition assay.44 However, if the sensitivity of these tests are similar they 
can be pooled together to generate historical data.
Outcome consistency
In addition to population and methods, the infection rates should be compared and must be 
comparable between studies. A model with consistent outcomes was shown in the S. Typhi 
8.
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model with 65%–67% of volunteers developing infection according to predefined criteria.47–49 
This finding contrasts with the enterotoxigenic E.coli model which resulted in infection rates of 
between 50% and 100% when the same infection dose is being used.46 Consistent outcomes 
with low variability are suitable data for historical controls.
Figure 2. Considerations for choosing the control group in controlled human infection trials.
Suitable data
The variability of the data should be offset by the size of the dataset, and large numbers of 
participants, such as with the rhinovirus model (5760 individuals),7 are more likely to generate 
suitable historical evidence than models that have recently been established (eg, Schistosoma 
spp infections with only 17 participants).50,51
As with any sample size calculation, the estimated group size needed depends on the 
expected efficacy of the vaccine and the variability in infection rates between vaccinated and 
control groups. Historical controls will probably have a high variability in infection rates because 
of the heterogeneous nature of the data. Therefore, for studies that are testing a vaccine with 
a low expected efficacy, the use of a placebo control group (with a lower variability in infection 
rates) is likely to lead to more robust results. In general, historical data are suitable to use when 
they are robust and the expected vaccine efficacy is high (figure 2). Realising that historical 
controls have uncertainties and cannot be used as fixed-effect estimators is important.52,53 
However, there are sophisticated modelling techniques that can analyse different datasets 
separately and together to better assess the effects of data pooling and corresponding sample 
size calculations to more accurately estimate infection rates and the variability around these 
estimates.53 Although caution should be taken when pooling historical data—for example, if 
there is variability in the outcome between centres—one could envision selecting historical data 
from the trial site where the intervention was performed, instead of pooling all available data.
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In conclusion, the use of historical data needs to be carefully considered and must take into 
account the population, method, outcome, and the amount of available data. The suitability 
to use historical data depends on the controlled human infection model and the design of the 
study. All of these factors should be evaluated before the start of a new controlled human 
infection trial.
Future directions
Given the public and research community’s perception regarding the deliberate infection of 
healthy volunteers,8,13 participants should be included with the utmost care and through solid 
scientific justification. The design of controlled human infection studies should be scrutinised 
so that the output is scientifically impactful, yet minimises the cumulative risk with proper 
justification of placebo controls.
Controlled human infection studies are designed to generate uniform outcomes (eg, infection 
rates). When these data are sufficiently consistent, they can be used to generate an historical 
control group as an alternative to a placebo control, reducing the number of participants 
exposed to a pathogen. To facilitate data pooling, study designs should be harmonised between 
centres. Agreement on the route and dose of infection, the use of similar inclusion and exclusion 
criteria to reduce the variability of study populations, harmonisation of endpoints by using 
similar microbiological techniques or clinical criteria, and optimisation of pathogen production 
according to good manufacturing practice guidelines are likely to optimise controlled human 
infection models, generating better quality historical data in the future. Such efforts have been 
undertaken for the malaria model, resulting in guidelines for the “Standardization and conduct 
of P. falciparum sporozoite controlled human malaria infection trials”.54 This could also be done 
for other controlled human infection models by establishing consensus groups that will outline 
methods aimed to harmonise between centres.
Moreover, several open access data repositories are available, such as ImmPort (https://
immport.niaid.nih.gov/home) from the National Institutes of Health and Zenodo (https://zenodo.
org/) from OpenAIRE, where controlled human infection trial data can be deposited.55,56 These 
repositories improve access to trial results, making it easier to pool historical data, analyse 
variability, and ultimately work with larger and more exhaustive datasets. In addition, a newly 
established digital platform funded by the Wellcome Trust (https://tghn.org/) aims to promote 
sharing of protocols and data, complementing the existing network from the Bill and Melinda 
Gates Foundation (see https://chimstudies.org). As these initiatives show, funders can actively 
promote and support open data sharing, creating opportunities for data pooling, data reuse, 
and the identification of consistent endpoints.
Whether the use of historical controls will be considered acceptable to the regulators for 
licensure depends on the balance between the risk of controls, whether alternative investment 
is required, and the position of the trial in the development pathway. The considerations 
presented here are meant to ignite and guide the discussion around the use of historical controls 
in controlled human infection studies.
Are placebo controls necessary in controlled human infection trials for vaccines? The answer 
depends on the pathogen-specific model, the expected vaccine efficacy, and the quality of the 
8.
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available historical data. In our opinion, each researcher has the moral obligation to consider 
alternatives to the randomised controlled study design. Alternative approaches, such as the use 
of an historical control group, should be explored and prespecified. If the use of a placebo group 
is deemed absolutely necessary, this decision should be justified in the protocol, trial register, 
and in the research paper.
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CHAPTER 9
The importance of this thesis
In this thesis we describe the use of controlled human infection models for various primary 
outcome measures. We show the importance of the established controlled human malaria 
infection (CHMI) model to test the kinetics of new strains, NF135.C10 and NF166.C8. In addition, 
the CHMI model was used to evaluate the efficacy of the first vaccine based on genetically 
attenuated parasites (GAP) administered by direct venous inoculation, PfSPZ-GA1 vaccine. We 
also describe how we developed a new model, the controlled human Schistosoma infection 
(CoHSI) model. We describe a dose-finding study, to determine the lowest pathogen dose 
resulting in a high infection rate while still being safe. The results of this study show that this 
model is a useful tool to test new vaccines, drugs and diagnostic tests in the future. Finally, we 
describe how some well-established controlled human infection models can be designed to result 
in a lower cumulative risk of the whole study. This study design involves the use of historical 
controls instead of placebo controls.
Malaria
Genetic diversity
1. Variation between strains
Whole sporozoite vaccines are immunisation strategies based on the administration of 
attenuated whole sporozoites to prevent blood stage parasitaemia. Currently these whole 
sporozoite vaccines are based on the Plasmodium falciparum strain NF54 or its daughter strain 
3D7.1 Immunisations are followed by controlled human malaria infection (CHMI) to determine 
the protective efficacy of the whole sporozoite vaccine. This CHMI is either homologous, same 
strain, or heterologous, another strain. A protective efficacy up to 100% can be reached by 
homologous CHMI after whole sporozoite immunisations. Where the protective efficacy depends 
on the immunisation dose, interval and route of administration.2-5
These high efficacy rates in homologous CHMIs do not reflect the efficacy in field studies. 
As there is a large genetic diversity of P. falciparum between geographical regions,6 it is likely 
that data of heterologous CHMIs are more representative of what will happen in field trials. 
Unfortunately, so far the results of heterologous CHMIs are poor compared to the high protective 
efficacy rates of homologous CHMIs. After whole sporozoite immunisations 11-80% efficacy 
was shown after heterologous CHMI.3,7-10 Hence, it is important to improve the vaccine efficacy 
in heterologous CHMIs and to investigate whether study results from heterologous CHMIs are 
comparable to the field.
To be able to perform heterologous CHMIs new P. falciparum strains are being investigated. 
The strain NF135.C10, originating from Cambodia, was first introduced a few years ago. This strain 
shows a shorter prepatent period after infection compared to NF54, but comparable clinical 
signs and symptoms.11 To expand the number of strains for vaccine research we introduced 
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the new P. falciparum strain NF166.C8, originating from Guinea (West Africa), and performed 
additional tests on NF135.C10 as described in Chapter 2. We showed that infection with one 
of these two strains, compared to NF54 infection, resulted in shorter pre-patent periods and 
higher first peak of parasitaemia. The latter can be used to determine the number of parasites 
released from the liver. This data was supported by our in vitro data showing more infected 
hepatocytes and a higher number of nuclei per schizont with the strains NF135.C10 and NF166.
C8 compared to NF54.
We performed additional research, which was described in Chapter 3, to determine 
whether these differences in kinetics of NF135.C10 and NF166.C8 should change the CHMI. We 
hypothesised that a lower number of bites from NF135.C10 or NF166.C8-infected mosquitoes 
should be sufficient to reach comparable infection rates and parasitaemia compared to NF54. 
The standard number of mosquito bites in NF54-CHMIs are five, which results in >99% infection 
rates,12 while lower number of infected mosquito bites result in lower infection rates.13,14 We 
found comparable data with NF135.C10 and NF166.C8, as five infected mosquito bites resulted 
in an 100% infection rate, while one or two infected mosquito bites resulted in an infection rate 
of 75%. In conclusion, as the same number of infected mosquito bites were needed to reach 
comparable infection rates, the results of our research did not support our hypothesis that due to 
kinetic differences a lower number of NF135.C10 or NF166.C6-infected mosquito bites will result 
in 100% infection. As infection with less than 5 mosquito bites with either of the three strains 
results in an infection rate below 100%, there appears to be a strain-independent threshold 
that should be overcome in order to develop blood stage malaria. The cause of this threshold 
is unclear and may occur at the stage of probing by the mosquito, the number of sporozoites 
entering the blood stream, or the number of sporozoites that invade the hepatocytes. The 
differences in parasite multiplication after hepatocyte invasion (Chapter 3) result in higher first 
peak of parasitaemia in these new strains. For future research this means that infection with 
five NF135.C10 or NF166.C6-infected mosquito bites results in higher levels of parasitaemia. In 
addition, this might lead to an increased immunogenicity of these strains during liver stage as 
more parasites are present.
Both of our studies described in Chapter 2 and Chapter 3 showed differences in the kinetics 
of various strains. It is possible that these variations will lead to a suboptimal vaccine efficacy 
when tested in heterologous CHMI.
2. Future perspective
Although the whole sporozoite vaccines show high efficacy rates when used in homologous 
CHMIs,2-5 the efficacy of these vaccines is low with heterologous CHMIs. Several study designs 
might lead to an increased protection against heterologous strains, making the vaccine more 
suitable to use in the field: 1. Increase immunisation dose, 2. Other immunisation strain, or 3. 
Combine strains for immunisation.
1. Increase immunisation dose
Increasing the immunisation dose of a vaccine could result in better protection rates. Several 
homologous and heterologous studies were performed with PfSPZ vaccine, which is based on 
radiation attenuated sporozoites (RAS). Overall, these studies show a higher immunisation dose 
results in higher protection rates.2,3,9 However, when PfSPZ Vaccine was administered with a 
9.
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dose higher than one million sporozoites, this seems to result in a reduced efficacy compared 
to a dose lower than one million sporozoites.15
2. Other immunisation strain
As was shown in Chapter 2 some strains result in a higher first peak of parasitaemia than others. 
This higher first peak of parasitaemia is present in strains NF135.C10 and NF166.C8, and it reflects 
a higher number of parasites released from the liver. It is possible that this parasite load in the 
liver results in a better immune response of the host during liver stage. This could ultimately 
lead to higher antigenic loads. To test this hypothesis, a whole sporozoite vaccine should be 
developed with either NF135.C10 or NF166.C8. Based on Chapter 2 and Chapter 3 this strain 
could be NF166.C8. If this hypothesis holds, this would result in a higher protective efficacy after 
heterologous CHMI with vaccines based on NF166.C8, compared to heterologous CHMIs with 
vaccines based on NF54. This hypothesis is being investigated with NF135.C10, where NF135.C10 
CPS immunisations are followed by homologous and heterologous (NF166.C8) CHMI (clinicaltrials.
gov NCT03813108).
3. Combine strains for immunisation
A recent study shows the genetic differences between the P. falciparum strains that are most 
commonly used in whole sporozoite vaccine studies; NF54, 3D7, NF135.C10, NF166.C8 and 7G8.16 
These include immunologically important pre-erythrocytic antigens. These differences could 
be an explanation why vaccines tested by heterologous CHMIs show less protective efficacy 
as compared to homologous CHMIs. As an immune response against a specific antigen in NF54 
might not fully protect against another strain which lacks the exact same antigen.
One way to optimise whole sporozoite vaccines could be to generate a vaccine with multiple 
P. falciparum strains. To design a multiple strain vaccine it is important to include strains that are 
genetically diverse. The genetical differences between geographical regions are larger than the 
genetical differences found within geographical regions. Based on the genetic differences there 
are four geographical regions, which are largely covered by the most commonly used strains; 
NF54, NF7G8, NF135, and NF166.16 It remains to be seen whether this combination of strains is 
sufficient to generate a potent whole sporozoite vaccine. However, since all genetic regions are 
covered, it could have great potential.
Two types of multiple strain vaccines can be distinguished. The first option is one vaccine 
with multiple strains that is administered several times, while the second is a combination 
of several vaccines, each with one strain, that are applied sequentially. The first vaccination 
strategy is based on the idea that an immune response against multiple epitopes of all strains 
will be generated, which are boosted each immunisation. The disadvantage is that it could 
lead to the dominance of an immune response against some strains over other strains as was 
seen with the Dengue vaccine.17,18 The second vaccination strategy is based on the idea that an 
immune response against conserved and strain specific epitopes is being generated. Where 
each new vaccine induces an immune response against the new strain combined with a boost 
against conserved epitopes of the parasite. The main disadvantage is that this boost might not 
be sufficient when there is only a mild immune response against conserved epitopes.
Another option would be to generate four separate vaccines for various regions. Based on 
their genetic differences, these regions could be Africa, South America, Asia and Papua-New 
Guinea.16 All these regions, except Papua-New Guinea are largely covered by the most commonly 
used strains; NF54, NF7G8, NF135, and NF166.




Most of the CHMI studies are performed using a randomised placebo-controlled study design. 
However, as we discussed in Chapter 8 this is not always the study design with lowest cumulative 
risk and burden while reaching reliable outcomes. The infection rate after a CHMI with five 
infected mosquito bites is well known and is >99%.1,12 As such, the use of a placebo control group 
to determine the primary outcome “efficacy” is not necessary, and could even be considered 
unethical. Before studies with new malaria strains are performed it should be investigated what 
number of mosquitoes are needed in CHMI to reach 100% infection rates, as we did in Chapter 
3. When this number is repeatedly similar, the use of a placebo group to determine the vaccine 
efficacy is no longer needed. In those situations infectivity controls can be used instead to 
ensure an adequate infection procedure and guarantee lower cumulative risk and burden of the 
study. In Chapter 2 we used placebo controls, since historical data on all strains were not yet 
sufficient. In Chapter 4 we used placebo controls to be able to study the secondary outcome, 
the immunological response to a CHMI with or without PfSPZ-GA1 Vaccine immunisations.
Whole sporozoite vaccines
1. Genetically attenuated vaccines
There are several types of whole sporozoite immunisation strategies which have been developed. 
The first is immunisation with radiation attenuated sporozoites (RAS). The US- based biotech 
Sanaria® produced aseptic, purified, cryopreserved P. falciparum RAS, PfSPZ Vaccine, for direct 
venous inoculation (DVI).19 The second is immunisation by the administration of sporozoites under 
chemoprophylaxis (CPS; chemoprophylactic sporozoites).5 Sanaria® developed ‘PfSPZ-CVAC’ 
(aseptic purified cryopreserved PfSPZ sporozoites under chemoprophylaxis) as immunisation 
strategy.20 And the third is altering the parasite genetically to generate a specific phenotype, 
the genetically attenuated parasites (GAP).
When we compare these three immunisation strategies, most studies are being performed 
with RAS. RAS are able to enter hepatocytes where they will only partially develop.21,22 The 
degree of development depends on the irradiation dose, with the standard dose of 15,000RAD.23 
Remarkably, sporozoites exposed to a higher irradiation dose do not enter hepatocytes and 
immunisations with these sporozoites does not result in protection. This implies that the invasion 
of hepatocytes is crucial to generate an immune response.8,22,24 It is thought that a longer duration 
of parasite exposure during liver stage, e.g. late arrester, will result in a better immune response 
of the host.25 Unfortunately late arrest during liver stage cannot be reached with irradiated 
sporozoites, as irradiation with less than 15,000RAD results in incomplete attenuation and as 
consequence blood stage malaria develops.22
In contrast to RAS, CPS enter the liver where they develop until they are released in the 
blood stream. As chloroquine acts on the asexual blood stage parasite only, the parasites will 
develop normally throughout the entire liver stage, but they do not develop within the blood. 
As a consequence volunteers do not develop clinical disease.26 CPS immunisation results in a 
longer exposure time to parasites in liver stage compared to RAS, which leads to a better immune 
response.5 However, this immunisation strategy is very difficult to introduce to millions of people 
in the field due to the main safety risk, the chance of developing malaria under inadequate 
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chloroquine levels. RAS, especially PfSPZ Vaccine which can be administrated by DVI instead 
of mosquito bites, is easier to introduce in the field and without the risk of developing blood 
stage malaria.22
Comparable to CPS, a GAP would ideally replicate throughout most of the liver stage. The 
advantage over CPS would be that it does not carry the risk of developing malarial disease. GAPs 
rely on the deletion of genes that are crucial for the parasite to continue development within liver 
stage. Depending on the genes that are deleted, the parasite will arrest early or late during liver 
stage development. At first, several GAPs were tested in animal studies, showing the potential 
of GAP vaccines.27,28 Recently the first P. falciparum GAPs were developed for human testing, 
all based on the strain NF54. The first GAP tested in humans was GAP2KO with deletion of P52 
(also known as P36p) and P36.29 Both P52 and P36 are 6-CYS proteins. This family of proteins 
has various roles in the establishment and maintenance of the parasitophorous vacuole during 
liver stage development.30 The deletion of either P52 or P36 in Plasmodium berghei did not 
result in complete attenuation.31,32 Deletion of both P52 and P36 in P. berghei did not result in 
compete attenuation in vivo,33 while deletion of both P52 and P36 in P. falciparum resulted in 
full arrest during liver stage development in humanised mice.34 In line with these pre-clinical 
data, this GAP was not fully attenuated and blood stage parasitaemia did develop in a trial with 
human volunteers. It is possible that this GAP did not result in full attenuation as deletion of 
either one of this paralogue genes did not result in complete attenuation either.25 Hereafter GAPs 
were developed that included the deletion of genes that were considered key developmental 
factors, combined with another gene.25 This resulted in the development of the first GAP tested 
in humans with a triple deletion, the P. falciparum GAP3KO with deletion of P53, P36 and slarp 
(sporozoite and liver stage asparagine-rich protein). In addition to the deletions of P53 and P26 
in GAP2KO, slarp was deleted. Slarp is a differentiation factor which down-regulates liver stage 
specific proteins, such as UIS3 and UIS4.35,36 In vivo experiments showed that deletion of slarp 
resulted in complete arrest early in liver stage.36 Similar results were found with P. falciparum 
GAP3KO in human volunteers as none developed blood stage malaria after exposure by mosquito 
bites.37 A study on the protective efficacy of P. falciparum GAP3KO was performed recently 
(clinicaltrials.gov NCT03168854).
In addition to these studies we performed the first study using direct venous inoculation (DVI) 
to administer a GAP vaccine, PfSPZ-GA1 Vaccine of which the results are described in Chapter 4. 
PfSPZ-GA1 Vaccine has a deletion of the P. falciparum genes b9 and slarp.38 B9 is also member 
of the 6-CYS protein family. Pre-clinical data showed that deletion of both genes resulted in 
complete arrest in vitro and in vivo in humanised mice. Exposure to various dosages of PfSPZ-
GA1 Vaccine in human volunteers did not result in blood stage parasitaemia. Unfortunately the 
efficacy of the PfSPZ-GA1 Vaccine, was lower than expected, with a sterile protection in 12% of 
volunteers and a delayed time to patency in 68% of the volunteers. In addition, immunisation 
with 4.5x105 sporozoites of PfSPZ Vaccine, the active control group, showed no protective 
efficacy. This was remarkably and unexpectedly lower than the 86.7% sterile protection shown 
with the same dose in a prior study.3 The specific cause of this reduced efficacy of PfSPZ Vaccine 
remains unclear, but lies either in the difference in immunogenicity of the PfSPZ Vaccine or the 
difference in stringency of the CHMI compared to other studies. In case the stringency of CHMI 
caused the reduced efficacy of PfSPZ Vaccine, this could also have affected the efficacy of PfSPZ-
GA1 Vaccine. However, it seems to be unlikely that there were differences in stringency between 
CHMIs. Both studies immunised with mosquito bites three weeks after the last immunisation. Our 
study used NF54 as CHMI, while the other study used 3D7, its daughter strain, which could have 
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small genetic differences. As the NF54 CHMI is more homologous to this NF54-based vaccine it is 
unlikely that this explains the differences in vaccine efficacy, as homologous CHMIs show better 
protection than heterologous CHMIs.2-5,7-10 As such, it is more likely that there was a difference 
in immunogenicity of the PfSPZ Vaccine between both studies.
2. Future perspective
All three GAP vaccines that were tested in humans, GAP2KO, GAP3KO and PfSPZ-GA1 vaccine, are 
early arresters.25 This means that they arrest early during liver stage development, only forming 
a single-cell liver stage trophozoite. So far, no successful late arrester GAPs have been developed 
for P. falciparum. In rodent studies not only early arrester GAPs, but also late arrester GAPs 
were developed.25 Several late arresters remain without breakthrough infections, e.g. double 
deletion of PlasMei2 and LISP2.39-41 These rodent studies show that successful development of 
fully attenuated late arrester GAPs is possible. Unfortunately it has been shown that the deleted 
genes used in the full late liver stage arresting rodent GAPs do not guarantee similar results in 
P. falciparum GAPs with orthologue gene(s) deleted. For example, deletion of FabI from the 
type two fatty acid biosynthesis pathway (FAS II) results is complete arrest during liver stage in 
a rodent GAP, while FabI deletion in P. falciparum results in severely attenuated development 
of salivary gland sporozoites.42 For future studies it remains interesting to further explore the 
possibilities for the development of P. falciparum late arrester GAPs. The advantage of a late 
arrester GAP is thought to be a stronger immune response due to longer time of exposure with 
a higher number of parasites. This is what can be seen in vaccines based on RAS with limited 
liver stage development, compared to CPS with full liver stage development. CPS immunisations 
result in a better immune response.5,24
3. Clinical development pathway
The potency of a vaccine is generally tested in animal models before testing these in humans. 
There are two main options available to test GAP vaccines in an animal model. One option is 
to develop and test a rodent Plasmodium spp. with deletion of orthologue genes. However, 
as discussed before, it is possible that deletion of genes in rodent Plasmodium spp lead to a 
different phenotype than deletion of orthologue genes in P. falciparum.40-42 As a consequence 
it is preferred to test the GAP in humanised mice.34 After testing vaccines in animal models, 
promising vaccine candidates will enter the clinical development pathway (figure).
The first step in the clinical development pathway is focussed on testing the safety of a 
vaccine, a phase I trial. Hereafter, safe vaccines can be put to test in a CHMI trial. The use of CHMI 
trials is common in RAS and CPS, but can also be used for GAPs. In these trials healthy volunteers 
are immunised several times followed by a CHMI. The CHMI trial can be divided into two separate 
trials. At first, as a proof of principle, the GAP can be administered by mosquito bites. In such 
studies the phenotype and immunogenicity will be investigated. The disadvantage is that this 
can only be used as an immunisation strategy and not as a vaccine. The advantage is that it is 
much cheaper than the next step, the development of a GAP-vaccine that can be administered 
by DVI. It is possible to skip the proof of principle step and directly develop the vaccine for 
administration by DVI. For both of these CHMI trials the primary outcome is the vaccine efficacy. 
As groups are small the estimate of the vaccine efficacy will not be very reliable, but it gives a hint 
on the potency of the vaccine. This potency could be divided in not potent (<25% of volunteers 
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protected against malaria) and mild, moderate or very potent (≥25-50%, ≥50-75%, ≥75% of 
volunteers protected against malaria, respectively). These percentages are suggested based 
on the malaria vaccine technology roadmap. In the initial version of the roadmap the goal was 
a malaria vaccine with a protective efficacy of ≥50% by 2015, while the new goal is a malaria 
vaccine with a protective efficacy of ≥75% by 2030.43 As groups in CHMI trials are small and only 
give an estimation of the efficacy it is suggested to proceed to field studies with vaccines that 
are moderate or very potent (≥50% efficacy in CHMI) immediately, while mild potent vaccines 
(≥25-50% efficacy in CHMI) should be further improved or tested, if possible, before testing in 
field studies.
If the vaccine passes the proof-of-concept CHMI trials, the first step is another CMHI trial 
in an endemic area. Results of this CHMI trial can be different from the clinical CHMI studies, as 
the population in the field CHMI trial will likely have been exposed to malaria before. This extra 
step gives another hint on the potency of the vaccine.
Vaccines which pass the field study CHMI may move to phase II studies in endemic areas. 
Based on the new vaccine goals, reaching an efficacy of ≥75%, only vaccines that are moderate 
or very potent in phase II studies should be introduced to a large phase III field study in an 
endemic area. Vaccines with an efficacy of ≥75% in a phase III study could be registered, while 
vaccines that are mild or moderate potent should first be further improved. This is in contrast 
to the study results previously found with Mosquirix (RTS,S), the only malaria vaccine currently 
tested in large phase IV field studies. Mosquirix showed a vaccine efficacy of 56% before 2015,44 
these results were in line with the previous goal; ≥50% efficacy by 2015. New vaccines should, 
however, meet the new, higher, efficacy standards.
Although this clinical development pathway appears to be clear, there are some marginal 
issues to be addressed. Administration of whole sporozoite vaccines by DVI on a large scale is 
difficult, as the transport and preparation of the vaccine requires strict conditions. At first the 
transportation and storage of the vaccine should be in nitrogen. Hereafter the vaccine should be 
prepared and administered within 30 minutes after start of the preparation. Lastly, the vaccine 
should be injected directly into the veins, which requires additional technical skills of the people 
administering vaccines. So preferably, for practical use, there should be some adjustments, such 
as being able to keep the vaccine in high temperature, room temperature or in the refrigerator, 
extend the time the vaccine is stable and being able to administer the vaccine intramuscular.
In Chapter 8 another important issue was addressed, namely the use of placebo controls in 
controlled human infection studies. In CHMI studies the infection rate of the placebo group after 
CHMI is >99% based on the data of studies performed the last decades.1,12 For future studies 
there is no need to include a placebo group to determine the efficacy of a vaccine since a small 
group with infectivity controls should be sufficient. However, there may be a need for a placebo 
control group to determine secondary outcomes, such as the variation in immune response.

































































































































A new controlled human infection model
1. The importance of a controlled human schistosome infection model
Schistosomiasis can be treated with the drug Praziquantel, which has a cure rate of only 42-
91%.45,46 This cure rate could be higher, as it is impossible to distinguish between uncured 
infections and reinfections in an endemic setting. Also, praziquantel has no effect on the 
immature worms, so it will not cure people that were recently (re-)infected. In addition, it is 
likely that in some patients praziquantel treatment leads to a reduced worm- and egg burden 
and not to complete eradication.
If schistosomiasis is left untreated this can lead to severe pathology. Since it takes years 
before this pathology develops it is important to detect and treat the disease at an early 
stage. This is difficult as people often have no symptoms until severe pathology develops. 
In areas with known high endemicity, preventive chemotherapy is given. Depending on the 
schistosomiasis prevalence this mass drug administration (MDA) can be administered up to 
once a year.47 The prevalence of schistosomiasis is reduced with 37% in school children one year 
after administration, and the intensity of infection with 41%. Based on modelling a substantial 
reduction of prevalence can be reached with MDA when administered yearly with at least 70% 
community participation.48 However, this data might be too optimistic as there are indications 
that repetitive MDA reduces the efficacy of praziquantel.49 If MDA would be discontinued, 
schistosomiasis will likely return to pre-control levels within 30 years.48 In conclusion, since 
MDA does not prevent from reinfection and results in modest prevalence reduction, its effect 
is limited and temporary.
A more sustainable method to achieve schistosomiasis control would be to prevent infection. 
One way would be to prevent exposure to cercariae, which are present in infected water. 
Since the infected water is often used by the endemic population to wash laundry and wash 
themselves, to cook or clean and to collect fish, it is often impossible to prevent exposure. 
However, this preventive advice can be given at travellers to endemic areas. Another way to 
prevent infection is through vaccination. Unfortunately no vaccine against schistosomiasis is 
registered yet, but there are several vaccines against Schistosoma mansoni in pre-clinical testing; 
rSm-TSP-2/Alhydrogel, rSm14/GLA-SE, and rSm-p80/GLA-SE.50-53 Testing these vaccines in field 
trials is expensive and takes a long time. To reduce the time to test a vaccine, reduce the costs and 
prevent exposure of a vulnerable population to a vaccine that might not work,54 we developed 
a controlled human schistosome infection (CoHSI) model as described in Chapter 5.
2. How to design and optimize a new model
We think there are several steps to be taken before a new controlled human infection (CHI) 
model can be developed and tested: 1. Is there a need to design a model for this pathogen?; 
2. Is the expected burden/risk for volunteers after exposure to the pathogen acceptable?; 
3. Can we produce this pathogen safe and according to all regulations so it can be used to infect 
volunteers?; and 4. What pathogen dose should be used?
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1. Is there a need to design a model for this pathogen?
CHI models should only be used if there is additional value to be expected in addition to the 
current research.55 The use of a CHI model to test vaccines or drugs would reduce the time and 
costs to test a vaccine, compared to field studies.54,56,57 Also the number of volunteers needed is 
less, as only non pre-exposed volunteers, without any immunity to or presence of the pathogen, 
are used. Also the conditions are more controlled as the time of infection and the pathogen dose 
are similar. This is in contrast to field studies where larger groups are needed as not all volunteers 
will be exposed to the pathogen in the months after vaccination or, in drug research, the time 
of exposure and pre-exposed dose is not standardised.54 In addition, it could prevent exposing 
a vulnerable population to a vaccine or drug that might not work. The use of CHI studies reduce 
late clinical failure as only potent candidates will be tested in large field studies.54,56
We concluded that the use of a schistosomiasis CHI model would be beneficial based on the 
advantages of CHI models just described, combined with insufficient disease control with MDA, 
and inadequate preventive options. A schistosomiasis CHI model could be of additional value, 
not only to accelerate vaccine research, but also to speed up drug research, to gain a better 
understanding of the host-pathogen interaction, and to investigate the host immune-response 
to the pathogen.58
2. Is the expected burden/risk for volunteers after exposure to the pathogen acceptable?
Before establishing a model it should be clear that no harm and low risks are expected in 
volunteers. For cercarial exposure and schistosomiasis there are some adverse events that are 
likely to develop in some volunteers. Directly after cercarial invasion in the skin a cercarial 
dermatitis can develop which can last for days.59 In the acute phase of schistosomiasis one 
could expect symptoms related to an acute schistosomiasis syndrome (Katayama fever), which 
are likely to be acceptable, temporary and do not result in permanent harm or death 60,61 In 
addition, angio-oedema could develop.62-65 After years of chronical infection various symptoms 
can develop which are related to the formation of granulomas around Schistosoma eggs that get 
trapped in tissue. These symptoms depend on the location and extent of the granulomas, e.g. 
liver cirrhosis, portal hypertension, or malignant transformation of tissue.59,60
We considered all of the above risks to be acceptable, except those related to long term 
infection. To eliminate these long-term risks, a model was designed which we described in 
Chapter 5, with exposure to single-sex male cercariae only, as these do not deposit eggs.
3. Can we produce this pathogen safe and according to all regulations so it can be used to infect 
volunteers.
When developing a new CHI model it is important to adhere to all regulations and determine 
the safest way to use the pathogen. In Chapter 5 we described how we were able to develop 
the pathogen according to all European Union (EU) regulations and how we were able to select 
male cercariae only, to ensure safest exposure to the pathogen. There are, however, no clear 
guidelines on the development and manufacture of human CHI agents. The International Alliance 
for Biological Standardization (IABS) recently recommended the development of these guidelines, 
ideally coordinated by WHO officials.66
4. What infection dose should be used
Once a CHI model is designed it is important to establish a pathogen dose. A dose-escalation 
study can be used to determine the optimal dose, which is the lowest pathogen dose resulting 
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in a high infection rate, with acceptable side effects for volunteers. For example, in malaria trials 
the dose was standardised to five infected mosquito bites resulting in an infection rate of >99% 
with limited side effects.12
We started with a low dose of 10 cercariae and planned to increase to a higher dose of 30, 60 
and eventually 100 cercariae until 10 volunteers were infected with the same dose. In Chapter 7 
we describe that exposure to 10 cercariae did not lead to an 100% infection rate and symptoms 
of volunteers were mild. Although 30 cercariae did lead to an 100% infection rate, the adverse 
events were too severe to continue with this dose. These adverse events, described in Chapter 
6, mainly existed of long-term fever and headache. Two out of three volunteers exposed to 30 
cercariae experienced multiple severe adverse events. Hereafter the dose was reduced to 20 
cercariae, resulting in acceptable side effects with a high infection rate of 82%. We concluded 
that future vaccine and drug research using this single-sex male-only CoHSI model could be 
performed safely with a dose of 20 cercariae per volunteer.
3. Clinical development pathway and future perspective.
With the establishment of the CoHSI model a new tool to test schistosomiasis vaccines is 
available. This model gives the option to test vaccines as a proof of concept without having to 
proceed directly to the field. This is a great advantage as limited resources are available for this 
neglected tropical disease.67,68 Testing vaccines with the CoHSI model is expected to be cheaper 
than directly performing large field trials. This is related to the controlled conditions, which result 
in a shorter period of time needed for a trial, and a reduced number of participants.56 CoHSI trials 
last only several months, as several immunisations with a vaccine or placebo are followed by 
CoHSI a few weeks later. Hereafter there are weekly visits until 12 weeks after cercarial exposure, 
to determine the development of schistosomiasis and the intensity of infection, based on serum 
CAA levels, as we described in Chapter 7. Only a small group of Schistosoma‑naïve volunteers, 
selected on stringent criteria, is included in CoHSI trials in non-endemic areas. As a consequence 
the vaccine efficacy, which is determined as the reduced intensity of infection, cannot be directly 
translated to the efficacy in the field, but refers to the potency of the vaccine. It is suggested to 
group vaccines as not potent (efficacy <25%), mild potent (25-40%), moderate potent (40-75%), 
or very potent (≥75%). This suggested classification is based on schistosomiasis vaccine targets 
put forward by the WHO and experts in schistosomiasis, with targets of ≥40% or ≥75% vaccine 
efficacy respectively.69,70
With the advantages described, the CoHSI model could be implemented in a clinical 
development pathway (figure). This proposed clinical development pathway for a schistosomiasis 
vaccine is similar to the clinical development pathway for a malaria vaccine that was described 
before. However, the CHMI model is well-established and its position in the clinical development 
pathway is clear, while the importance of and the exact position of the CoHSI model in the clinical 
development pathway still needs to be determined.
The proposed clinical development pathway of a schistosomiasis vaccine also starts with 
a clinical phase I trial to determine the safety of a vaccine. If safe, a CoHSI trial in a clinical 
setting in Schistosoma-naïve volunteers could follow. When the vaccine passes, a CoHSI trial 
in an endemic area will follow. The outcome of this study is the vaccine efficacy in the target 
population. Depending on the outcome, a large field study could follow. It is likely that the 
vaccine efficacy will differ because variations in immune responses are to be expected in non-
pre-exposed volunteers from a non-endemic area and pre-exposed volunteers from an endemic 
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area, as we discussed in Chapter 7. For this purpose, efforts are made to implement the CoHSI 
model in the schistosomiasis endemic country Uganda.71
The next step of the clinical development pathway depends on the outcome of the CoHSI 
studies. Moderate and very potent vaccines may be put forward to phase II field trials. Mild 
potent vaccines could be further developed to improve efficacy, e.g. by combining vaccines 
and/or changing the adjuvants. If the vaccine passes towards phase II studies, the results of 
this phase II study determines whether a phase III field study may follow. It is suggested to stop 
further research on vaccines that are not potent in phase III, continue research on vaccines 
that are mild potent and register vaccines that are moderate or very potent (expected efficacy 
≥40%) in phase III studies. When a vaccine is implemented, additional research may continue 
to improve the efficacy.
However, the CoHSI model also faces limitations. So far, the vaccine based on Sm-p80 showed 
promising efficacy data in baboons and a phase I study will follow soon.52,72 For both vaccines 
based on Sm14 and Sm-TSP-2, phase I studies have been performed in non-endemic areas and 
showed good safety profiles and immune responses.51,73 A phase Ib dose-escalation study on rSm-
TSP-2/Alydrogel +/- AP 10-701 started recently (clinicaltrials.gov NCT03910972). And a phase II 
trial has been performed with the rSm14/GLA-SE vaccine in 30 adult males in a high endemic area 
in Senegal (clinicaltrials.gov NCT03041766). As this study confirmed the safety and long-lasting 
immunogenicity of the vaccine, a phase IIb study in Senegalese school children was performed 
(clinicaltrials.gov NCT03799510).74,75 For the vaccine rSm14/GLA-SE there is no additional value 
to perform a CoHSI trial as the vaccine is already in phase II testing. It would be interesting to 
perform CoHSI trials on rSm-p80/GLA-SE and on rSm-TSP-2/Alydrogel before introducing these 
in large field studies.
Before using the CoHSI models for these vaccines, it is good to realise that there are some 
limitations to the CoHSI model in its current form. The major limitation is that the current 
CoHSI model only uses male cercariae. As a consequence the effect of vaccines on worm pairs, 
female worms and eggs cannot be evaluated. This is important when determining the efficacy 
of a vaccine based on an antigen that is expressed more on female than male worm, such as 
the vaccine Sm-p80. Research in baboons with Sm-p80/GLA-SE showed a 82-93% reduction of 
female worms, tissue egg load and hatching of eggs into miracidia, while only a 43% reduction 
of male worms was seen.52 Determining the potency of this specific vaccine in a CoHSI trial 
would be more interesting using a single-sex female CoHSI model instead of the single-sex male 
CoHSI model we described in Chapter 7. Before using a single-sex female model a new dose-
finding study should be performed, where the number of cercariae needed to safely establish an 
infection, determined by serum CAA levels, is tested. It is possible that female worms produce 
other amounts of CAA than males, as female worms do not fully mature without the presence 
of males, and female adult worms remain smaller than males.76 Also female worms can lay non-
viable eggs without the presence of males,77 although the number of eggs deposited are lower 
than in the presence of males.78 Despite the deposition of eggs in a single-sex female model this 
could still be safe as there is exposure to a limited number of cercariae, which will result in a 
limited number of non-viable eggs that will be deposited. Is addition, volunteers will be treated 
after 2-3 months so there will be egg deposition during a very limited time. As such, it is thought 
that a single- sex female CoHSI model could be safe and there are plans to perform a dose-finding 
single-sex female CoHSI study this year.
9.




This thesis contributed to several steps of vaccine development pathways for both malaria 
and schistosomiasis by the use of controlled human infection models. Two new malaria strains 
were shown to be safe for vaccine testing, with a similar risk profile as the generally used strain. 
These strains can now be used for vaccine testing with heterologous CHMIs, which is likely to 
give more comparable results to field studies. The first in human GAP vaccine administered by 
DVI was shown to be safe, but resulted in limited less protective efficacy against malaria. For 
schistosomiasis a controlled human infection model was developed. The dose-finding study 
showed that exposure to a dose of 20 cercariae is safe and results in a high infection rate. Finally, 
suggestions were made to further improve the safety of controlled human infection studies, 
with the use of historical controls. Overall, this thesis shows the importance on how controlled 
human infection models contribute to vaccine development.
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Gecontroleerde humane  infectiemodellen als 
hulpmiddel bij malaria en schistosomiasis 
vaccinatie onderzoek
 
In dit proefschrift is het gebruik van gecontroleerde humane infecties (CHI) voor diverse doeleinden 
beschreven. Als eerste komt het belang van het bestaande malaria CHI-model aan bod. Om 
malariavaccin onderzoek te kunnen verbeteren zijn nieuwe malaria stammen getest (Hoofstuk 
2 en 3). Daarnaast is middels het gebruik van het malaria CHI-model een nieuw vaccin getest 
(Hoofdstuk 4). Als tweede is beschreven hoe de ontwikkeling van het nieuwe schistosomiasis CHI 
model tot stand is gekomen (Hoofdstuk 5). Waarna de resultaten van het eerste onderzoek met 
behulp van dit schistosoma CHI-model worden beschreven (Hoofdstuk 6 en 7). Als laatste wordt 
besproken hoe deze CHI-studies veiliger gemaakt kunnen worden (Hoofdstuk 8).
Parasieten
Parasieten zijn een groep ziekteverwekkers die gedurende hun leven in of op minimaal één gastheer 
verblijven. Een gastheer is een levend wezen, bijvoorbeeld mens, slak of mug, die een parasiet nodig 
heeft om te kunnen ontwikkelen en overleven. Iedere parasiet heeft zijn eigen levenscyclus met 
specifieke gastheer. Vaak zijn er meerdere parasiet-stadia per gastheer. De kleinste parasieten zijn 
eencellig, zoals malaria, terwijl wormen de grootste parasieten zijn. Deze wormen variëren enorm 
in lengte, van kleiner dan een centimeter tot enkele meters lang. De meeste parasitaire infecties 
zijn goed te behandelen met medicijnen. Diverse infecties kunnen voorkomen worden met behulp 
van een vaccin, maar deze zijn er voor parasitaire infecties nauwelijks.
Gecontroleerde humane infecties (CHI)
Er wordt op grote schaal onderzoek verricht naar het ontwikkelen van vaccins tegen parasieten 
die dodelijk kunnen zijn of veel ziektelast kunnen veroorzaken. Als een vaccin geschikt lijkt te 
zijn wordt eerst de veiligheid van een vaccin onderzocht door deze te testen op vrijwilligers. 
Dit heet fase I onderzoek. Hierbij worden vrijwilligers eenmalig blootgesteld aan het vaccin en 
wordt gekeken welke klachten zij in de weken hierna ontwikkelen.
Om na te gaan of een vaccin ook werkt, dat wil zeggen ziekte voorkomt, wordt de laatste 
tientallen jaren veel onderzoek verricht middels gecontroleerde humane infectie (CHI) studies. 
Dit zijn studies waarbij een groep vrijwilligers enkele keren een vaccin toegediend krijgen 
(immunisaties) waarbij meestal gelijktijdig een andere groep een placebo toegediend krijgt. 
Een placebo is een middel dat er fysiek uit ziet als het vaccin, maar geen werkzame stof bevat. 
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Hierna worden beide groepen blootgesteld aan de parasiet. Deze manier van infecteren is de 
daadwerkelijke CHI. Vervolgens worden alle vrijwilligers goed onder controle gehouden en wordt 
gekeken wie de ziekte ontwikkelen. Aan de hand van het aantal zieken in de vaccinatie- en de 
placebogroep is te berekenen hoe goed het vaccin lijkt te werken.
Bij CHI-studies wordt over het algemeen getest op gezonde vrijwilligers die niet eerder een 
infectie met de specifieke ziekteverwekker hebben gehad. Hierdoor hebben CHI-studies diverse 
voordelen boven het onderzoeken van vaccins in gebieden waar de ziekte veel voor komt, de 
endemische gebieden. De grootste voordelen zijn dat meerdere vaccins tegelijk getest kunnen 
worden, dat er minder vrijwilligers nodig zijn door de gecontroleerde omstandigheden (dat 
wil zeggen dezelfde hoeveelheid van een ziekteverwekker op hetzelfde moment in gezonde 
vrijwilligers) en dat het onderzoek goedkoper is om te verrichten. Daarnaast worden uiteindelijk 
alleen de vaccins die erg potent lijken te zijn onderzocht in grote groepen, soms kwetsbare, 
mensen in endemische gebieden. Waardoor zij niet onnodig worden blootgesteld aan vaccins 
die mogelijk niet werken.
Malaria
Malaria is de ziekte die veroorzaakt wordt door de parasiet Plasmodium. Er zijn verschillende 
soorten Plasmodium die ziekte kunnen veroorzaken in mensen. Plasmodium falciparum is de 
soort die malaria tropica veroorzaakt. Dit is de dodelijkste soort malaria. In totaal ontwikkelen 
jaarlijks ruim 200 miljoen mensen malaria en overlijden ruim 400.000 mensen aan deze ziekte. 
Het merendeel hiervan zijn kinderen onder de vijf jaar. Daarnaast lopen zwangeren een groter 
risico op het ontwikkelen van de ziekte.
Levenscyclus en klachten
De parasiet heeft verschillende levensstadia in zowel de mens als de mug, welke ieder een 
andere naam hebben. Als je wordt gestoken door een geïnfecteerde mug kunnen malaria-
sporozoieten vanuit de speekselklieren van de mug de huid binnendringen. Vervolgens migreren 
ze naar de lever, waar ze een levercel binnengaan en zich ontwikkelen tot malaria-schizonten. 
Als deze volledig ontwikkeld zijn, barsten deze open en komen er malaria-merozoieten vrij 
in de bloedbaan. Deze infecteren vervolgens rode bloedcellen waarin ze zich verder kunnen 
vermenigvuldigen. Na verloop van tijd ontstaan er vrouwtjes en mannetjes malaria-gametocyten. 
Als patiënten op dat moment gestoken worden door een mug, kunnen de gametocyten door de 
mug opgezogen worden en kunnen zij in de mug paren. Vervolgens zal de parasiet diverse stadia 
in de mug doorlopen. Na enkele weken kan de mug een nieuw persoon infecteren.
Mensen die geïnfecteerd zijn met malaria worden pas ziek als de parasieten vanuit de lever 
in de bloedbaan terecht komen. Hier gaat, in het geval van malaria tropica, minimaal een week 
overheen. Mensen hebben vaak last van koorts, hoofdpijn en algehele malaise. Als de ziekte 
onbehandeld wordt gelaten nemen klachten toe en kan dit leiden tot neurologische klachten, 
uitval van organen, coma en uiteindelijk de dood.




Malaria is goed te behandelen met medicijnen, mits deze op tijd worden toegediend. Het 
probleem is dat het overgrote deel van patiënten in ontwikkelingslanden woont waar zij vaak 
slechte toegang tot zorg hebben. Hierdoor komen patiënten vaak pas in het ziekenhuis aan als 
zij al erg ziek zijn. Een behandeling komt dan niet altijd meer op tijd.
Door muggenbeten te voorkomen kan de ziekte malaria ook voorkomen worden. In de 
praktijk is dit lastig en maatregelen om beten te voorkomen helpen dan ook onvoldoende. Een 
malariavaccin kan voorkomen dat mensen de ziekte ontwikkelen. Op het moment is er één vaccin 
beschikbaar tegen malaria, Mosquirix. Dit vaccin wordt momenteel op grote schaal getest in 
sub-Sahara Afrika en geeft goede resultaten. Zo komen er minder gevallen van ernstige malaria 
voor en overlijden minder kinderen aan de ziekte. Het grootste probleem is echter dat het vaccin 
maar bij ruim de helft van de kinderen werkt en dat het in de loop van de tijd steeds minder goed 
werkt in dezelfde patiënt. Om deze reden blijft onderzoek naar een beter vaccin in volle gang.
Vaccins van hele parasieten (Hoofdstuk 4)
De laatste jaren wordt veel onderzoek verricht naar vaccins op basis van de volledige parasiet en 
dan met name de sporozoiet. Deze vaccins zijn onder te verdelen in drie verschillende soorten. 
1. Bestraalde parasieten (RAS). 2. Parasieten met gelijktijdig toedienen van een anti-malaria 
medicijn (CPS). 3. Parasieten waarvan de genetische code, het DNA, is aangepast (GAP).
1.  RAS: als malaria-sporozoieten bestraald worden kunnen ze nog wel een levercel binnen 
gaan, maar zich hier vervolgens niet volledig ontwikkelen. Hierdoor zal de parasiet overlijden 
voordat deze in de bloedbaan terecht kan komen en zal je er ook niet ziek van worden. 
Tijdens deze kortdurende leverfase zal het menselijk lichaam wel een afweerreactie maken 
tegen de parasiet.
2.  CPS: chloroquine is een anti-malaria medicijn dat malariaparasieten doodt zodra deze in het 
bloed terecht komen. Als malaria sporozoieten gelijktijdig met deze behandeling worden 
gegeven zullen ze zich volledig ontwikkelen in de lever, waarna ze zullen overlijden zodra ze in 
het bloed terecht komen. Het voordeel hiervan is dat de parasieten zich volledig ontwikkelen 
in de lever, waardoor zich gedurende een langere tijd een afweerreactie kan ontwikkelen.
3.  GAP: het is mogelijk het DNA van malariaparasieten aan te passen; genetische modificatie. 
Hierdoor is het mogelijk de parasiet zo aan te passen dat deze zich niet volledig ontwikkelt 
in de lever. Door deze ontwikkeling in de lever kan wel een afweerreactie plaatsvinden.
Zowel bij RAS als bij CPS kan volledige bescherming tegen malaria optreden nadat deze meerdere 
keren zijn gegeven. In beide gevallen neemt deze bescherming af in de loop van de tijd. Voor 
een GAP is dit nog onvoldoende onderzocht. De reden om hier onderzoek naar te verrichten is 
omdat GAP twee voordelen heeft. Afhankelijk van het type GAP kan deze zich mogelijk langer 
ontwikkelen in de lever dan RAS. In dat geval wordt er een beter afweerreactie gemaakt, net als 
bij CPS. Daarbij kan zich geen malaria ontwikkelen. Dat is wel het risico van CPS als de medicatie 
niet goed gebruikt wordt.
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In Hoofdstuk 4 beschrijven we het testen van een GAP-vaccin, PfSPZ-GA1 Vaccine, met behulp 
van een malaria CHI-onderzoek. Bij deze GAP zijn twee genen verwijderd uit de parasiet, 
waardoor deze zich in een vroeg leverstadium niet verder kan ontwikkelen. We toonden eerst 
aan dat het vaccin veilig was om te gebruiken. Hierna immuniseerden we vrijwilligers drie keer 
waarna ze een gecontroleerde humane malaria infectie (CHMI) kregen. Van alle vrijwilligers die 
PfSPZ-GA1 Vaccine kregen, was 12% volledig beschermd tegen malaria. Uit de groep vrijwilligers 
die een placebo hadden ontvangen was niemand beschermd. De overige vrijwilligers die PfSPZ-
GA1 Vaccine hadden gekregen ontwikkelden pas enkele dagen later malaria dan de vrijwilliger 
in de placebogroep. Dit wijst erop dat deze vrijwilligers wel deels beschermd waren.
Het gebruik van verschillende stammen (Hoofdstuk 2 & 3)
In ieder gebied waar de malariaparasiet Plasmodium falciparum voorkomt zijn er geringe 
verschillen in het DNA van de parasiet. Dit worden verschillende stammen genoemd. De vaccins 
op basis van hele parasieten zijn allemaal ontwikkeld met de stam NF54. Deze stam komt van 
een patiënt die malaria opliep in de omgeving van een Nederlands vliegveld. Sinds 30 jaar wordt 
deze gekweekt in een laboratorium en gebruikt voor onderzoeksdoeleinden. Bovenstaande 
vaccins, RAS, CPS en GAP, zijn op dit moment allemaal op basis van deze stam. De CHMI die 
plaats vindt om te beoordelen of een vaccin goed werkt is ook op basis van deze stam NF54. 
Deze CHMI vindt meestal plaats met behulp van muggenbeten. De beten van vijf geïnfecteerde 
muggen zorgen voor het ontwikkelen van malaria in >99% van alle vrijwilligers die geen vaccin 
kregen toegediend.
Om te weten of vaccins op basis van deze ene stam ook werken tegen parasieten van een 
andere stam is het van belang om met meerdere stammen onderzoek te verrichtten. Hiervoor 
zijn naast NF54 ook de stammen 7G8 en NF135.C10 beschikbaar. In Hoofdstuk 2 beschrijven we 
voor het eerst onderzoek met de nieuwe stam NF166.C8. We laten zien dat deze stam veilig is 
om te gebruiken. Daarnaast laat ons onderzoek zien dat een infectie met de stammen NF135.
C10 of NF166.C8 leidt tot meer parasieten die uit de lever in het bloed terecht komen dan 
bij NF54. Om een CHMI met NF135.C10 of NF166.C8 mogelijk te maken hebben we gekeken 
hoeveel geïnfecteerde muggenbeten er nodig zijn om een infectie met een van deze stammen te 
ontwikkelen, wat we in Hoofdstuk 3 hebben beschreven. Dit aantal blijkt hetzelfde te zijn als bij 
NF54, namelijk de beten van vijf geïnfecteerde muggen. Als vrijwilligers aan minder muggenbeten 
worden blootgesteld, ontwikkelt 75% van de vrijwilligers malaria.
Schistosomiasis
Schistosomiasis is de ziekte die veroorzaakt wordt door de parasiet Schistosoma. Er zijn 
verschillende soorten Schistosoma die de ziekte kunnen veroorzaken in mensen, waarvan 
Schistosoma mansoni en Schistosoma haematobium het vaakst voorkomen. Wereldwijd hebben 
290 miljoen mensen schistosomiasis, waarvan ruim de helft van de mensen klachten heeft. Het 
is lastig vast te stellen hoeveel mensen jaarlijks aan de ziekte overlijden, maar naar schatting 
zijn dit er tussen de 24.000 en 150.000.




De parasiet Schistosoma heeft verschillende levensstadia in zowel de mens als de zoetwaterslak. 
Infectie vindt plaats door te zwemmen in water waar geïnfecteerde slakken voorkomen. De slak 
laat Schistosoma larven vrij, de cercariën, welke door de huid van de mens naar binnen kunnen 
dringen. Ze ontwikkelen zich in de mens tot volwassen wormen die zich uiteindelijk als paar 
zullen gaan nestelen in een van de grote vaten rondom de blaas (S. haematobium) of rondom 
de darmen (S. mansoni). Als de wormen hun eindbestemming bereiken zal het vrouwtje eitjes 
uitscheiden welke door het weefsel van de darm of de blaas in de ontlasting of urine terecht 
komen. Een deel van de eitjes blijft vast zitten in het weefsel waardoor ontstekingen kunnen 
ontstaan. Als de eitjes uit de ontlasting of urine terecht komen in zoet water kan zich in het ei 
het stadium miracidium ontwikkelen. Als deze miracidia uit de eitjes komen kunnen deze slakken 
infecteren. In de slak vinden opnieuw diverse ontwikkelingsstadia plaats. Uiteindelijk leidt dit tot 
de ontwikkeling van cercariën welke weer door de slak kunnen worden vrijgelaten.
Tijdens deze cyclus in de mens kunnen verschillende klachten optreden. De eerste weken 
na infectie kan zwemmersjeuk optreden op de plaatsen waar de cercariën de huid binnen zijn 
gedrongen. Hierna kunnen in de acute fase, de eerste maanden, hevige klachten optreden, 
met name bij mensen die voor de eerste keer geïnfecteerd zijn. Dit wordt Katayama syndroom 
genoemd, waarbij klachten zoals koorts, hoofdpijn en algehele malaise op de voorgrond staan. 
Vervolgens kan de ontsteking rond de eitjes die vast zitten in het weefsel zich in de loop van de 
jaren uitbreiden, naarmate er meer eitjes vast komen te zitten. Het duurt lange tijd voor mensen 
hier klachten van ontwikkelen en het kan na jaren van infectie zelfs leiden tot kanker.
Behandelen of voorkomen
Schistosomiasis is te behandelen met het medicijn praziquantel. Het probleem is dat praziquantel 
niet bij iedereen werkt. Er wordt geschat dat het middel in gebieden waar de ziekte veel voor 
komt, endemische gebieden, in 42-91% van de gevallen werkt. Praziquantel werkt alleen tegen 
volwassen wormen en voorkomt niet dat mensen opnieuw besmet raken. Omdat mensen vaak 
niet weten dat ze de infectie hebben totdat klachten optreden, kan er lange tijd overheen 
gaan voordat behandeling plaats vindt. In endemische gebieden wordt jaarlijks praziquantel 
uitgedeeld, mass drugs administration (MDA), om de ziekte zoveel mogelijk beperkt te houden. 
Dit is echter onvoldoende om de ziekte uit te kunnen roeien.
De infectie is te voorkomen door contact met zoet water te vermijden. Dit advies is geschikt 
voor reizigers, maar is lastig voor mensen die in endemische gebieden wonen. Zij zijn vaak 
afhankelijk van het water wat gebruikt wordt om hun kleding en zichzelf te wassen, te koken en 
om vis te vangen. Een andere manier om infectie te voorkomen is het gebruik van een vaccin. 
Echter een vaccin tegen schistosomiasis is nog niet beschikbaar. Er zijn momenteel drie vaccins 
tegen Schistosoma mansoni in verschillende stadia van ontwikkeling. Of deze voldoende effectief 
zijn zal verder onderzoek uit moeten wijzen.
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Gecontroleerd humaan Schistosoma infectie onderzoek 
(Hoofdstuk 5, 6 & 7)
Vanwege de bovengenoemde voordelen van CHI-studies samen met het belang van het snel 
ontwikkelen van een vaccin voor schistosomiasis, hebben we een gecontroleerd humaan 
schistosomiasis infectie (CoHSI) model opgezet. Het opzetten van dit model werd beschreven 
in Hoofdstuk 5. Het belangrijkste was om dit nieuwe model zo veilig mogelijk te maken voor 
vrijwilligers. Aangezien de eitjes van Schistosoma kunnen zorgen voor klachten op lange termijn is 
besloten een model op te zetten waarbij vrijwilligers alleen aan mannelijke cercariën blootgesteld 
worden. De eerste studie die we met het model hebben verricht was om te beoordelen aan hoeveel 
cercariën vrijwilligers blootgesteld moeten worden om een aantoonbare infectie te ontwikkelen. 
De eerste groep is blootgesteld aan 10 cercariën, waarna niet alle vrijwilligers geïnfecteerd 
waren. Vervolgens is een groep blootgesteld aan 30 cercariën. Van deze groep waren alle drie de 
vrijwilligers geïnfecteerd, maar ontwikkelde twee vrijwilligers klachten die passen bij het Katayama 
syndroom, zoals staat beschreven in Hoofdstuk 6. Vanwege de hevige klachten is besloten om 
de volgende groep aan 20 cercariën bloot te stellen. In totaal zijn 11 vrijwilligers aan deze dosis 
blootgesteld. Een deel van de vrijwilligers heeft klachten ontwikkeld, maar niet van dezelfde 
hevigheid als bij de vrijwilligers blootgesteld aan 30 cercariën. In Hoofdstuk 7 beschrijven we de 
uitkomsten van dit eerste CoHSI onderzoek. Van de 11 vrijwilligers blootgesteld aan 20 cercariën 
heeft uiteindelijk 82% een Schistosoma-infectie opgelopen. Ondanks dat dit niet resulteert in 100% 
van de vrijwilligers met een infectie, is toch besloten om bij een vervolgonderzoek deze dosis van 
20 cercariën te gebruiken. De bijwerkingen zijn bij deze dosis acceptabel en vergelijkbaar met 
andere modellen, terwijl dat bij een hogere dosis niet het geval is.
Optimaliseren CHI-modellen (Hoofdstuk 8)
Zoals hierboven beschreven, zijn sommige CHI-modellen reeds uitgebreid getest. Hierdoor zijn 
deze in de loop van de jaren gestandaardiseerd, waardoor wereldwijd dezelfde opzet gebruikt 
wordt. Het voordeel hiervan is dat resultaten van verschillende onderzoekscentra vergeleken 
kunnen worden. Daarnaast kunnen deze resultaten gebruikt worden om CHI-modellen veiliger 
te maken, waarbij het geringe risico voor vrijwilligers nog verder afneemt. De meest gebruikte 
studie opzet is een vaccin groep vergelijken met een controlegroep. In Hoofdstuk 8 beschrijven 
we dat er naast deze studie opzet ook andere mogelijkheden zijn. Een mogelijkheid is het gebruik 
van historische data. Hierbij worden resultaten uit andere studies gebruikt, de historische 
controlegroep, in plaats van een placebogroep. Een goed voorbeeld hiervoor is het malariamodel. 
Zoals eerder beschreven weten we dat >99% van de gezonde vrijwilligers in de placebogroep 
malaria ontwikkelen als ze worden blootgesteld aan vijf malaria geïnfecteerde muggen. Deze 
historische data kan voor een vervolgstudie gebruikt worden in plaats van een placebogroep. 
Om zeker te weten dat er niks mis gaat met de CHMI-procedure, kan ervoor gekozen worden 
om een kleine groep vrijwilligers een CHMI te laten ondergaan. Het gebruik van historische data 
is vooralsnog niet mogelijk voor het schistosomiasis model, omdat er nog maar één studie met 
dit model uitgevoerd. De toekomst zal uitwijzen of blootstelling aan 20 cercariën altijd leidt tot 
hetzelfde percentage geïnfecteerde vrijwilligers.
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